Insulin A chain
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein–DNA Heteromer Protein × 4 DNA 1 PDB declaration: pentameric（5） Consistent with all polymer counts | Chain A； UniProt 90–110 | Not recorded | Insulin, isoform 2 × 1 （F8WCM5） Isoform Short of Insulin receptor × 2 （P06213） IR-A43 aptamer × 1 | ELECTRON MICROSCOPY cryo-EM buffer：pH 7.5 cryo-EM vitrification conditions：Cryogen ETHANE | Resolution 3.60 Å |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 7YQ3 | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1A7F INSULIN MUTANT B16 GLU, B24 GLY, DES-B30, NMR, 20 STRUCTURES Deposited 1998-03-12 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Mutation：Y16E, F24G, DEL(T30) | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 8；305 K
NMR sample composition
WATER
|
Resolution not provided |
| 1AI0 R6 HUMAN INSULIN HEXAMER (NON-SYMMETRIC), NMR, 10 STRUCTURES Deposited 1997-04-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 2 IPH PHENOL × 6 |
SOLUTION NMR
NMR measurement conditions
pH 8；310 K
|
Resolution not provided |
| 1AIY R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 10 STRUCTURES Deposited 1997-04-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 2 IPH PHENOL × 6 |
SOLUTION NMR
NMR measurement conditions
pH 8；310 K
|
Resolution not provided |
| 1B9E HUMAN INSULIN MUTANT SERB9GLU Deposited 1998-11-12 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：S9E Mutation：S9E | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 3.5；HANGING DROP, 0.1M AMMONIA CITRATE, 0.12% CHROMIUM DICHLORIDE (W/V), 10%
ACETONE (V/V), 4% DIMETHYL FORMAMIDE (V/V), PH 3.8, pH 3.5, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.50 Å R-free 0.264 |
| 1B9E HUMAN INSULIN MUTANT SERB9GLU Deposited 1998-11-12 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：S9E Mutation：S9E | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 3.5；HANGING DROP, 0.1M AMMONIA CITRATE, 0.12% CHROMIUM DICHLORIDE (W/V), 10%
ACETONE (V/V), 4% DIMETHYL FORMAMIDE (V/V), PH 3.8, pH 3.5, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.50 Å R-free 0.264 |
| 1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
31–51（21 aa）
Chain B
1–30（30 aa）
|
Not recorded | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
|
Resolution 1.40 Å |
| 1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 10 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric |
Chain A
31–51（21 aa）
Chain B
1–30（30 aa）
Chain D
1–30（30 aa）
|
Not recorded | ZN ZINC ION × 6 HBD 4-HYDROXYBENZAMIDE × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
|
Resolution 1.40 Å |
| 1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 11 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric |
Chain A
31–51（21 aa）
Chain B
1–30（30 aa）
Chain D
1–30（30 aa）
|
Not recorded | ZN ZINC ION × 6 HBD 4-HYDROXYBENZAMIDE × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
|
Resolution 1.40 Å |
| 1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 12 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric |
Chain B
1–30（30 aa）
Chain C
31–51（21 aa）
Chain D
1–30（30 aa）
|
Not recorded | ZN ZINC ION × 6 HBD 4-HYDROXYBENZAMIDE × 6 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
|
Resolution 1.40 Å |
| 1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 13 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain B
1–30（30 aa）
Chain D
1–30（30 aa）
|
Not recorded | ZN ZINC ION × 6 HBD 4-HYDROXYBENZAMIDE × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
|
Resolution 1.40 Å |
| 1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
31–51（21 aa）
Chain D
1–30（30 aa）
|
Not recorded | ZN ZINC ION × 1 HBD 4-HYDROXYBENZAMIDE × 2 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
|
Resolution 1.40 Å |
| 1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
31–51（21 aa）
Chain B
1–30（30 aa）
Chain C
31–51（21 aa）
Chain D
1–30（30 aa）
|
Not recorded | ZN ZINC ION × 6 HBD 4-HYDROXYBENZAMIDE × 6 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
|
Resolution 1.40 Å |
| 1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
31–51（21 aa）
Chain B
1–30（30 aa）
Chain C
31–51（21 aa）
Chain D
1–30（30 aa）
|
Not recorded | ZN ZINC ION × 6 HBD 4-HYDROXYBENZAMIDE × 6 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
|
Resolution 1.40 Å |
| 1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
31–51（21 aa）
Chain B
1–30（30 aa）
Chain C
31–51（21 aa）
Chain D
1–30（30 aa）
|
Not recorded | ZN ZINC ION × 6 HBD 4-HYDROXYBENZAMIDE × 6 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
|
Resolution 1.40 Å |
| 1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric |
Chain A
31–51（21 aa）
Chain B
1–30（30 aa）
Chain C
31–51（21 aa）
|
Not recorded | ZN ZINC ION × 3 HBD 4-HYDROXYBENZAMIDE × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
|
Resolution 1.40 Å |
| 1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 7 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
31–51（21 aa）
Chain D
1–30（30 aa）
|
Not recorded | ZN ZINC ION × 3 HBD 4-HYDROXYBENZAMIDE × 6 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
|
Resolution 1.40 Å |
| 1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 8 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
31–51（21 aa）
Chain B
1–30（30 aa）
|
Not recorded | ZN ZINC ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
|
Resolution 1.40 Å |
| 1BEN INSULIN COMPLEXED WITH 4-HYDROXYBENZAMIDE Deposited 1996-02-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 9 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric |
Chain B
1–30（30 aa）
Chain C
31–51（21 aa）
Chain D
1–30（30 aa）
|
Not recorded | ZN ZINC ION × 6 HBD 4-HYDROXYBENZAMIDE × 6 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 5.7；0.05M SODIUM CITRATE, 0.007M ZINC ACETATE, 0.06M 4-HYDROXYBENZAMIDE, 1.0M SODIUM CHLORIDE, PH=5.7. CRYSTALS GROWN BY SLOW COOLING., slow cooling
|
Resolution 1.40 Å |
| 1EFE AN ACTIVE MINI-PROINSULIN, M2PI Deposited 2000-02-08 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–54（30 aa）
Chain A
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 2.3；303 K；Pressure ambient
NMR sample composition
2mM M2PI U-15N; 20% acetic acid; 70% H2O, 10% D2O | 20% acetic acid, 70% H2O, 10% D2O
NMR sample composition
2mM M2PI; 20% acetic acid; 70% H2O, 10% D2O | 20% acetic acid, 70% H2O, 10%
|
Resolution not provided |
| 1EV3 Structure of the rhombohedral form of the M-cresol/insulin R6 hexamer Deposited 2000-04-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：RESIDUES 87-107
Chain B
25–54（30 aa）
Fragment：RESIDUES 25-54
Chain C
90–110（21 aa）
Fragment：RESIDUES 87-107
Chain D
25–54（30 aa）
Fragment：RESIDUES 25-54
|
Not recorded | CRS M-CRESOL × 9 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 8.5；298 K；30 mg insulin, 3.0 ml of 0.02 M HCl, 0.3 ml of 0.15 M Zinc Acetate,
1.5 ml of 0.2 M Sodium Citrate, 1.2 ml of 2.5% m-cresol in acetone, 0.36 gm sodium chloride, pH 8.5, SLOW COOLING, temperature 298K
|
Resolution 1.78 Å R-free 0.266 |
| 1EV6 Structure of the monoclinic form of the M-cresol/insulin R6 hexamer Deposited 2000-04-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：RESIDUES 87-107
Chain B
25–54（30 aa）
Fragment：RESIDUES 25-54
Chain C
90–110（21 aa）
Fragment：RESIDUES 87-107
Chain D
25–54（30 aa）
Fragment：RESIDUES 25-54
Chain E
90–110（21 aa）
Fragment：RESIDUES 87-107
Chain F
25–54（30 aa）
Fragment：RESIDUES 25-54
Chain G
90–110（21 aa）
Fragment：RESIDUES 87-107
Chain H
25–54（30 aa）
Fragment：RESIDUES 25-54
Chain I
90–110（21 aa）
Fragment：RESIDUES 87-107
Chain J
25–54（30 aa）
Fragment：RESIDUES 25-54
Chain K
90–110（21 aa）
Fragment：RESIDUES 87-107
Chain L
25–54（30 aa）
Fragment：RESIDUES 25-54
|
Not recorded | CRS M-CRESOL × 7 ZN ZINC ION × 2 CL CHLORIDE ION × 2 NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 6.5；298 K；30 mg insulin, 3.0 ml 0.02 M HCl, 0.3 ml 0.15 M Zinc Acetate, 1.5 ml 0.2 M Sodium Citrate,
1.2 ml 5% m-Cresol in ethanol, pH 6.5, SLOW COOLING, temperature 298.0K
|
Resolution 1.90 Å R-free 0.235 |
| 1EVR The structure of the resorcinol/insulin R6 hexamer Deposited 2000-04-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：RESIDUES 87-107
Chain B
25–54（30 aa）
Fragment：RESIDUES 25-54
Chain C
90–110（21 aa）
Fragment：RESIDUES 87-107
Chain D
25–54（30 aa）
Fragment：RESIDUES 25-54
Chain E
90–110（21 aa）
Fragment：RESIDUES 87-107
Chain F
25–54（30 aa）
Fragment：RESIDUES 25-54
Chain G
90–110（21 aa）
Fragment：RESIDUES 87-107
Chain H
25–54（30 aa）
Fragment：RESIDUES 25-54
Chain I
90–110（21 aa）
Fragment：RESIDUES 87-107
Chain J
25–54（30 aa）
Fragment：RESIDUES 25-54
Chain K
90–110（21 aa）
Fragment：RESIDUES 87-107
Chain L
25–54（30 aa）
Fragment：RESIDUES 25-54
|
Not recorded | RCO RESORCINOL × 8 ZN ZINC ION × 2 CL CHLORIDE ION × 2 NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 6.7；298 K；30 mg insulin, 3.0 ml 0.02 M HCl, 0.3 ml 0.15 M Zinc Acetate, 1.5 ml 0.2 M Sodium Citrate,
1.2 ml 5% Resorcinol in water, 0.36 gm NaCl, pH 6.7, SLOW COOLING, temperature 298.0K
|
Resolution 1.90 Å R-free 0.218 |
| 1FU2 FIRST PROTEIN STRUCTURE DETERMINED FROM X-RAY POWDER DIFFRACTION DATA Deposited 2000-09-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 8 PDB declaration: octameric |
Chain A
90–110（21 aa）
Fragment：A CHAIN OF T3R3 VARIANT
Chain B
25–54（30 aa）
Fragment：B CHAIN OF T3R3 VARIANT
Chain C
90–110（21 aa）
Fragment：A CHAIN OF T3R3 VARIANT
Chain D
25–54（30 aa）
Fragment：B CHAIN OF T3R3 VARIANT
Chain E
90–110（21 aa）
Fragment：A CHAIN OF T3R3 VARIANT
Chain F
25–54（30 aa）
Fragment：B CHAIN OF T3R3 VARIANT
Chain G
90–110（21 aa）
Fragment：A CHAIN OF T3R3 VARIANT
Chain H
25–54（30 aa）
Fragment：B CHAIN OF T3R3 VARIANT
|
Not recorded | ZN ZINC ION × 4 CL CHLORIDE ION × 4 NA SODIUM ION × 2 | POWDER DIFFRACTION mmCIF provides none of the parsed conditions | Resolution not provided |
| 1FU2 FIRST PROTEIN STRUCTURE DETERMINED FROM X-RAY POWDER DIFFRACTION DATA Deposited 2000-09-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain E
90–110（21 aa）
Fragment：A CHAIN OF T3R3 VARIANT
Chain F
25–54（30 aa）
Fragment：B CHAIN OF T3R3 VARIANT
Chain G
90–110（21 aa）
Fragment：A CHAIN OF T3R3 VARIANT
Chain H
25–54（30 aa）
Fragment：B CHAIN OF T3R3 VARIANT
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 NA SODIUM ION × 3 | POWDER DIFFRACTION mmCIF provides none of the parsed conditions | Resolution not provided |
| 1FU2 FIRST PROTEIN STRUCTURE DETERMINED FROM X-RAY POWDER DIFFRACTION DATA Deposited 2000-09-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：A CHAIN OF T3R3 VARIANT
Chain B
25–54（30 aa）
Fragment：B CHAIN OF T3R3 VARIANT
Chain C
90–110（21 aa）
Fragment：A CHAIN OF T3R3 VARIANT
Chain D
25–54（30 aa）
Fragment：B CHAIN OF T3R3 VARIANT
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 NA SODIUM ION × 3 | POWDER DIFFRACTION mmCIF provides none of the parsed conditions | Resolution not provided |
| 1FU2 FIRST PROTEIN STRUCTURE DETERMINED FROM X-RAY POWDER DIFFRACTION DATA Deposited 2000-09-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain C
90–110（21 aa）
Fragment：A CHAIN OF T3R3 VARIANT
Chain D
25–54（30 aa）
Fragment：B CHAIN OF T3R3 VARIANT
Chain E
90–110（21 aa）
Fragment：A CHAIN OF T3R3 VARIANT
Chain F
25–54（30 aa）
Fragment：B CHAIN OF T3R3 VARIANT
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 | POWDER DIFFRACTION mmCIF provides none of the parsed conditions | Resolution not provided |
| 1FUB FIRST PROTEIN STRUCTURE DETERMINED FROM X-RAY POWDER DIFFRACTION DATA Deposited 2000-09-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Fragment：A CHAIN OF T3R3 VARIANT
Chain B
25–54（30 aa）
Fragment：B CHAIN OF T3R3 VARIANT
Chain C
90–110（21 aa）
Fragment：A CHAIN OF T3R3 VARIANT
Chain D
25–54（30 aa）
Fragment：B CHAIN OF T3R3 VARIANT
|
Not recorded | ZN ZINC ION × 2 CL CHLORIDE ION × 2 NA SODIUM ION × 1 |
POWDER DIFFRACTION
X-ray crystallization conditions
grinding；300 K；grinding, temperature 300K
|
Resolution not provided |
| 1FUB FIRST PROTEIN STRUCTURE DETERMINED FROM X-RAY POWDER DIFFRACTION DATA Deposited 2000-09-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：A CHAIN OF T3R3 VARIANT
Chain B
25–54（30 aa）
Fragment：B CHAIN OF T3R3 VARIANT
Chain C
90–110（21 aa）
Fragment：A CHAIN OF T3R3 VARIANT
Chain D
25–54（30 aa）
Fragment：B CHAIN OF T3R3 VARIANT
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 NA SODIUM ION × 3 |
POWDER DIFFRACTION
X-ray crystallization conditions
grinding；300 K；grinding, temperature 300K
|
Resolution not provided |
| 1G7A 1.2 A structure of T3R3 human insulin at 100 K Deposited 2000-11-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
87–107（21 aa）
Fragment：A-CHAIN
Chain B
25–54（30 aa）
Fragment：B-CHAIN
Chain C
87–107（21 aa）
Fragment：A-CHAIN
Chain D
25–54（30 aa）
Fragment：B-CHAIN
|
Not recorded | ZN ZINC ION × 15 CL CHLORIDE ION × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 6.3；298 K；5 mg/ml human insulin, 0.01 M HCl, 0.007 M zinc acetate, 0.05 M sodium citrate,
17% acetone, 1.0 M NaCl. pH 6.3, SLOW COOLING at 298K
|
Resolution 1.20 Å R-free 0.193 |
| 1G7A 1.2 A structure of T3R3 human insulin at 100 K Deposited 2000-11-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain E
87–107（21 aa）
Fragment：A-CHAIN
Chain F
25–54（30 aa）
Fragment：B-CHAIN
Chain G
87–107（21 aa）
Fragment：A-CHAIN
Chain H
25–54（30 aa）
Fragment：B-CHAIN
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 9 ACN ACETONE × 6 GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 6.3；298 K；5 mg/ml human insulin, 0.01 M HCl, 0.007 M zinc acetate, 0.05 M sodium citrate,
17% acetone, 1.0 M NaCl. pH 6.3, SLOW COOLING at 298K
|
Resolution 1.20 Å R-free 0.193 |
| 1G7B 1.3 A STRUCTURE OF T3R3 HUMAN INSULIN AT 100 K Deposited 2000-11-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
87–107（21 aa）
Fragment：A-CHAIN
Chain B
25–54（30 aa）
Fragment：B-CHAIN
Chain C
87–107（21 aa）
Fragment：A-CHAIN
Chain D
25–54（30 aa）
Fragment：B-CHAIN
|
Not recorded | ZN ZINC ION × 15 CL CHLORIDE ION × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 6.3；298 K；5 mg/ml human insulin, 0.01 M HCl, 0.007 M zinc acetate, 0.05 M sodium citrate,
17% acetone, 1.0 M NaCl. pH 6.3, SLOW COOLING at 298K
|
Resolution 1.30 Å R-free 0.204 |
| 1G7B 1.3 A STRUCTURE OF T3R3 HUMAN INSULIN AT 100 K Deposited 2000-11-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain E
87–107（21 aa）
Fragment：A-CHAIN
Chain F
25–54（30 aa）
Fragment：B-CHAIN
Chain G
87–107（21 aa）
Fragment：A-CHAIN
Chain H
25–54（30 aa）
Fragment：B-CHAIN
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 9 GOL GLYCEROL × 3 ACN ACETONE × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 6.3；298 K；5 mg/ml human insulin, 0.01 M HCl, 0.007 M zinc acetate, 0.05 M sodium citrate,
17% acetone, 1.0 M NaCl. pH 6.3, SLOW COOLING at 298K
|
Resolution 1.30 Å R-free 0.204 |
| 1GUJ Insulin at pH 2: structural analysis of the conditions promoting insulin fibre formation. Deposited 2002-01-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 2.1；HANGING DROP VAPOUR DIFFUSION METHOD PROTEIN SOL: 5 MG/ML HUMAN INSULIN IN SULPHURIC ACID PH 2.1 RESERVOIR SOL: SULPHURIC ACID PH 2.1,0.025 M SODIUM SULPHATE
|
Resolution 1.62 Å R-free 0.207 |
| 1GUJ Insulin at pH 2: structural analysis of the conditions promoting insulin fibre formation. Deposited 2002-01-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 2.1；HANGING DROP VAPOUR DIFFUSION METHOD PROTEIN SOL: 5 MG/ML HUMAN INSULIN IN SULPHURIC ACID PH 2.1 RESERVOIR SOL: SULPHURIC ACID PH 2.1,0.025 M SODIUM SULPHATE
|
Resolution 1.62 Å R-free 0.207 |
| 1HIQ PARADOXICAL STRUCTURE AND FUNCTION IN A MUTANT HUMAN INSULIN ASSOCIATED WITH DIABETES MELLITUS Deposited 1993-03-05 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：F24S | No recorded non-water small molecule | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 1HIS Structure and dynamics of des-pentapeptide-insulin in solution: the molten-globule hypothesis. Deposited 1992-02-28 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–49（25 aa）
|
Not recorded | No recorded non-water small molecule | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 1HIT Receptor binding redefined by a structural switch in a mutant Human Insulin Deposited 1992-02-28 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：F24G | No recorded non-water small molecule | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 1HLS NMR STRUCTURE OF THE HUMAN INSULIN-HIS(B16) Deposited 1995-06-28 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：TYR 16 B HIS Mutation：TYR 16 B HIS | No recorded non-water small molecule | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 1HTV CRYSTAL STRUCTURE OF DESTRIPEPTIDE (B28-B30) INSULIN Deposited 2001-01-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：INSULIN A CHAIN
Chain B
25–51（27 aa）
Fragment：INSULIN B CHAIN
Chain C
90–110（21 aa）
Fragment：INSULIN A CHAIN
Chain D
25–51（27 aa）
Fragment：INSULIN B CHAIN
Chain E
90–110（21 aa）
Fragment：INSULIN A CHAIN
Chain F
25–51（27 aa）
Fragment：INSULIN B CHAIN
Chain G
90–110（21 aa）
Fragment：INSULIN A CHAIN
Chain H
25–51（27 aa）
Fragment：INSULIN B CHAIN
Chain I
90–110（21 aa）
Fragment：INSULIN A CHAIN
Chain J
25–51（27 aa）
Fragment：INSULIN B CHAIN
Chain K
90–110（21 aa）
Fragment：INSULIN A CHAIN
Chain L
25–51（27 aa）
Fragment：INSULIN B CHAIN
|
Not recorded | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；298 K；sodium citrate, dimethylformamide, zinc acetate, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 298.0K
|
Resolution 1.90 Å R-free 0.240 |
| 1HUI INSULIN MUTANT (B1, B10, B16, B27)GLU, DES-B30, NMR, 25 STRUCTURES Deposited 1996-03-29 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
26–53（28 aa）
|
Mutation：CHAIN B, F1E, H10E, Y16E, T27E, DEL(T30) Mutation：CHAIN B, F1E, H10E, Y16E, T27E, DEL(T30) | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.5；307 K
|
Resolution not provided |
| 1IOG INSULIN MUTANT A3 GLY,(B1, B10, B16, B27)GLU, DES-B30, NMR, 19 STRUCTURES Deposited 1998-08-13 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
26–53（28 aa）
|
Mutation：V3G Mutation：F1E, H10E, Y16E, T27E | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.5；307 K
|
Resolution not provided |
| 1IOH INSULIN MUTANT A8 HIS,(B1, B10, B16, B27)GLU, DES-B30, NMR, 26 STRUCTURES Deposited 1998-08-13 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：90-110
Chain B
26–53（28 aa）
Fragment：25-53
|
Mutation：T8H Mutation：F1E, H10E, Y16E, T27E | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.5；307 K
|
Resolution not provided |
| 1J73 Crystal structure of an unstable insulin analog with native activity. Deposited 2001-05-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：T8(DAB) Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：T8(DAB) Non-standard monomer：Yes (specific site not provided by mmCIF) | ZN ZINC ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；298 K；Tris, phonel, acetone, sodium citrate, pH 6.4, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å R-free 0.273 |
| 1JCA Non-standard Design of Unstable Insulin Analogues with Enhanced Activity Deposited 2001-06-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：T8K | ZN ZINC ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；Tris, sodium citrate, acetone, phenol, pH 7.0, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.50 Å R-free 0.241 |
| 1JCA Non-standard Design of Unstable Insulin Analogues with Enhanced Activity Deposited 2001-06-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：T8K | ZN ZINC ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；Tris, sodium citrate, acetone, phenol, pH 7.0, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.50 Å R-free 0.241 |
| 1JCA Non-standard Design of Unstable Insulin Analogues with Enhanced Activity Deposited 2001-06-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：T8K Mutation：T8K | ZN ZINC ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；Tris, sodium citrate, acetone, phenol, pH 7.0, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.50 Å R-free 0.241 |
| 1JCO Solution structure of the monomeric [Thr(B27)->Pro,Pro(B28)->Thr] insulin mutant (PT insulin) Deposited 2001-06-11 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：T27P, P28T | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 3.13；298 K；Pressure 1
NMR sample composition
2.8 mM PT-insulin; 10%D2O; 90%H2O | 10% D2O, 90% H2O
NMR sample composition
2.8 mM PT-insulin; 100% D2O | 100% D2O
NMR sample composition
2.8 mM PT-insulin; 35% Trifluoroethanol; 5% D2O; 60% H2O | 35% Trifluoroethanol; 5% D2O; 60% H2O
NMR sample composition
2.8 mM PT-insulin; 35% Trifluoroethanol; 65% D2O; | 35% Trifluoroethanol; 65% D2O;
|
Resolution not provided |
| 1K3M NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE-A2-ALA, HIS-B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES Deposited 2001-10-03 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：INSULIN A CHAIN (residues 90-110)
Chain B
25–54（30 aa）
Fragment：INSULIN B CHAIN (residues 25-54)
|
Mutation：I2A Mutation：H10D, P28K, K29P | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；298 K；Pressure ambient
NMR measurement conditions
pH 7.6；303 K；Pressure ambient
NMR measurement conditions
pH 1.9；298 K；Pressure ambient
NMR sample composition
1.2 mM AlaA2-DKP-Insulin; 100% D2O; | 100% D2O
NMR sample composition
1.2 mM AlaA2-DKP-Insulin; 90% H2O, 10% D2O; | 90% H2O/10% D2O
NMR sample composition
1.2 mM AlaA2-DKP-Insulin; 20% Deuteroacetic Acid, 80% D2O; | 20% Deuteroacetic Acid, 80% D2O;
|
Resolution not provided |
| 1KMF NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE-A2-ALLO-ILE, HIS-B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES Deposited 2001-12-14 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
87–107（21 aa）
Chain B
25–54（30 aa）
|
Mutation：I2(IIL) Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：H10D, P28K, K29P | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；298 K；Pressure ambient
NMR measurement conditions
pH 7.6；305 K；Pressure ambient
NMR sample composition
1.2 mM Allo-Ile-A2-DKP-insulin; 90% H2O, 10% D2O | 90% H2O/10% D2O
NMR sample composition
1.2 mM Allo-Ile-A2-DKP-insulin; 100% D2O | 100% D2O
|
Resolution not provided |
| 1LKQ NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE-A2-GLY, VAL-A3-GLY, HIS-B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 20 STRUCTURES Deposited 2002-04-25 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：I2G,V3G Mutation：H10D,P28K,K29P | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；298 K；Pressure AMBIENT
NMR sample composition
1.0 MM GLYA2,A3-DKP- INSULIN; 90% H2O/10% D2O;
|
Resolution not provided |
| 1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P | ZN ZINC ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.30 Å |
| 1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P | ZN ZINC ION × 1 IPH PHENOL × 1 CL CHLORIDE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.30 Å |
| 1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P | ZN ZINC ION × 6 IPH PHENOL × 3 CL CHLORIDE ION × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.30 Å |
| 1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P | ZN ZINC ION × 6 IPH PHENOL × 3 CL CHLORIDE ION × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.30 Å |
| 1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P | ZN ZINC ION × 6 IPH PHENOL × 3 CL CHLORIDE ION × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.30 Å |
| 1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P | ZN ZINC ION × 2 IPH PHENOL × 1 CL CHLORIDE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.30 Å |
| 1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 7 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P | ZN ZINC ION × 2 IPH PHENOL × 1 CL CHLORIDE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.30 Å |
| 1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 8 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P | ZN ZINC ION × 3 IPH PHENOL × 3 CL CHLORIDE ION × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.30 Å |
| 1LPH LYS(B28)PRO(B29)-HUMAN INSULIN Deposited 1995-04-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 9 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：CHAIN B, D, P28K, K29P Mutation：CHAIN B, D, P28K, K29P | ZN ZINC ION × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.30 Å |
| 1MHI THREE-DIMENSIONAL SOLUTION STRUCTURE OF AN INSULIN DIMER. A STUDY OF THE B9(ASP) MUTANT OF HUMAN INSULIN USING NUCLEAR MAGNETIC RESONANCE DISTANCE GEOMETRY AND RESTRAINED MOLECULAR DYNAMICS Deposited 1994-11-30 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：S(B 9)D Mutation：S(B 9)D | No recorded non-water small molecule | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 1MHJ SOLUTION STRUCTURE OF THE SUPERACTIVE MONOMERIC DES-[PHE(B25)] HUMAN INSULIN MUTANT. ELUCIDATION OF THE STRUCTURAL BASIS FOR THE MONOMERIZATION OF THE DES-[PHE(B25)] INSULIN AND THE DIMERIZATION OF NATIVE INSULIN Deposited 1994-11-30 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–48（24 aa）
|
Mutation：DES-[PHE(B 25)] Mutation：DES-[PHE(B 25)] | No recorded non-water small molecule | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 1MSO T6 Human Insulin at 1.0 A Resolution Deposited 2002-09-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 6.3；298 K；0.001 M HCl, 0.007 M Zinc Acetate, 0.05 M Sodium Citrate, 17% acetone,
pH 6.3, SLOW COOLING at 298K, temperature 298.0K
|
Resolution 1.00 Å R-free 0.201 |
| 1OS3 Dehydrated T6 human insulin at 100 K Deposited 2003-03-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：A-chain
Chain B
25–54（30 aa）
Fragment：B-chain
Chain C
90–110（21 aa）
Fragment：A-chain
Chain D
25–54（30 aa）
Fragment：B-chain
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 6.3；295 K；hydrochloric acid, zinc acetate, sodium citrate, acetone, pH 6.3, SLOW COOLING, temperature 295.0K
|
Resolution 1.95 Å R-free 0.253 |
| 1OS4 Dehydrated T6 human insulin at 295 K Deposited 2003-03-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：A-chain
Chain B
25–54（30 aa）
Fragment：B-chain
Chain C
90–110（21 aa）
Fragment：A-chain
Chain D
25–54（30 aa）
Fragment：B-chain
Chain E
90–110（21 aa）
Fragment：A-chain
Chain F
25–54（30 aa）
Fragment：B-chain
Chain G
90–110（21 aa）
Fragment：A-chain
Chain H
25–54（30 aa）
Fragment：B-chain
Chain I
90–110（21 aa）
Fragment：A-chain
Chain J
25–54（30 aa）
Fragment：B-chain
Chain K
90–110（21 aa）
Fragment：A-chain
Chain L
25–54（30 aa）
Fragment：B-chain
|
Not recorded | ZN ZINC ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
SLOW COOLING；pH 6.3；295 K；hydrochloric acid, zinc acetate, sodium citrate, acetone, pH 6.3, SLOW COOLING, temperature 295.K
|
Resolution 2.25 Å R-free 0.295 |
| 1QIY HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR COMPLEXED WITH PHENOL Deposited 1999-06-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES | IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.8；CRYSTALLISATION IN BATCH, 10 MG B5 TYR INSULIN DISSOLVED IN 2 ML 0.02M HCL. TO THIS ADDED 0.1 ML 0.12M ZINC ACETATE, 1.5 ML 0.2 M TRI-SODIUM CITRATE, 0.4 ML 2.5% (AQ.) PHENOL AND 120 MG NACL. PH ADJUSTED TO 6.5-7.8 .
|
Resolution 2.30 Å |
| 1QIZ HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR COMPLEXED WITH RESORCINOL Deposited 1999-06-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES | RCO RESORCINOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.8；CRYSTALLISATION IN BATCH, 10 MG B5 TYR INSULIN DISSOLVED IN 2 ML 0.02M HCL. TO THIS ADDED 0.1 ML 0.12M ZINC ACETATE, 1.04 ML 0.2 M TRI-SODIUM CITRATE, 0.4 ML 5.0% (AQ.) PHENOL AND 120 MG NACL. PH ADJUSTED TO 6.5-7.8 .
|
Resolution 2.00 Å |
| 1QJ0 HUMAN INSULIN HEXAMERS WITH CHAIN B HIS MUTATED TO TYR Deposited 1999-06-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：YES Mutation：YES | ZN ZINC ION × 6 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.8；CRYSTALLISATION IN BATCH: 10 MG B5 TYR INSULIN DISSOLVED IN 2 ML 0.02M HCL. TO THIS ADDED 0.05 ML 0.15M ZINC ACETATE, 1.0 ML 0.2 M TRI-SODIUM CITRATE, 1.0 ML ACETONE. PH ADJUSTED TO 6.4-7.1 .
|
Resolution 2.40 Å |
| 1RWE Enhancing the activity of insulin at receptor edge: crystal structure and photo-cross-linking of A8 analogues Deposited 2003-12-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Fragment：insulin A chain
Chain B
25–54（30 aa）
Fragment：insulin B chain
|
Mutation：T8H | ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.8；298 K；Tris, sodium citrate, acetone, phenol, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 298K, pH 6.80
|
Resolution 1.80 Å R-free 0.245 |
| 1RWE Enhancing the activity of insulin at receptor edge: crystal structure and photo-cross-linking of A8 analogues Deposited 2003-12-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Fragment：insulin A chain
Chain D
25–54（30 aa）
Fragment：insulin B chain
|
Mutation：T8H | ZN ZINC ION × 3 CL CHLORIDE ION × 3 IPH PHENOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.8；298 K；Tris, sodium citrate, acetone, phenol, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 298K, pH 6.80
|
Resolution 1.80 Å R-free 0.245 |
| 1RWE Enhancing the activity of insulin at receptor edge: crystal structure and photo-cross-linking of A8 analogues Deposited 2003-12-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：insulin A chain
Chain B
25–54（30 aa）
Fragment：insulin B chain
Chain C
90–110（21 aa）
Fragment：insulin A chain
Chain D
25–54（30 aa）
Fragment：insulin B chain
|
Mutation：T8H Mutation：T8H | ZN ZINC ION × 6 CL CHLORIDE ION × 6 IPH PHENOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.8；298 K；Tris, sodium citrate, acetone, phenol, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 298K, pH 6.80
|
Resolution 1.80 Å R-free 0.245 |
| 1SF1 NMR STRUCTURE OF HUMAN INSULIN under Amyloidogenic Condition, 15 STRUCTURES Deposited 2004-02-19 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 2.4；333 K；Pressure ambient
NMR sample composition
0.5 mM 15N-labeled sample | pH 2.4 and 60C, 90% H2O/10%D2O
|
Resolution not provided |
| 1SJT MINI-PROINSULIN, TWO CHAIN INSULIN ANALOG MUTANT: DES B30, HIS(B 10)ASP, PRO(B 28)ASP, NMR, 20 STRUCTURES Deposited 1997-10-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Mutation：CHAIN B, DEL(A30), H10D, P28D Mutation：CHAIN B, DEL(A30), H10D, P28D | No recorded non-water small molecule | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 1SJU MINI-PROINSULIN, SINGLE CHAIN INSULIN ANALOG MUTANT: DES B30, HIS(B 10)ASP, PRO(B 28)ASP AND PEPTIDE BOND BETWEEN LYS B 29 AND GLY A 1, NMR, 20 STRUCTURES Deposited 1997-10-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–110（86 aa）
|
Mutation：SINGLE CHAIN MUTANT WITH CHAIN B, DEL(A30), H10D, P28D, AND A PEPTIDE BOND BETWEEN LYS B 29 AND GLY A 1 OF THE WILD TYPE | No recorded non-water small molecule | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 1T0C Solution Structure of Human Proinsulin C-Peptide Deposited 2004-04-08 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
57–87（31 aa）
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；283 K；Ionic strength (raw mmCIF value) 0；Pressure ambient
NMR sample composition
3mM C-peptide | 50% H2O / 50% TFE-d2
|
Resolution not provided |
| 1T1K NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS-B10-ASP, VAL-B12-ALA, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES Deposited 2004-04-16 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：INSULIN A CHAIN
Chain B
25–54（30 aa）
Fragment：INSULIN B CHAIN
|
Mutation：HIS-B10-ASP, VAL-B12-ALA, PRO-B28-LYS, LYS-B29-PRO | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；298 K；Ionic strength (raw mmCIF value) null；Pressure ambient
NMR measurement conditions
pH 7.6；305 K；Ionic strength (raw mmCIF value) null；Pressure ambient
NMR measurement conditions
pH 1.9；298 K；Ionic strength (raw mmCIF value) null；Pressure ambient
NMR sample composition
1.2 mM Ala-B12-DKP-insulin, 90% H2O, 10% D2O | 90% H2O/10% D2O
NMR sample composition
1.2 mM Ala-B12-DKP-insulin, 100% D2O | 100% D2O
NMR sample composition
1.2 mM Ala-B12-DKP-insulin, 20% deuterated acetic acid, 80% D2O | 20% deuterated acetic acid, 80% D2O
|
Resolution not provided |
| 1T1P NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS-B10-ASP, VAL-B12-THR, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES Deposited 2004-04-16 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：INSULIN A CHAIN
Chain B
25–54（30 aa）
Fragment：INSULIN B CHAIN
|
Mutation：HIS-B10-ASP, VAL-B12-THR, PRO-B28-LYS, LYS-B29-PRO | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；298 K；Ionic strength (raw mmCIF value) null；Pressure ambient
NMR measurement conditions
pH 7.6；305 K；Ionic strength (raw mmCIF value) null；Pressure ambient
NMR sample composition
1.2 mM Thr-B12-DKP-insulin, 90% H2O, 10% D2O | 90% H2O/10% D2O
NMR sample composition
1.2 mM Thr-B12-DKP-insulin, 100% D2O | 100% D2O
|
Resolution not provided |
| 1T1Q NMR STRUCTURE OF HUMAN INSULIN MUTANT HIS-B10-ASP, VAL-B12-ABA, PRO-B28-LYS, LYS-B29-PRO, 15 STRUCTURES Deposited 2004-04-16 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
1–21（21 aa）
Fragment：INSULIN A CHAIN
Chain B
25–54（30 aa）
Fragment：INSULIN B CHAIN
|
Mutation：HIS-B10-ASP, VAL-B12-ABA, PRO-B28-LYS, LYS-B29-PRO Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；298 K；Pressure ambient
NMR measurement conditions
pH 7.6；305 K；Pressure ambient
NMR sample composition
1.2 mM ABA-B12-DKP-insulin, 90% H2O, 10% D2O | 90% H2O/10% D2O
NMR sample composition
1.2 mM ABA-B12-DKP-insulin,100% D2O | 100% D2O
|
Resolution not provided |
| 1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
31–51（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
|
Resolution 1.60 Å |
| 1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
31–51（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 1 CL CHLORIDE ION × 1 NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
|
Resolution 1.60 Å |
| 1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
31–51（21 aa）
Chain B
25–54（30 aa）
Chain C
31–51（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 NA SODIUM ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
|
Resolution 1.60 Å |
| 1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
31–51（21 aa）
Chain B
25–54（30 aa）
Chain C
31–51（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 NA SODIUM ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
|
Resolution 1.60 Å |
| 1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
31–51（21 aa）
Chain B
25–54（30 aa）
Chain C
31–51（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 NA SODIUM ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
|
Resolution 1.60 Å |
| 1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
31–51（21 aa）
Chain B
25–54（30 aa）
Chain C
31–51（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 2 CL CHLORIDE ION × 2 NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
|
Resolution 1.60 Å |
| 1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 7 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
31–51（21 aa）
Chain B
25–54（30 aa）
Chain C
31–51（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 2 CL CHLORIDE ION × 2 NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
|
Resolution 1.60 Å |
| 1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 8 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
31–51（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 3 CL CHLORIDE ION × 3 NA SODIUM ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
|
Resolution 1.60 Å |
| 1TRZ CRYSTALLOGRAPHIC EVIDENCE FOR DUAL COORDINATION AROUND ZINC IN THE T3R3 HUMAN INSULIN HEXAMER Deposited 1993-11-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 9 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
31–51（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.4；Crystals were grown from 0.05M sodium citrate and 0.007M zinc acetate in the presence of 0.75M sodium chloride at pH6.4
|
Resolution 1.60 Å |
| 1TYL THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å |
| 1TYL THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 1 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 1 CL CHLORIDE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å |
| 1TYL THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 3 CL CHLORIDE ION × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å |
| 1TYL THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 2 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 1 CL CHLORIDE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å |
| 1TYL THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 2 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 1 CL CHLORIDE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å |
| 1TYL THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
|
Not recorded | ZN ZINC ION × 3 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å |
| 1TYL THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 7 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 3 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 3 CL CHLORIDE ION × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å |
| 1TYL THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 8 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å |
| 1TYM THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å |
| 1TYM THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 1 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 1 CL CHLORIDE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å |
| 1TYM THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 3 CL CHLORIDE ION × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å |
| 1TYM THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 2 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 1 CL CHLORIDE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å |
| 1TYM THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 2 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 1 CL CHLORIDE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å |
| 1TYM THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 3 TYL N-(4-HYDROXYPHENYL)ACETAMIDE (TYLENOL) × 3 CL CHLORIDE ION × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å |
| 1TYM THE STRUCTURE OF A COMPLEX OF HEXAMERIC INSULIN AND 4'-HYDROXYACETANILIDE Deposited 1994-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 7 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.90 Å |
| 1UZ9 Crystallographic and solution studies of N-lithocholyl insulin: a new generation of prolonged-acting insulins. Deposited 2004-03-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：INSULIN A CHAIN, RESIDUES 90-110
Chain B
25–53（29 aa）
Fragment：INSULIN B CHAIN, RESIDUES 25-53
|
Not recorded | CRS M-CRESOL × 6 UZ9 (2S)-2-AMINO-6-({(4R)-4-[(10R,13S)-10,13-DIMETHYL-3-OXOHEXADECAHYDRO-1H-CYCLOPENTA[A]PHENANTHREN-17-YL]PENTANOYL}AMINO)HEXANOIC ACID × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；0.5 M TRIS-HCL PH 8.0 0.1M TRI-SODIUM CITRATE, 2MM ZINC ACETATE, 0.05% W/V M-CRESOL
|
Resolution 1.60 Å R-free 0.206 |
| 1VKT HUMAN INSULIN TWO DISULFIDE MODEL, NMR, 10 STRUCTURES Deposited 1996-10-14 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：CHAIN A, C6S, C11S, CHAIN B, H10D, P28K, K29P Mutation：CHAIN A, C6S, C11S, CHAIN B, H10D, P28K, K29P | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 6.8；298 K
|
Resolution not provided |
| 1W8P Structural properties of the B25Tyr-NMe-B26Phe insulin mutant. Deposited 2004-09-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES | IPH PHENOL × 6 ZN ZINC ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；0.1 M TRI-SODIUM CITRATE, 0.02 % W/V ZINC ACETATE, 6 % W/V TRIS/HCL PH 8.2, 0.1 % W/V PHENOL.
|
Resolution 2.08 Å R-free 0.256 |
| 1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Not recorded | IPH PHENOL × 1 ZN ZINC ION × 1 CL CHLORIDE ION × 1 MYR MYRISTIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
|
Resolution 1.80 Å |
| 1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 10 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 MYR MYRISTIC ACID × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
|
Resolution 1.80 Å |
| 1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 11 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain E
90–110（21 aa）
Chain F
25–53（29 aa）
Chain G
90–110（21 aa）
Chain H
25–53（29 aa）
|
Not recorded | IPH PHENOL × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 2 MYR MYRISTIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
|
Resolution 1.80 Å |
| 1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 12 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | IPH PHENOL × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 2 MYR MYRISTIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
|
Resolution 1.80 Å |
| 1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | IPH PHENOL × 1 ZN ZINC ION × 1 CL CHLORIDE ION × 1 MYR MYRISTIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
|
Resolution 1.80 Å |
| 1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain E
90–110（21 aa）
Chain F
25–53（29 aa）
|
Not recorded | IPH PHENOL × 1 ZN ZINC ION × 1 CL CHLORIDE ION × 1 MYR MYRISTIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
|
Resolution 1.80 Å |
| 1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain G
90–110（21 aa）
Chain H
25–53（29 aa）
|
Not recorded | IPH PHENOL × 1 ZN ZINC ION × 1 CL CHLORIDE ION × 1 MYR MYRISTIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
|
Resolution 1.80 Å |
| 1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain E
90–110（21 aa）
Chain F
25–53（29 aa）
Chain G
90–110（21 aa）
Chain H
25–53（29 aa）
|
Not recorded | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
|
Resolution 1.80 Å |
| 1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
|
Resolution 1.80 Å |
| 1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 7 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Not recorded | IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 MYR MYRISTIC ACID × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
|
Resolution 1.80 Å |
| 1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 8 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain E
90–110（21 aa）
Chain F
25–53（29 aa）
|
Not recorded | IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 MYR MYRISTIC ACID × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
|
Resolution 1.80 Å |
| 1XDA STRUCTURE OF INSULIN Deposited 1996-12-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 9 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain G
90–110（21 aa）
Chain H
25–53（29 aa）
|
Not recorded | IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 MYR MYRISTIC ACID × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；HANGING DROP, 0.1M TRI-SODIUM CITRATE, 6% (W/V) TRIS, 0.02% (W/V) ZINC ACETATE, PH 8.2.
|
Resolution 1.80 Å |
| 1XGL HUMAN INSULIN DISULFIDE ISOMER, NMR, 10 STRUCTURES Deposited 1996-10-10 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
31–51（21 aa）
Chain B
1–30（30 aa）
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 1.9；298 K
|
Resolution not provided |
| 1XW7 Diabetes-Associated Mutations in Human Insulin: Crystal Structure and Photo-Cross-Linking Studies of A-Chain Variant Insulin Wakayama Deposited 2004-10-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：V3L | IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.2；290 K；Tris, sodium citrate, acetone, phenol, pH 6.2, VAPOR DIFFUSION, HANGING DROP, temperature 290K, pH 6.20
|
Resolution 2.30 Å R-free 0.269 |
| 1XW7 Diabetes-Associated Mutations in Human Insulin: Crystal Structure and Photo-Cross-Linking Studies of A-Chain Variant Insulin Wakayama Deposited 2004-10-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：V3L | IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.2；290 K；Tris, sodium citrate, acetone, phenol, pH 6.2, VAPOR DIFFUSION, HANGING DROP, temperature 290K, pH 6.20
|
Resolution 2.30 Å R-free 0.269 |
| 1XW7 Diabetes-Associated Mutations in Human Insulin: Crystal Structure and Photo-Cross-Linking Studies of A-Chain Variant Insulin Wakayama Deposited 2004-10-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：V3L Mutation：V3L | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.2；290 K；Tris, sodium citrate, acetone, phenol, pH 6.2, VAPOR DIFFUSION, HANGING DROP, temperature 290K, pH 6.20
|
Resolution 2.30 Å R-free 0.269 |
| 1XW7 Diabetes-Associated Mutations in Human Insulin: Crystal Structure and Photo-Cross-Linking Studies of A-Chain Variant Insulin Wakayama Deposited 2004-10-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：V3L Mutation：V3L | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.2；290 K；Tris, sodium citrate, acetone, phenol, pH 6.2, VAPOR DIFFUSION, HANGING DROP, temperature 290K, pH 6.20
|
Resolution 2.30 Å R-free 0.269 |
| 1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D | IPH PHENOL × 2 ZN ZINC ION × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
|
Resolution 1.60 Å R-free 0.192 |
| 1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D | IPH PHENOL × 1 ZN ZINC ION × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
|
Resolution 1.60 Å R-free 0.192 |
| 1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D | IPH PHENOL × 9 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
|
Resolution 1.60 Å R-free 0.192 |
| 1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D | IPH PHENOL × 3 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
|
Resolution 1.60 Å R-free 0.192 |
| 1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D | IPH PHENOL × 3 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
|
Resolution 1.60 Å R-free 0.192 |
| 1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric |
Chain A
90–110（21 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D | IPH PHENOL × 6 ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
|
Resolution 1.60 Å R-free 0.192 |
| 1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 7 Protein homooligomer Homooligomer；Protein × 9 PDB declaration: nonameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
|
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D | IPH PHENOL × 9 ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
|
Resolution 1.60 Å R-free 0.192 |
| 1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 8 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D | IPH PHENOL × 6 ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
|
Resolution 1.60 Å R-free 0.192 |
| 1ZEG STRUCTURE OF B28 ASP INSULIN IN COMPLEX WITH PHENOL Deposited 1998-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 9 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D | IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 6.5；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) PHENOL IN ETHANOL + 60 MG NACL, pH 6.5, batch method
|
Resolution 1.60 Å R-free 0.192 |
| 1ZEH STRUCTURE OF INSULIN Deposited 1998-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
31–51（21 aa）
Chain B
25–54（30 aa）
|
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D | CRS M-CRESOL × 1 ZN ZINC ION × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 6.8；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) M-CRESOL IN ETHANOL + 60 MG NACL, pH 6.8, batch method
|
Resolution 1.50 Å R-free 0.193 |
| 1ZEH STRUCTURE OF INSULIN Deposited 1998-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
31–51（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D | CRS M-CRESOL × 4 ZN ZINC ION × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 6.8；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) M-CRESOL IN ETHANOL + 60 MG NACL, pH 6.8, batch method
|
Resolution 1.50 Å R-free 0.193 |
| 1ZEH STRUCTURE OF INSULIN Deposited 1998-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
31–51（21 aa）
Chain B
25–54（30 aa）
Chain C
31–51（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D | CRS M-CRESOL × 15 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 6.8；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) M-CRESOL IN ETHANOL + 60 MG NACL, pH 6.8, batch method
|
Resolution 1.50 Å R-free 0.193 |
| 1ZEH STRUCTURE OF INSULIN Deposited 1998-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
31–51（21 aa）
Chain B
25–54（30 aa）
Chain C
31–51（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D | CRS M-CRESOL × 5 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 6.8；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) M-CRESOL IN ETHANOL + 60 MG NACL, pH 6.8, batch method
|
Resolution 1.50 Å R-free 0.193 |
| 1ZEH STRUCTURE OF INSULIN Deposited 1998-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
31–51（21 aa）
Chain B
25–54（30 aa）
Chain C
31–51（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D | CRS M-CRESOL × 5 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 6.8；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) M-CRESOL IN ETHANOL + 60 MG NACL, pH 6.8, batch method
|
Resolution 1.50 Å R-free 0.193 |
| 1ZEH STRUCTURE OF INSULIN Deposited 1998-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
31–51（21 aa）
Chain B
25–54（30 aa）
|
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D | CRS M-CRESOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 6.8；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) M-CRESOL IN ETHANOL + 60 MG NACL, pH 6.8, batch method
|
Resolution 1.50 Å R-free 0.193 |
| 1ZEH STRUCTURE OF INSULIN Deposited 1998-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 7 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
31–51（21 aa）
Chain D
25–54（30 aa）
|
Mutation：CHAIN B, D, P28D Mutation：CHAIN B, D, P28D | CRS M-CRESOL × 12 ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 6.8；BATCH METHOD, COMPOSITION OF CRYSTALLISATION SOLUTION 3.5 MG INSULIN + 0.5 ML 0.02M HCL + 0.05 ML 0.12M ZINC ACETATE + 0.25 ML 0.2M TRI-SODIUM CITRATE + 0.2 ML 2.5% (W/V) M-CRESOL IN ETHANOL + 60 MG NACL, pH 6.8, batch method
|
Resolution 1.50 Å R-free 0.193 |
| 1ZNJ INSULIN, MONOCLINIC CRYSTAL FORM Deposited 1997-09-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | IPH PHENOL × 7 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
batch method；pH 7.44；BATCH, 1.7MG/ML INSULIN, 0.02 ZINC ACETATE, 0.7% (V/V) PHENOL, 0.34M SODIUM CHLORIDE, pH 7.44, batch method
|
Resolution 2.00 Å |
| 25HF SFX crystal structure of insulin aspart Deposited 2026-04-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | CRS M-CRESOL × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.2 M sodium acetate trihydrate, pH 8.5, 0.1 M Tris-HCl.
|
Resolution 2.20 Å R-free 0.289 |
| 25HL SFX crystal structure of insulin detemir Deposited 2026-04-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | IPH PHENOL × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 2 MYR MYRISTIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.2 M sodium acetate trihydrate, pH 8.5, 0.1 M Tris-HCl
|
Resolution 2.85 Å R-free 0.285 |
| 25HL SFX crystal structure of insulin detemir Deposited 2026-04-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain E
90–110（21 aa）
Chain F
25–53（29 aa）
Chain G
90–110（21 aa）
Chain H
25–53（29 aa）
|
Not recorded | IPH PHENOL × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 2 MYR MYRISTIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.2 M sodium acetate trihydrate, pH 8.5, 0.1 M Tris-HCl
|
Resolution 2.85 Å R-free 0.285 |
| 2AIY R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 20 STRUCTURES Deposited 1998-12-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain B
25–54（30 aa）
Fragment：BETA CHAIN
Chain C
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain D
25–54（30 aa）
Fragment：BETA CHAIN
Chain E
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain F
25–54（30 aa）
Fragment：BETA CHAIN
Chain G
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain H
25–54（30 aa）
Fragment：BETA CHAIN
Chain I
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain J
25–54（30 aa）
Fragment：BETA CHAIN
Chain K
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain L
25–54（30 aa）
Fragment：BETA CHAIN
|
Not recorded | IPH PHENOL × 6 |
SOLUTION NMR
NMR measurement conditions
pH 8；310 K；Pressure 1
NMR sample composition
H2O AND D2O
|
Resolution not provided |
| 2C8Q insuline(1sec) and UV laser excited fluorescence Deposited 2005-12-06 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 9；pH 9.00
|
Resolution 1.95 Å R-free 0.230 |
| 2C8R insuline(60sec) and UV laser excited fluorescence Deposited 2005-12-06 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 9；pH 9.00
|
Resolution 1.50 Å R-free 0.224 |
| 2CEU Despentapeptide insulin in acetic acid (pH 2) Deposited 2006-02-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–49（25 aa）
Chain C
90–110（21 aa）
Chain D
25–49（25 aa）
|
Not recorded | SO4 SULFATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 2；20 % ACETIC ACID, 0.05 M SODIUM SULPHATE, PH 2
|
Resolution 1.80 Å R-free 0.211 |
| 2G54 Crystal structure of Zn-bound human insulin-degrading enzyme in complex with insulin B chain Deposited 2006-02-22 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
25–54（30 aa）
Fragment：Insulin B chain, residues 25-54
|
Not recorded | ZN ZINC ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；PEGMME5000, dioxane, HEPES buffer, tacismate, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.25 Å R-free 0.233 |
| 2G54 Crystal structure of Zn-bound human insulin-degrading enzyme in complex with insulin B chain Deposited 2006-02-22 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
25–54（30 aa）
Fragment：Insulin B chain, residues 25-54
|
Not recorded | ZN ZINC ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；PEGMME5000, dioxane, HEPES buffer, tacismate, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.25 Å R-free 0.233 |
| 2G56 crystal structure of human insulin-degrading enzyme in complex with insulin B chain Deposited 2006-02-22 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
25–54（30 aa）
Fragment：Insulin B chain, residues 25-54
|
Not recorded | DIO 1,4-DIETHYLENE DIOXIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；PEGMME5000, dioxane, tacismate, hepes, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.20 Å R-free 0.225 |
| 2G56 crystal structure of human insulin-degrading enzyme in complex with insulin B chain Deposited 2006-02-22 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
25–54（30 aa）
Fragment：Insulin B chain, residues 25-54
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；PEGMME5000, dioxane, tacismate, hepes, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.20 Å R-free 0.225 |
| 2H67 NMR structure of human insulin mutant HIS-B5-ALA, HIS-B10-ASP PRO-B28-LYS, LYS-B29-PRO, 20 structures Deposited 2006-05-30 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：H29A,H34D,P52K, K53P | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；298 K
NMR measurement conditions
pH 8；305 K
NMR measurement conditions
pH 2；298 K；Ionic strength (raw mmCIF value) 20% acetic acid
|
Resolution not provided |
| 2HHO NMR structure of human insulin mutant GLY-B8-SER, HIS-B10-ASP PRO-B28-LYS, LYS-B29-PRO, 20 structures Deposited 2006-06-28 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：G8S, H10D, P28K, K29P | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；298 K
|
Resolution not provided |
| 2HIU NMR STRUCTURE OF HUMAN INSULIN IN 20% ACETIC ACID, ZINC-FREE, 10 STRUCTURES Deposited 1996-10-08 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 1.9；298 K
|
Resolution not provided |
| 2JMN NMR structure of human insulin mutant His-B10-Asp, Pro-B28-Lys, Lys-B29-Pro, 20 structures Deposited 2006-11-21 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：H10D, P28K, K29P | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；298 K
NMR sample composition
0.7 mM INSULIN, 90% H2O, 10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2JUM ThrA3-DKP-insulin Deposited 2007-08-31 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：V3T Mutation：H10D,P28K,K29P | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；308 K；Pressure ambient
NMR measurement conditions
pH 7；308 K；Pressure ambient
NMR measurement conditions
pH 8；315 K；Pressure ambient
NMR measurement conditions
pH 1.9；308 K；Pressure ambient
NMR measurement conditions
pH 1.9；308 K；Pressure ambient
NMR sample composition
1 mM ThrA3-DKP-insulin, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1 mM ThrA3-DKP-insulin, 100% D2O | 100% D2O
NMR sample composition
1 mM ThrA3-DKP-insulin, 100% D2O | 100% D2O
NMR sample composition
1 mM ThrA3-DKP-insulin, 3.1 M D-acetic acid, 20% D-acetic acid/80% H2O | 20% D-acetic acid/80% H2O
NMR sample composition
1 mM ThrA3-DKP-insulin, 3.1 M D-acetic acid, 20%D-acetic acid/80% D2O | 20%D-acetic acid/80% D2O
|
Resolution not provided |
| 2JUU allo-ThrA3 DKP-insulin Deposited 2007-09-03 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：V3T Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：H10D,P28K,K29P | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；308 K；Pressure ambient
NMR measurement conditions
pH 8；315 K；Pressure ambient
NMR measurement conditions
pH 1.9；308 K；Pressure ambient
NMR sample composition
1 mM allo-ThrA3 DKP-insulin, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1 mM allo-ThrA3-DKP-insulin, 100% D2O | 100% D2O
NMR sample composition
1 mM allo-ThrA3 DKP-insulin, 100% D2O | 100% D2O
NMR sample composition
1 mM allo-ThrA3 DKP-insulin, 3.1 M D-acetic acid, 20% D-acetic acid/80% H2O | 20% D-acetic acid/80% H2O
NMR sample composition
1 mM ThrA3-DKP-insulin, 3.1 M D-acetic acid, 20%D-acetic acid/80% D2O | 20%D-acetic acid/80% D2O
|
Resolution not provided |
| 2JUV AbaA3-DKP-insulin Deposited 2007-09-05 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：V3T Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：H10D,P28K,K29P | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；308 K；Pressure ambient
NMR measurement conditions
pH 8；315 K；Pressure ambient
NMR measurement conditions
pH 1.9；308 K；Pressure ambient
NMR sample composition
1 mM AbaA3-DKP-insulin, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
1 mM AbaA3-DKP-insulin, 100% D2O | 100% D2O
NMR sample composition
1 mM AbaA3-DKP-insulin, 100% D2O | 100% D2O
NMR sample composition
1 mM AbaA3-DKP-insulin, 20% D-acetic acid/80% H2O | 20% D-acetic acid/80% H2O
NMR sample composition
1 mM AbaA3-DKP-insulin, 20%D-acetic acid/80% D2O | 20%D-acetic acid/80% D2O
|
Resolution not provided |
| 2JV1 NMR structure of human insulin monomer in 35% CD3CN zinc free, 50 structures Deposited 2007-09-11 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：Insulin A chain: Residues 90-110
Chain B
25–54（30 aa）
Fragment：Insulin B chain: Residues 25-54
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 3.6；303 K；Ionic strength (raw mmCIF value) None；Pressure ambient
NMR sample composition
2.0 mM Insulin_chain_A, 2.0 mM Insulin_chain_B, 35% CD3CN/ 65%H2O | 35% CD3CN/ 65%H2O
|
Resolution not provided |
| 2JZQ Design of an Active Ultra-Stable Single-Chain Insulin Analog 20 Structures Deposited 2008-01-11 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–54（30 aa）
Chain A
90–110（21 aa）
|
Mutation：H34D, P52D, K53P, T97H Mutation：H34D, P52D, K53P, T97H | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 8；305 K；Pressure ambient
NMR sample composition
0.5-0.8 mM protein, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2K91 Enhancing the activity of insulin by stereospecific unfolding Deposited 2008-09-29 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
|
Mutation：H10D, F24A, P28K, K29P | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7.4；298 K；Pressure AMBIENT
NMR sample composition
0.5-0.8 MM PROTEIN, 90% H2O/ 10% D2O AND 20% ACETIC ACID
|
Resolution not provided |
| 2K9R Enhancing the activity of insulin by stereospecific unfolding Deposited 2008-10-23 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：Insulin A chain
Chain B
25–54（30 aa）
Fragment：Insulin B chain
|
Mutation：H10D, F24A, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7.4；298 K；Ionic strength (raw mmCIF value) 0；Pressure AMBIENT
NMR sample composition
0.5-0.8 mM INSULIN A CHAIN, 0.5-0.8 mM INSULIN B CHAIN, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2KJJ Dynamics of insulin probed by 1H-NMR amide proton exchange anomalous flexibility of the receptor-binding surface Deposited 2009-05-29 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：Insulin A chain, UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：Insulin B chain, UNP residues 25-54
|
Mutation：P28K,K29P | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7.4；298 K；Ionic strength (raw mmCIF value) 0.1；Pressure AMBIENT
NMR sample composition
0.5 mM INSULIN A CHAIN-1, 0.5 mM INSULIN B CHAIN-2, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2KJU NMR structure of human insulin mutant glu-b21-d-glu, his-b10 asp pro-b28-lys, lys-b29-pro, 20 structures Deposited 2009-06-10 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：Insulin A chain, residues 90-110
Chain B
25–54（30 aa）
Fragment：Insulin B chain, residues 25-54
|
Mutation：HIS10ASP, GLU21DGL, PRO28LYS, LYS29PRO Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；298 K；Ionic strength (raw mmCIF value) 0.1；Pressure 1
NMR measurement conditions
pH 2；298 K；Ionic strength (raw mmCIF value) 0.1；Pressure 1
NMR measurement conditions
pH 7.6；305 K；Ionic strength (raw mmCIF value) 0.1；Pressure 1
NMR sample composition
0.5 mM INSULIN A CHAIN, 0.5 mM INSULIN B CHAIN, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2KQP NMR Structure of Proinsulin Deposited 2009-11-12 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–110（86 aa）
|
Mutation：H10D, P28K, K29P | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7.1；298 K；Pressure ambient
NMR sample composition
0.3 mM [U-100% 13C; U-100% 15N] proinsulin-1, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2KQQ NMR structure of human insulin mutant gly-b8-d-ala, his-b10-asp, pro-b28-lys, lys-b29-pro, 20 structures Deposited 2009-11-13 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：G8Dal, H10D, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；298 K；Ionic strength (raw mmCIF value) 0；Pressure AMBIENT
NMR sample composition
0.5-0.8 mM entity_1-1, 0.5-0.8 mM entity_2-2, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2KXK Human Insulin Mutant A22Gly-B31Lys-B32Arg Deposited 2010-05-07 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：R31K | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 3.5；298 K；Ionic strength (raw mmCIF value) 0；Pressure ambient
NMR sample composition
2.5 mM protein_1 and protein_2-1, 65% H2O / 35% CD3CN | 65% H2O / 35% CD3CN
NMR sample composition
2.5 mM protein_1 and protein_2-2, 65% D2O / 35% CD3CN | 65% D2O / 35% CD3CN
|
Resolution not provided |
| 2L1Y NMR Structure of human insulin mutant GLY-B20-D-ALA, GLY-B23-D-ALA PRO-B28-LYS, LYS-B29-PRO, 20 Structures Deposited 2010-08-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：UNP rsidues 90-110
Chain B
25–54（30 aa）
Fragment：UNP rsidues 25-54
|
Mutation：P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；298 K
NMR sample composition
0.5 mM entity_1-1, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2L1Z NMR Structure of human insulin mutant GLY-B20-D-ALA, GLY-B23-D-ALA PRO-B28-LYS, LYS-B29-PRO, 20 Structures Deposited 2010-08-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：P28K, K29P | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；298 K
NMR sample composition
0.5 mM entity_1-1, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2LGB Modified A22Gly-B31Arg Human Insulin Deposited 2011-07-25 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–55（31 aa）
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 3.5；298 K；Ionic strength (raw mmCIF value) 0；Pressure ambient
NMR sample composition
3.0 - 2.0 mM Insulin A chain, 3.0 - 2.0 mM Insulin B chain, 65% H2O / 35% CD3CN | 65% H2O / 35% CD3CN
NMR sample composition
3.0 - 2.0 mM Insulin A chain, 3.0 - 2.0 mM Insulin B chain, 65% D2O / 35% CD3CN | 65% D2O / 35% CD3CN
|
Resolution not provided |
| 2LWZ NMR Structures of Single-chain Insulin Deposited 2012-08-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–54（30 aa）
Chain A
89–110（22 aa）
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；298 K；Ionic strength (raw mmCIF value) 0.1；Pressure ambient
NMR sample composition
0.9 mM [U-100% 13C; U-100% 15N] insulin, 93% H2O/7% D2O | 93% H2O/7% D2O
|
Resolution not provided |
| 2M1D Biosynthetic engineered B28K-B29P human insulin monomer structure in in water/acetonitrile solutions. Deposited 2012-11-26 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：P28K, K29P | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 2.5；298 K；Ionic strength (raw mmCIF value) 1；Pressure ambient
NMR sample composition
2.5 - 3.0 mM insulin, residues 90-110, 2.5 - 3.0 mM insulin, residues 25-54, 73 % H2O, 27 % CD3CN, H2O / CD3CN | H2O / CD3CN
NMR sample composition
2.5 - 3.0 mM insulin, residues 90-110, 2.5 - 3.0 mM insulin, residues 25-54, 73 % D2O-7, 27 % CD3CN-8, D2O / CD3CN | D2O / CD3CN
|
Resolution not provided |
| 2M1E Biosynthetic engineered B28K-B29P human insulin monomer structure in in water solutions. Deposited 2012-11-26 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：P28K, K29P | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 2.5；298 K；Ionic strength (raw mmCIF value) 1；Pressure ambient
NMR sample composition
2.5 - 3.0 mM insulin, residues 90-110, 2.5 - 3.0 mM insulin, residues 25-54, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
2.5 - 3.0 mM insulin, residues 90-110, 2.5 - 3.0 mM insulin, residues 25-54, 100% D2O | 100% D2O
|
Resolution not provided |
| 2M2M Structure of [L-HisB24] insulin analogue at pH 1.9 Deposited 2012-12-28 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：F24H | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 1.9；298 K；Pressure ambient
NMR sample composition
0.250 mM protein_1, 20% [U-99% 2H] acetic acid, 0.250 mM protein_2, 95% H2O/5% D2O | 95% H2O/5% D2O
|
Resolution not provided |
| 2M2N Structure of [L-HisB24] insulin analogue at pH 8.0 Deposited 2012-12-29 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：F24H | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 8；298 K；Ionic strength (raw mmCIF value) 0.025；Pressure ambient
NMR sample composition
0.250 mM chain_A, 0.250 mM chain_B, 25 mM [U-99% 2H] TRIS, 95% H2O/5% D2O | 95% H2O/5% D2O
|
Resolution not provided |
| 2M2O Structure of [D-HisB24] insulin analogue at pH 1.9 Deposited 2012-12-29 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Fragment：F24(D-HIS)
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 1.9；298 K；Pressure ambient
NMR sample composition
0.250 mM chain_A, 0.250 mM chain_B, 20% [U-2H] acetic acid, 95% H2O/5% D2O
|
Resolution not provided |
| 2M2P Structure of [D-HisB24] insulin analogue at pH 8.0 Deposited 2012-12-29 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：F24(D-HIS) Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 8；298 K；Ionic strength (raw mmCIF value) 0.025；Pressure ambient
NMR sample composition
0.250 mM chain_A, 0.250 mM chain_B, 25 mM [U-2H] TRIS, 95% H2O/5% D2O
|
Resolution not provided |
| 2MLI NMR structure of B25-(alpha, beta)-dehydro-phenylalanine insulin Deposited 2014-02-27 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：A chain (UNP residues 90-110)
Chain B
25–54（30 aa）
Fragment：B chain (UNP residues 25-54)
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；298 K；Ionic strength (raw mmCIF value) 0.01；Pressure ambient
NMR measurement conditions
pH 7；298 K；Ionic strength (raw mmCIF value) 0.01
NMR sample composition
0.5 mM [U-13C; U-15N] insulin, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
0.5 mM insulin, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2MPG Solution structure of the [AibB8,LysB28,ProB29]-insulin analogue Deposited 2014-05-17 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：G32X,P52K,K53P Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 1.9；298 K；Pressure ambient
NMR sample composition
0.3 mM protein_1, 20 % [U-2H] acetic acid, 95% H2O/5% D2O | 95% H2O/5% D2O
|
Resolution not provided |
| 2MPI Solution structure of B24G insulin Deposited 2014-05-19 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：K53P P52K F48G H34D | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 8；305 K；Ionic strength (raw mmCIF value) 0.5；Pressure ambient
NMR sample composition
0.3 mM protein, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
0.3 mM protein, 100% D2O | 100% D2O
|
Resolution not provided |
| 2MVC Solution structure of human insulin at pH 1.9 Deposited 2014-10-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 1.9；298 K；Pressure ambient
NMR sample composition
4 mM protein_1, 4 mM protein_2, 20 % [U-99% 2H] acetic acid, 5 % [U-99% 2H] D2O, 95% H2O/5% D2O | 95% H2O/5% D2O
|
Resolution not provided |
| 2MVD Solution structure of [GlnB22]-insulin mutant at pH 1.9 Deposited 2014-10-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
|
Mutation：R46Q | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 1.9；298 K；Pressure ambient
NMR sample composition
0.2 mM protein_1, 0.2 mM protein_2, 20 % [U-99% 2H] acetic acid, 5 % [U-99% 2H] D2O, 95% H2O/5% D2O | 95% H2O/5% D2O
|
Resolution not provided |
| 2N2V Solution structure of [B26-B29 triazole cross-linked]-insulin analogue at pH 1.9 Deposited 2015-05-15 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：Y26(NVA), K29(HIX) Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 1.9；298 K；Pressure ambient
NMR sample composition
1.5 mM chain_A, 1.5 mM chain_B, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2N2W Solution structure of [B26-B29 triazole cross-linked]-insulin analogue at pH 8.0 Deposited 2015-05-15 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：Y26(NVA), K29(HIX) Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 8；298 K；Pressure ambient
NMR sample composition
1.5 mM chain_A, 1.5 mM chain_B, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2N2X Solution structure of [GlyB24,B27-B29 triazole cross-linked]-insulin analogue at pH 1.9 Deposited 2015-05-15 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：Y26(NVA), K29(HIX) Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 1.9；298 K；Pressure ambient
NMR sample composition
1.5 mM chain_A, 1.5 mM chain_B, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2OLY Structure of human insulin in presence of urea at pH 7.0 Deposited 2007-01-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | RCO RESORCINOL × 8 URE UREA × 7 ZN ZINC ION × 2 CL CHLORIDE ION × 5 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；2.5M NaCl, 4M urea, 100mM phosphate buffer, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.70 Å R-free 0.221 |
| 2OLZ Structure of human insulin in presence of thiocyanate at pH 7.0 Deposited 2007-01-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | RCO RESORCINOL × 6 ZN ZINC ION × 2 SCN THIOCYANATE ION × 2 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；15mM Na-SCN, 5%(v/v) ethanol, 200mM phosphate buffer pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.70 Å R-free 0.221 |
| 2OM0 Structure of human insulin in presence of urea at pH 6.5 Deposited 2007-01-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | RCO RESORCINOL × 6 URE UREA × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；2M NaCl, 3M urea, 100mM phosphate buffer, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.05 Å R-free 0.227 |
| 2OM0 Structure of human insulin in presence of urea at pH 6.5 Deposited 2007-01-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain 1
90–110（21 aa）
Chain 2
25–54（30 aa）
Chain 3
90–110（21 aa）
Chain 4
25–54（30 aa）
Chain Q
90–110（21 aa）
Chain R
25–54（30 aa）
Chain S
90–110（21 aa）
Chain T
25–54（30 aa）
Chain U
90–110（21 aa）
Chain V
25–54（30 aa）
Chain X
90–110（21 aa）
Chain Y
25–54（30 aa）
|
Not recorded | RCO RESORCINOL × 6 URE UREA × 4 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；2M NaCl, 3M urea, 100mM phosphate buffer, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.05 Å R-free 0.227 |
| 2OM0 Structure of human insulin in presence of urea at pH 6.5 Deposited 2007-01-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain a
90–110（21 aa）
Chain b
25–54（30 aa）
Chain c
90–110（21 aa）
Chain d
25–54（30 aa）
Chain e
90–110（21 aa）
Chain f
25–54（30 aa）
Chain g
90–110（21 aa）
Chain h
25–54（30 aa）
Chain i
90–110（21 aa）
Chain j
25–54（30 aa）
Chain k
90–110（21 aa）
Chain l
25–54（30 aa）
|
Not recorded | RCO RESORCINOL × 6 URE UREA × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；2M NaCl, 3M urea, 100mM phosphate buffer, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.05 Å R-free 0.227 |
| 2OM1 Structure of human insulin in presence of thiocyanate at pH 6.5 Deposited 2007-01-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | RCO RESORCINOL × 6 ZN ZINC ION × 2 SCN THIOCYANATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；15mM Na-SCN, 5%(v/v) ethanol, 200mM phosphate buffer, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.97 Å R-free 0.212 |
| 2OM1 Structure of human insulin in presence of thiocyanate at pH 6.5 Deposited 2007-01-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain 1
90–110（21 aa）
Chain 2
25–54（30 aa）
Chain 3
90–110（21 aa）
Chain 4
25–54（30 aa）
Chain Q
90–110（21 aa）
Chain R
25–54（30 aa）
Chain S
90–110（21 aa）
Chain T
25–54（30 aa）
Chain U
90–110（21 aa）
Chain V
25–54（30 aa）
Chain X
90–110（21 aa）
Chain Y
25–54（30 aa）
|
Not recorded | RCO RESORCINOL × 6 ZN ZINC ION × 2 SCN THIOCYANATE ION × 2 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；15mM Na-SCN, 5%(v/v) ethanol, 200mM phosphate buffer, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.97 Å R-free 0.212 |
| 2OM1 Structure of human insulin in presence of thiocyanate at pH 6.5 Deposited 2007-01-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain a
90–110（21 aa）
Chain b
25–54（30 aa）
Chain c
90–110（21 aa）
Chain d
25–54（30 aa）
Chain e
90–110（21 aa）
Chain f
25–54（30 aa）
Chain g
90–110（21 aa）
Chain h
25–54（30 aa）
Chain i
90–110（21 aa）
Chain j
25–54（30 aa）
Chain k
90–110（21 aa）
Chain l
25–54（30 aa）
|
Not recorded | RCO RESORCINOL × 6 ZN ZINC ION × 2 SCN THIOCYANATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291 K；15mM Na-SCN, 5%(v/v) ethanol, 200mM phosphate buffer, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.97 Å R-free 0.212 |
| 2OMG Structure of human insulin cocrystallized with protamine and urea Deposited 2007-01-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | NA SODIUM ION × 2 CRS M-CRESOL × 6 URE UREA × 12 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.3；291 K；60mM m-cresol, 3M urea, 1.0 mg/ml protamine sulphate, 400mM NaCl, 40mM phosphate buffer, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.52 Å R-free 0.209 |
| 2OMH Structure of human insulin cocrystallized with ARG-12 peptide in presence of urea Deposited 2007-01-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
|
Not recorded | NA SODIUM ION × 2 RCO RESORCINOL × 6 URE UREA × 8 ZN ZINC ION × 2 CL CHLORIDE ION × 2 ARF FORMAMIDE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.3；291 K；500mM NaCl, 2.5M urea, 1.2mg/ml ARG-12 peptide, 50mM resorcinol, 50mM phosphate buffer, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.36 Å R-free 0.223 |
| 2OMH Structure of human insulin cocrystallized with ARG-12 peptide in presence of urea Deposited 2007-01-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
|
Not recorded | NA SODIUM ION × 2 RCO RESORCINOL × 6 URE UREA × 8 ZN ZINC ION × 2 CL CHLORIDE ION × 2 ARF FORMAMIDE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.3；291 K；500mM NaCl, 2.5M urea, 1.2mg/ml ARG-12 peptide, 50mM resorcinol, 50mM phosphate buffer, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.36 Å R-free 0.223 |
| 2OMI Structure of human insulin cocrystallized with protamine Deposited 2007-01-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | RCO RESORCINOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.3；291 K；50mM resorcinol, 400mM NaCl, 1.0mg/ml protamine 30mM phosphate buffer, pH 7.3, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.24 Å R-free 0.268 |
| 2QIU Structure of Human Arg-Insulin Deposited 2007-07-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
89–110（22 aa）
Fragment：Insulin A chain
Chain B
25–54（30 aa）
Fragment：Insulin B chain
Chain C
89–110（22 aa）
Fragment：Insulin A chain
Chain D
25–54（30 aa）
Fragment：Insulin B chain
|
Not recorded | ZN ZINC ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.7；293 K；Sodium Citrate, Acetone, Zinc Sulphate, pH 6.7, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å R-free 0.249 |
| 2R34 Crystal structure of MN human arg-insulin Deposited 2007-08-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
89–110（22 aa）
Fragment：Insulin A chain
Chain B
25–54（30 aa）
Fragment：Insulin B chain
Chain C
89–110（22 aa）
Fragment：Insulin A chain
Chain D
25–54（30 aa）
Fragment：Insulin B chain
|
Not recorded | MN MANGANESE (II) ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.7；293 K；Sodium Citrate, Ammonium Sulphate, Magnesium Chloride, pH 6.7, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.25 Å R-free 0.264 |
| 2R35 Crystal structure of RB human arg-insulin Deposited 2007-08-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
89–110（22 aa）
Fragment：Insulin A chain
Chain B
25–54（30 aa）
Fragment：Insulin B chain
Chain C
89–110（22 aa）
Fragment：Insulin A chain
Chain D
25–54（30 aa）
Fragment：Insulin B chain
|
Not recorded | NA SODIUM ION × 3 RB RUBIDIUM ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.7；293 K；Sodium Citrate, Acetone, Rubidium Chloride, pH 6.7, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.08 Å R-free 0.298 |
| 2R36 Crystal structure of ni human ARG-insulin Deposited 2007-08-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
89–110（22 aa）
Fragment：Insulin A chain
Chain B
25–54（30 aa）
Fragment：Insulin B chain
Chain C
89–110（22 aa）
Fragment：Insulin A chain
Chain D
25–54（30 aa）
Fragment：Insulin B chain
|
Not recorded | NI NICKEL (II) ION × 12 NA SODIUM ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.7；293 K；Sodium Citrate, Ammonium Sulphate, Nickel Chloride, pH 6.7, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å R-free 0.255 |
| 2RN5 Humal Insulin Mutant B31Lys-B32Arg Deposited 2007-12-06 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 3.6；300 K；Pressure ambient
NMR sample composition
2.0mM Insulin (chain A), 2.0mM Insulin (chain B), 35% CD3CN, 65% D2O, CD3CN/D2O | CD3CN/D2O
NMR sample composition
2.0mM Insulin (chain A), 2.0mM Insulin (chain B), 35% CD3CN, 65% H2O, CD3CN/H2O | CD3CN/H2O
|
Resolution not provided |
| 2VJZ Crystal structure form ultalente insulin microcrystals Deposited 2007-12-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：RESIDUES 90-110
Chain B
25–54（30 aa）
Fragment：RESIDUES 25-54
Chain C
90–110（21 aa）
Fragment：RESIDUES 90-110
Chain D
25–54（30 aa）
Fragment：RESIDUES 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 12 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 1.80 Å R-free 0.239 |
| 2VK0 Crystal structure form ultalente insulin microcrystals Deposited 2007-12-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：RESIDUES 90-110
Chain B
25–54（30 aa）
Fragment：RESIDUES 25-54
Chain C
90–110（21 aa）
Fragment：RESIDUES 90-110
Chain D
25–54（30 aa）
Fragment：RESIDUES 25-54
|
Not recorded | ZN ZINC ION × 12 MPB 4-HYDROXY-BENZOIC ACID METHYL ESTER × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5；pH 5.5
|
Resolution 2.20 Å R-free 0.282 |
| 2WBY Crystal structure of human insulin-degrading enzyme in complex with insulin Deposited 2009-03-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain C
90–109（20 aa）
Fragment：RESIDUES 90-109
Chain D
25–43（19 aa）
Fragment：RESIDUES 25-43
|
Not recorded | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE
|
Resolution 2.60 Å R-free 0.218 |
| 2WBY Crystal structure of human insulin-degrading enzyme in complex with insulin Deposited 2009-03-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain E
90–109（20 aa）
Fragment：RESIDUES 90-109
Chain F
25–43（19 aa）
Fragment：RESIDUES 25-43
|
Not recorded | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；10-13% PEG MME 5000, 100 MM HEPES PH 7.0, 4-14% TACSIMATE, 10% DIOXANE
|
Resolution 2.60 Å R-free 0.218 |
| 2WC0 crystal structure of human insulin degrading enzyme in complex with iodinated insulin Deposited 2009-03-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain C
90–110（21 aa）
Fragment：RESIDUES 90-110
Chain D
25–54（30 aa）
Fragment：RESIDUES 25-54
|
Not recorded | ZN ZINC ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7
|
Resolution 2.80 Å R-free 0.220 |
| 2WC0 crystal structure of human insulin degrading enzyme in complex with iodinated insulin Deposited 2009-03-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain E
90–110（21 aa）
Fragment：RESIDUES 90-110
Chain F
25–54（30 aa）
Fragment：RESIDUES 25-54
|
Not recorded | ZN ZINC ION × 1 DIO 1,4-DIETHYLENE DIOXIDE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7
|
Resolution 2.80 Å R-free 0.220 |
| 2WRU Semi-synthetic highly active analogue of human insulin NMeAlaB26-DTI- NH2 Deposited 2009-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–50（26 aa）
Fragment：RESIDUES 25-50
|
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) | ACT ACETATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3；0.32 M NA2SO4, PH 3.0
|
Resolution 1.57 Å R-free 0.255 |
| 2WRV Semi-synthetic highly active analogue of human insulin NMeHisB26-DTI- NH2 Deposited 2009-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–50（26 aa）
Fragment：RESIDUES 25-50
|
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) | ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；0.1 NA CITRATE, 0.3 M TRIS PH 8.2, 0.6 MM ZN ACETATE, 0.06% PHENOL
|
Resolution 2.15 Å R-free 0.277 |
| 2WRW Semi-synthetic highly active analogue of human insulin D-ProB26-DTI- NH2 Deposited 2009-09-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–50（26 aa）
Fragment：RESIDUES 25-50
|
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3；0.015 M CS2SO4 PH 3.0
|
Resolution 2.41 Å R-free 0.301 |
| 2WRX Semi-synthetic analogue of human insulin NMeAlaB26-insulin at pH 3.0 Deposited 2009-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) | NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3；0.18 M LI2SO4, 0.1M NA ACETATE PH 3.0
|
Resolution 1.50 Å R-free 0.251 |
| 2WS0 Semi-synthetic analogue of human insulin NMeAlaB26-insulin at pH 7.5 Deposited 2009-09-03 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；0.75 DILUTION IN WATER OF STOCK OF 0.1 M NA CITRATE,0.3M TRIS PH 7.5,0.6 MM ZN ACETATE, 0.06% PHENOL
|
Resolution 2.10 Å R-free 0.337 |
| 2WS1 Semi-synthetic analogue of human insulin NMeTyrB26-insulin in monomer form Deposited 2009-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3；0.055 M NA2SO4 PH 3.0
|
Resolution 1.60 Å R-free 0.248 |
| 2WS4 Semi-synthetic analogue of human insulin ProB26-DTI in monomer form Deposited 2009-09-03 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–50（26 aa）
Fragment：RESIDUES 25-50
|
Mutation：YES | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3；0.055M NA2SO4 PH 3.0
|
Resolution 1.90 Å R-free 0.278 |
| 2WS6 Semi-synthetic analogue of human insulin NMeTyrB26-insulin in hexamer form Deposited 2009-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 6 CL CHLORIDE ION × 2 ZN ZINC ION × 2 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；6% TRIS PH 8.2, 0.1 M NA CITRATE, 0.02% ZN ACETATE, 0.06% PHENOL
|
Resolution 1.50 Å R-free 0.200 |
| 2WS6 Semi-synthetic analogue of human insulin NMeTyrB26-insulin in hexamer form Deposited 2009-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 3 CL CHLORIDE ION × 1 ZN ZINC ION × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；6% TRIS PH 8.2, 0.1 M NA CITRATE, 0.02% ZN ACETATE, 0.06% PHENOL
|
Resolution 1.50 Å R-free 0.200 |
| 2WS6 Semi-synthetic analogue of human insulin NMeTyrB26-insulin in hexamer form Deposited 2009-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 3 CL CHLORIDE ION × 1 ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；6% TRIS PH 8.2, 0.1 M NA CITRATE, 0.02% ZN ACETATE, 0.06% PHENOL
|
Resolution 1.50 Å R-free 0.200 |
| 2WS6 Semi-synthetic analogue of human insulin NMeTyrB26-insulin in hexamer form Deposited 2009-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | IPH PHENOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；6% TRIS PH 8.2, 0.1 M NA CITRATE, 0.02% ZN ACETATE, 0.06% PHENOL
|
Resolution 1.50 Å R-free 0.200 |
| 2WS6 Semi-synthetic analogue of human insulin NMeTyrB26-insulin in hexamer form Deposited 2009-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 2 CL CHLORIDE ION × 2 ZN ZINC ION × 2 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；6% TRIS PH 8.2, 0.1 M NA CITRATE, 0.02% ZN ACETATE, 0.06% PHENOL
|
Resolution 1.50 Å R-free 0.200 |
| 2WS6 Semi-synthetic analogue of human insulin NMeTyrB26-insulin in hexamer form Deposited 2009-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；6% TRIS PH 8.2, 0.1 M NA CITRATE, 0.02% ZN ACETATE, 0.06% PHENOL
|
Resolution 1.50 Å R-free 0.200 |
| 2WS7 Semi-synthetic analogue of human insulin ProB26-DTI Deposited 2009-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–50（26 aa）
Fragment：RESIDUES 25-50
Chain C
90–110（21 aa）
Chain D
25–50（26 aa）
Fragment：RESIDUES 25-50
Chain E
90–110（21 aa）
Chain F
25–50（26 aa）
Fragment：RESIDUES 25-50
Chain G
90–110（21 aa）
Chain H
25–50（26 aa）
Fragment：RESIDUES 25-50
Chain I
90–110（21 aa）
Chain J
25–50（26 aa）
Fragment：RESIDUES 25-50
Chain K
90–110（21 aa）
Chain L
25–50（26 aa）
Fragment：RESIDUES 25-50
|
Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES Mutation：YES | IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；5 MM ZN ACETATE,35 MM NA CITRATE,0.7% PHENOL,).7M NACL,0.3M TRIS PH 7.5
|
Resolution 2.59 Å R-free 0.332 |
| 3AIY R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, REFINED AVERAGE STRUCTURE Deposited 1998-12-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain B
25–54（30 aa）
Fragment：BETA CHAIN
Chain C
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain D
25–54（30 aa）
Fragment：BETA CHAIN
Chain E
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain F
25–54（30 aa）
Fragment：BETA CHAIN
Chain G
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain H
25–54（30 aa）
Fragment：BETA CHAIN
Chain I
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain J
25–54（30 aa）
Fragment：BETA CHAIN
Chain K
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain L
25–54（30 aa）
Fragment：BETA CHAIN
|
Not recorded | IPH PHENOL × 6 |
SOLUTION NMR
NMR measurement conditions
pH 8；310 K；Pressure 1
NMR sample composition
H2O AND D2O
|
Resolution not provided |
| 3BXQ The structure of a mutant insulin uncouples receptor binding from protein allostery. An electrostatic block to the TR transition Deposited 2008-01-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：R29H Mutation：R29H | ZN ZINC ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；0.02 M Tris, 0.05 M sodium citrate, 5% acetone, 0.03% phenol, 0.01% zinc acetate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.30 Å R-free 0.232 |
| 3E7Y Structure of human insulin Deposited 2008-08-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Not recorded | ZN ZINC ION × 1 CL CHLORIDE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.60 Å R-free 0.212 |
| 3E7Y Structure of human insulin Deposited 2008-08-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | ZN ZINC ION × 1 CL CHLORIDE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.60 Å R-free 0.212 |
| 3E7Y Structure of human insulin Deposited 2008-08-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.60 Å R-free 0.212 |
| 3E7Y Structure of human insulin Deposited 2008-08-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.60 Å R-free 0.212 |
| 3E7Y Structure of human insulin Deposited 2008-08-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Not recorded | ZN ZINC ION × 3 CL CHLORIDE ION × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.60 Å R-free 0.212 |
| 3E7Y Structure of human insulin Deposited 2008-08-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | ZN ZINC ION × 3 CL CHLORIDE ION × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.60 Å R-free 0.212 |
| 3E7Y Structure of human insulin Deposited 2008-08-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 7 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | ZN ZINC ION × 2 CL CHLORIDE ION × 2 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.60 Å R-free 0.212 |
| 3E7Y Structure of human insulin Deposited 2008-08-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 8 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | ZN ZINC ION × 2 CL CHLORIDE ION × 2 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.60 Å R-free 0.212 |
| 3E7Z Structure of human insulin Deposited 2008-08-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Not recorded | ZN ZINC ION × 1 CL CHLORIDE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å R-free 0.271 |
| 3E7Z Structure of human insulin Deposited 2008-08-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | ZN ZINC ION × 1 CL CHLORIDE ION × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å R-free 0.271 |
| 3E7Z Structure of human insulin Deposited 2008-08-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å R-free 0.271 |
| 3E7Z Structure of human insulin Deposited 2008-08-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å R-free 0.271 |
| 3E7Z Structure of human insulin Deposited 2008-08-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Not recorded | ZN ZINC ION × 3 CL CHLORIDE ION × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å R-free 0.271 |
| 3E7Z Structure of human insulin Deposited 2008-08-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | ZN ZINC ION × 3 CL CHLORIDE ION × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å R-free 0.271 |
| 3E7Z Structure of human insulin Deposited 2008-08-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 7 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | ZN ZINC ION × 2 CL CHLORIDE ION × 2 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å R-free 0.271 |
| 3E7Z Structure of human insulin Deposited 2008-08-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 8 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | ZN ZINC ION × 2 CL CHLORIDE ION × 2 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.70 Å R-free 0.271 |
| 3EXX Structure of the T6 human insulin derivative with nickel at 1.35 A resolution Deposited 2008-10-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | NI NICKEL (II) ION × 1 NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；291 K；1 mM sodium citrate, 10% acetone, 15 mM nickel(II) acetate tetrahydrate, pH 6.4, vapor diffusion, hanging drop, temperature 291K
|
Resolution 1.35 Å R-free 0.171 |
| 3EXX Structure of the T6 human insulin derivative with nickel at 1.35 A resolution Deposited 2008-10-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | NI NICKEL (II) ION × 1 NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；291 K；1 mM sodium citrate, 10% acetone, 15 mM nickel(II) acetate tetrahydrate, pH 6.4, vapor diffusion, hanging drop, temperature 291K
|
Resolution 1.35 Å R-free 0.171 |
| 3FQ9 Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications Deposited 2009-01-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
91–110（20 aa）
Chain B
25–54（30 aa）
|
Mutation：A1 is DAL, A8 is DAB Non-standard monomer：Yes (specific site not provided by mmCIF) | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.8；298 K；0.02M Tris, o.o5M soduim citrate, 5%acetone,0.03% phenol,0.01% zinc acetone, pH 7.8, VAPOR DIFFUSION, temperature 298K
|
Resolution 1.35 Å R-free 0.228 |
| 3FQ9 Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications Deposited 2009-01-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
91–110（20 aa）
Chain D
25–54（30 aa）
|
Mutation：A1 is DAL, A8 is DAB Non-standard monomer：Yes (specific site not provided by mmCIF) | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.8；298 K；0.02M Tris, o.o5M soduim citrate, 5%acetone,0.03% phenol,0.01% zinc acetone, pH 7.8, VAPOR DIFFUSION, temperature 298K
|
Resolution 1.35 Å R-free 0.228 |
| 3FQ9 Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications Deposited 2009-01-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
91–110（20 aa）
Chain B
25–54（30 aa）
Chain C
91–110（20 aa）
Chain D
25–54（30 aa）
|
Mutation：A1 is DAL, A8 is DAB Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：A1 is DAL, A8 is DAB Non-standard monomer：Yes (specific site not provided by mmCIF) | ZN ZINC ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.8；298 K；0.02M Tris, o.o5M soduim citrate, 5%acetone,0.03% phenol,0.01% zinc acetone, pH 7.8, VAPOR DIFFUSION, temperature 298K
|
Resolution 1.35 Å R-free 0.228 |
| 3FQ9 Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications Deposited 2009-01-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
91–110（20 aa）
Chain B
25–54（30 aa）
Chain C
91–110（20 aa）
Chain D
25–54（30 aa）
|
Mutation：A1 is DAL, A8 is DAB Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：A1 is DAL, A8 is DAB Non-standard monomer：Yes (specific site not provided by mmCIF) | ZN ZINC ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.8；298 K；0.02M Tris, o.o5M soduim citrate, 5%acetone,0.03% phenol,0.01% zinc acetone, pH 7.8, VAPOR DIFFUSION, temperature 298K
|
Resolution 1.35 Å R-free 0.228 |
| 3FQ9 Design of an insulin analog with enhanced receptor-binding selectivity. Rationale, structure, and therapeutic implications Deposited 2009-01-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
91–110（20 aa）
Chain B
25–54（30 aa）
Chain C
91–110（20 aa）
Chain D
25–54（30 aa）
|
Mutation：A1 is DAL, A8 is DAB Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：A1 is DAL, A8 is DAB Non-standard monomer：Yes (specific site not provided by mmCIF) | ZN ZINC ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.8；298 K；0.02M Tris, o.o5M soduim citrate, 5%acetone,0.03% phenol,0.01% zinc acetone, pH 7.8, VAPOR DIFFUSION, temperature 298K
|
Resolution 1.35 Å R-free 0.228 |
| 3HYD LVEALYL peptide derived from human insulin chain B, residues 11-17 Deposited 2009-06-22 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
35–41（7 aa）
Fragment：UNP residues 34-41 of chain B
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；20% MPD, 0.1M sodium citrate pH 5.5, vapor diffusion, hanging drop, temperature 298K
|
Resolution 1.00 Å R-free 0.180 |
| 3I3Z Human insulin Deposited 2009-07-01 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.60 Å R-free 0.195 |
| 3I40 Human insulin Deposited 2009-07-01 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 1.85 Å R-free 0.228 |
| 3ILG Crystal structure of humnan insulin Sr+2 complex Deposited 2009-08-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | SR STRONTIUM ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；0.1M Sodium Citrate, 1M Ammonium Sulphate, 0.1M Strontium Chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 293.0K
|
Resolution 1.90 Å R-free 0.278 |
| 3INC Crystal structure of human insulin with Ni+2 complex Deposited 2009-08-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | NI NICKEL (II) ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；298 K；0.2M Sodium Citrate, 0.12M Nickel Chloride, 1M Ammonium Sulphate, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.85 Å R-free 0.257 |
| 3IR0 Crystal Structure of Human Insulin complexed with Cu+2 metal ion Deposited 2009-08-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | CU COPPER (II) ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；0.2M Sodium citrate, 1M Ammonium sulphate, 0.1M Copper chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å R-free 0.299 |
| 3IR0 Crystal Structure of Human Insulin complexed with Cu+2 metal ion Deposited 2009-08-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
|
Not recorded | CU COPPER (II) ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；0.2M Sodium citrate, 1M Ammonium sulphate, 0.1M Copper chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å R-free 0.299 |
| 3IR0 Crystal Structure of Human Insulin complexed with Cu+2 metal ion Deposited 2009-08-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | CU COPPER (II) ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；0.2M Sodium citrate, 1M Ammonium sulphate, 0.1M Copper chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å R-free 0.299 |
| 3IR0 Crystal Structure of Human Insulin complexed with Cu+2 metal ion Deposited 2009-08-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain M
90–110（21 aa）
Chain N
25–54（30 aa）
Chain O
90–110（21 aa）
Chain P
25–54（30 aa）
|
Not recorded | CU COPPER (II) ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；0.2M Sodium citrate, 1M Ammonium sulphate, 0.1M Copper chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å R-free 0.299 |
| 3IR0 Crystal Structure of Human Insulin complexed with Cu+2 metal ion Deposited 2009-08-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain R
90–110（21 aa）
Chain S
25–54（30 aa）
Chain T
90–110（21 aa）
Chain U
25–54（30 aa）
|
Not recorded | CU COPPER (II) ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；0.2M Sodium citrate, 1M Ammonium sulphate, 0.1M Copper chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å R-free 0.299 |
| 3IR0 Crystal Structure of Human Insulin complexed with Cu+2 metal ion Deposited 2009-08-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain V
90–110（21 aa）
Chain W
25–54（30 aa）
Chain X
90–110（21 aa）
Chain Y
25–54（30 aa）
|
Not recorded | CU COPPER (II) ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；293 K；0.2M Sodium citrate, 1M Ammonium sulphate, 0.1M Copper chloride, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å R-free 0.299 |
| 3JSD Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus Deposited 2009-09-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | ZN ZINC ION × 6 CL CHLORIDE ION × 6 IPH PHENOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；298 K；0.02M Tris-HCl, 0.05M Sodium citrate, 5% Acetone, 0.03% Phenol, 0.01% Zinc acetate, pH 8.0, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.50 Å R-free 0.274 |
| 3KQ6 Enhancing the Therapeutic Properties of a Protein by a Designed Zinc-Binding Site, Structural principles of a novel long-acting insulin analog Deposited 2009-11-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：E4H, T4H Mutation：E4H, T4H | ZN ZINC ION × 9 CL CHLORIDE ION × 6 IPH PHENOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；298 K；0.02 M Tris, 0.05 M sodium citrate, 5% acetone, 0.03% phenol, 0.01% zinc acetate, pH 8.0, VAPOR DIFFUSION, temperature 298K
|
Resolution 1.90 Å R-free 0.257 |
| 3P2X Insulin fibrillation is the Janus face of induced fit. A chiaral clamp stabilizes the native state at the expense of activity Deposited 2010-10-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Fragment：unp residues 90-110
Chain B
25–54（30 aa）
Fragment：unp residues 25-54
|
Mutation：G32(DAL) Non-standard monomer：Yes (specific site not provided by mmCIF) | ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å R-free 0.314 |
| 3P2X Insulin fibrillation is the Janus face of induced fit. A chiaral clamp stabilizes the native state at the expense of activity Deposited 2010-10-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Fragment：unp residues 90-110
Chain D
25–54（30 aa）
Fragment：unp residues 25-54
|
Mutation：G32(DAL) Non-standard monomer：Yes (specific site not provided by mmCIF) | ZN ZINC ION × 3 CL CHLORIDE ION × 3 IPH PHENOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å R-free 0.314 |
| 3P33 Insulin fibrillation is the Janus face of induced fit. A chiral clamp stabilizes the native state at the expense of activity Deposited 2010-10-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Fragment：unp residues 90-110
Chain B
25–54（30 aa）
Fragment：unp residues 25-54
|
Not recorded | IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å R-free 0.299 |
| 3P33 Insulin fibrillation is the Janus face of induced fit. A chiral clamp stabilizes the native state at the expense of activity Deposited 2010-10-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Fragment：unp residues 90-110
Chain D
25–54（30 aa）
Fragment：unp residues 25-54
|
Not recorded | IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å R-free 0.299 |
| 3P33 Insulin fibrillation is the Janus face of induced fit. A chiral clamp stabilizes the native state at the expense of activity Deposited 2010-10-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain E
90–110（21 aa）
Fragment：unp residues 90-110
Chain F
25–54（30 aa）
Fragment：unp residues 25-54
|
Not recorded | IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å R-free 0.299 |
| 3P33 Insulin fibrillation is the Janus face of induced fit. A chiral clamp stabilizes the native state at the expense of activity Deposited 2010-10-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain G
90–110（21 aa）
Fragment：unp residues 90-110
Chain H
25–54（30 aa）
Fragment：unp residues 25-54
|
Not recorded | IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å R-free 0.299 |
| 3Q6E Human insulin in complex with cucurbit[7]uril Deposited 2010-12-31 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：unp residues 90-110
Chain B
25–54（30 aa）
Fragment：unp residues 25-54
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 7；298 K；40 uM Q7, 40 uM insulin, 10 mM sodium phosphate, 4 mM EDTA, 1 mM lysine, EVAPORATION, temperature 298K, pH 7.0
|
Resolution 2.05 Å R-free 0.253 |
| 3Q6E Human insulin in complex with cucurbit[7]uril Deposited 2010-12-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Fragment：unp residues 90-110
Chain D
25–54（30 aa）
Fragment：unp residues 25-54
|
Not recorded | QQ7 cucurbit[7]uril × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 7；298 K；40 uM Q7, 40 uM insulin, 10 mM sodium phosphate, 4 mM EDTA, 1 mM lysine, EVAPORATION, temperature 298K, pH 7.0
|
Resolution 2.05 Å R-free 0.253 |
| 3ROV Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus Deposited 2011-04-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å R-free 0.307 |
| 3ROV Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus Deposited 2011-04-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å R-free 0.307 |
| 3ROV Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus Deposited 2011-04-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
|
Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 2 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å R-free 0.307 |
| 3ROV Insulin's biosynthesis and activity have opposing structural requirements: a new factor in neonatal diabetes mellitus Deposited 2011-04-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：G20DAL, G23DAL, P28K, K29P Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.3；298 K；0.05 M sodium citrate, 1% phenol, 0.04% zinc acetate, pH 8.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å R-free 0.307 |
| 3TT8 Crystal Structure Analysis of Cu Human Insulin Derivative Deposited 2011-09-14 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；1mM sodium citrate, volume fractions of acetone 10% and 7.5 mM cooper(II) acetate monohydrate, pH 6.4, VAPOR DIFFUSION, HANGING DROP
|
Resolution 1.12 Å R-free 0.179 |
| 3TT8 Crystal Structure Analysis of Cu Human Insulin Derivative Deposited 2011-09-14 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；1mM sodium citrate, volume fractions of acetone 10% and 7.5 mM cooper(II) acetate monohydrate, pH 6.4, VAPOR DIFFUSION, HANGING DROP
|
Resolution 1.12 Å R-free 0.179 |
| 3TT8 Crystal Structure Analysis of Cu Human Insulin Derivative Deposited 2011-09-14 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；1mM sodium citrate, volume fractions of acetone 10% and 7.5 mM cooper(II) acetate monohydrate, pH 6.4, VAPOR DIFFUSION, HANGING DROP
|
Resolution 1.12 Å R-free 0.179 |
| 3U4N A novel covalently linked insulin dimer Deposited 2011-10-10 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Mutation：F25C | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；0.1 M Bis-Tris pH 6.5, 3.0 M NaCl, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 1.98 Å R-free 0.217 |
| 3U4N A novel covalently linked insulin dimer Deposited 2011-10-10 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Mutation：F25C | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；291 K；0.1 M Bis-Tris pH 6.5, 3.0 M NaCl, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 1.98 Å R-free 0.217 |
| 3UTQ Human HLA-A*0201-ALWGPDPAAA Deposited 2011-11-26 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain C
15–24（10 aa）
Fragment：Pre-pro-insulin Derived Peptide (UNP residues 15-24)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；291 K；20% w/v PEG3350, 0.2 M potassium/sodium tartrate, 0.1 M Bis-tris propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
|
Resolution 1.67 Å R-free 0.244 |
| 3UTS 1E6-A*0201-ALWGPDPAAA Complex, Monoclinic Deposited 2011-11-26 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
15–24（10 aa）
Fragment：Pre-pro-insulin Derived Peptide (UNP residues 15-24)
|
Not recorded | SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；291 K；20% w/v PEG3350, 0.2 M sodium citrate, 0.1 M Bis-tris propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
|
Resolution 2.71 Å R-free 0.269 |
| 3UTS 1E6-A*0201-ALWGPDPAAA Complex, Monoclinic Deposited 2011-11-26 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain H
15–24（10 aa）
Fragment：Pre-pro-insulin Derived Peptide (UNP residues 15-24)
|
Not recorded | SO4 SULFATE ION × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；291 K；20% w/v PEG3350, 0.2 M sodium citrate, 0.1 M Bis-tris propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
|
Resolution 2.71 Å R-free 0.269 |
| 3UTT 1E6-A*0201-ALWGPDPAAA Complex, Triclinic Deposited 2011-11-26 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
15–24（10 aa）
Fragment：Pre-pro-insulin Derived Peptide (UNP residues 15-24)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；291 K；20% w/v PEG3350, 0.2 M sodium citrate, 0.1 M Bis-tris propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
|
Resolution 2.60 Å R-free 0.274 |
| 3UTT 1E6-A*0201-ALWGPDPAAA Complex, Triclinic Deposited 2011-11-26 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain H
15–24（10 aa）
Fragment：Pre-pro-insulin Derived Peptide (UNP residues 15-24)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；291 K；20% w/v PEG3350, 0.2 M sodium citrate, 0.1 M Bis-tris propane, pH 6.5, VAPOR DIFFUSION, temperature 291K
|
Resolution 2.60 Å R-free 0.274 |
| 3V19 Forestalling insulin fibrillation by insertion of a chiral clamp mechanism-based application of protein engineering to global health Deposited 2011-12-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 IPH PHENOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；298 K；0.02 M Tris, 0.05 M sodium citrate, 5% acetone, 0.03% phenol, 0.01% zinc acetate, pH 8.0, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.00 Å R-free 0.266 |
| 3V1G Forestalling insulin fibrillation by insertion of a chiral clamp mechanism-based application of protein engineering to global health Deposited 2011-12-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | ZN ZINC ION × 6 IPH PHENOL × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；298 K；0.02 M Tris, 0.05 M sodium citrate, 5%
acetone, 0.03% phenol, 0.01% zinc acetate, pH 8.0, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.20 Å R-free 0.323 |
| 3W11 Insulin receptor ectodomain construct comprising domains L1-CR in complex with human insulin, Alpha-CT peptide(704-719) and FAB 83-7 Deposited 2012-11-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；0.9-1.1M TRI-SODIUM CITRATE, 0.1M IMIDAZOLE-HCL, 0.02% SODIUM AZIDE, PH 8.0
|
Resolution 3.90 Å R-free 0.292 |
| 3W12 Insulin receptor ectodomain construct comprising domains L1-CR in complex with high-affinity insulin analogue [D-PRO-B26]-DTI-NH2, alpha-CT peptide(704-719) and FAB 83-7 Deposited 2012-11-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–50（26 aa）
Fragment：UNP residues 25-50
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；0.9-1.1M TRI-SODIUM CITRATE, 0.1M IMIDAZOLE-HCL, 0.02% SODIUM AZIDE, PH 8.0
|
Resolution 4.30 Å R-free 0.349 |
| 3W13 Insulin receptor ectodomain construct comprising domains L1-CR in complex with high-affinity insulin analogue [D-PRO-B26]-DTI-NH2, alphact peptide(693-719) and FAB 83-7 Deposited 2012-11-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–50（26 aa）
Fragment：UNP residues 25-50
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；0.9-1.1M TRI-SODIUM CITRATE, 0.1M IMIDAZOLE-HCL, 0.02% SOIDUM AZIDE, PH 8.0
|
Resolution 4.30 Å R-free 0.335 |
| 3W7Y 0.92A structure of 2Zn human insulin at 100K Deposited 2013-03-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.67；293 K；10mg/ml protein, 0.1M Sodium Citrate, 22% DMF(v/v) and 0.08% Zinc chloride(w/v), pH 8.67, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 0.92 Å R-free 0.180 |
| 3W7Y 0.92A structure of 2Zn human insulin at 100K Deposited 2013-03-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.67；293 K；10mg/ml protein, 0.1M Sodium Citrate, 22% DMF(v/v) and 0.08% Zinc chloride(w/v), pH 8.67, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 0.92 Å R-free 0.180 |
| 3W7Z 1.15A structure of human 2Zn insulin at 293K Deposited 2013-03-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.67；293 K；10mg/ml protein, 0.1M Sodium Citrate, 22%(v/v) DMF, 0.08%(w/v) Zinc chloride, pH 8.67, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.15 Å R-free 0.195 |
| 3W7Z 1.15A structure of human 2Zn insulin at 293K Deposited 2013-03-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.67；293 K；10mg/ml protein, 0.1M Sodium Citrate, 22%(v/v) DMF, 0.08%(w/v) Zinc chloride, pH 8.67, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.15 Å R-free 0.195 |
| 3W80 Crystal structure of dodecamer human insulin with double C-axis length of the hexamer 2 Zn insulin cell Deposited 2013-03-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.67；293 K；10mg/ml protein, 0.1M Sodium Citrate, 22%(v/v) DMF, 0.08%(w/v) Zinc chloride, pH 8.67, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.40 Å R-free 0.248 |
| 3W80 Crystal structure of dodecamer human insulin with double C-axis length of the hexamer 2 Zn insulin cell Deposited 2013-03-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain E
90–110（21 aa）
Fragment：UNP residues 90-110
Chain F
25–54（30 aa）
Fragment：UNP residues 25-54
Chain G
90–110（21 aa）
Fragment：UNP residues 90-110
Chain H
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.67；293 K；10mg/ml protein, 0.1M Sodium Citrate, 22%(v/v) DMF, 0.08%(w/v) Zinc chloride, pH 8.67, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.40 Å R-free 0.248 |
| 3ZI3 Crystal structure of the B24His-insulin - human analogue Deposited 2013-01-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：YES | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 3；0.075 M LI2SO4, PH 3.0
|
Resolution 1.70 Å R-free 0.221 |
| 3ZQR NMePheB25 insulin analogue crystal structure Deposited 2011-06-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；0.6 M NA2SO4, 0.3 M TRIS PH 8.2, 0.6 M ZN(AC)2, 0.06% PHENOL.
|
Resolution 1.90 Å R-free 0.281 |
| 3ZS2 TyrB25,NMePheB26,LysB28,ProB29-insulin analogue crystal structure Deposited 2011-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 6 CL CHLORIDE ION × 2 ZN ZINC ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.2；0.1 M NACITRATE, 0.3 M TRIS PH 8.2, 0.6 MM ZN(AC)2, 0.06% PHENOL
|
Resolution 1.97 Å R-free 0.252 |
| 3ZU1 Structure of LysB29(Nepsilon omega-carboxyheptadecanoyl) des(B30) Human Insulin Deposited 2011-07-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | RCO RESORCINOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；100MM HEPES, 300MM NA-CITRATE, 24% 2-PROPANOL PH 7.5
|
Resolution 1.60 Å R-free 0.214 |
| 4AIY R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 'GREEN' SUBSTATE, AVERAGE STRUCTURE Deposited 1998-12-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain B
25–54（30 aa）
Fragment：BETA CHAIN
Chain C
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain D
25–54（30 aa）
Fragment：BETA CHAIN
Chain E
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain F
25–54（30 aa）
Fragment：BETA CHAIN
Chain G
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain H
25–54（30 aa）
Fragment：BETA CHAIN
Chain I
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain J
25–54（30 aa）
Fragment：BETA CHAIN
Chain K
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain L
25–54（30 aa）
Fragment：BETA CHAIN
|
Not recorded | IPH PHENOL × 6 |
SOLUTION NMR
NMR measurement conditions
pH 8；310 K；Pressure 1
NMR sample composition
H2O AND D2O
|
Resolution not provided |
| 4AJX Ligand controlled assembly of hexamers, dihexamers, and linear multihexamer structures by an engineered acylated insulin Deposited 2012-02-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Fragment：RESIDUES 25-53
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
Fragment：RESIDUES 25-53
Chain E
90–110（21 aa）
Chain F
25–53（29 aa）
Fragment：RESIDUES 25-53
Chain G
90–110（21 aa）
Chain H
25–53（29 aa）
Fragment：RESIDUES 25-53
Chain I
90–110（21 aa）
Chain J
25–53（29 aa）
Fragment：RESIDUES 25-53
Chain K
90–110（21 aa）
Chain L
25–53（29 aa）
Fragment：RESIDUES 25-53
|
Not recorded | 16E N-(16-Carboxyhexadecanoyl)-L-glutamic acid × 2 RCO RESORCINOL × 6 NA SODIUM ION × 2 IMD IMIDAZOLE × 3 ZN ZINC ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；0.6 M IMIDAZOLE/MALONIC ACID PH 7.0
|
Resolution 1.20 Å R-free 0.160 |
| 4AJZ Ligand controlled assembly of hexamers, dihexamers, and linear multihexamer structures by an engineered acylated insulin Deposited 2012-02-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Fragment：DELTA B30, RESIDUES 25-53
|
Not recorded | ZN ZINC ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICROBATCH；pH 7.5；MICROBATCH METHOD 5MM PHENOL, 0.4M NACL; 6% (V/V) ETHANOL, 100MM HEPES PH 7.5
|
Resolution 1.80 Å R-free 0.255 |
| 4AJZ Ligand controlled assembly of hexamers, dihexamers, and linear multihexamer structures by an engineered acylated insulin Deposited 2012-02-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
Fragment：DELTA B30, RESIDUES 25-53
|
Not recorded | ZN ZINC ION × 3 CL CHLORIDE ION × 3 IPH PHENOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICROBATCH；pH 7.5；MICROBATCH METHOD 5MM PHENOL, 0.4M NACL; 6% (V/V) ETHANOL, 100MM HEPES PH 7.5
|
Resolution 1.80 Å R-free 0.255 |
| 4AK0 Ligand controlled assembly of hexamers, dihexamers, and linear multihexamer structures by an engineered acylated insulin Deposited 2012-02-21 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Fragment：DELTA B30, RESIDUES 25-53
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.8；pH 7.8
|
Resolution 2.28 Å R-free 0.232 |
| 4AKJ Ligand controlled assembly of hexamers, dihexamers, and linear multihexamer structures by an engineered acylated insulin Deposited 2012-02-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Not recorded | IPH PHENOL × 3 16E N-(16-Carboxyhexadecanoyl)-L-glutamic acid × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 2.01 Å R-free 0.229 |
| 4AKJ Ligand controlled assembly of hexamers, dihexamers, and linear multihexamer structures by an engineered acylated insulin Deposited 2012-02-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | IPH PHENOL × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 2.01 Å R-free 0.229 |
| 4CXL Human insulin analogue (D-ProB8)-insulin Deposited 2014-04-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) | CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；0.1 M TRIS/HCL PH 8.0, 0.2 SODIUM CITRATE, 40% V/V MPD, PROTEIN CONCENTRATION 5MG/ML IN 20 MM HCL
|
Resolution 1.50 Å R-free 0.197 |
| 4CXL Human insulin analogue (D-ProB8)-insulin Deposited 2014-04-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) | CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；0.1 M TRIS/HCL PH 8.0, 0.2 SODIUM CITRATE, 40% V/V MPD, PROTEIN CONCENTRATION 5MG/ML IN 20 MM HCL
|
Resolution 1.50 Å R-free 0.197 |
| 4CXN Crystal structure of human insulin analogue (NMe-AlaB8)-insulin crystal form I Deposited 2014-04-07 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；0.1 M TRIS/HCL PH 8.0, 0.2 M SODIUM CITRATE, 40% V/V MPD, PROTEIN IN 20 MM HCL AT 7 MG/ML
|
Resolution 1.70 Å R-free 0.209 |
| 4CXN Crystal structure of human insulin analogue (NMe-AlaB8)-insulin crystal form I Deposited 2014-04-07 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；0.1 M TRIS/HCL PH 8.0, 0.2 M SODIUM CITRATE, 40% V/V MPD, PROTEIN IN 20 MM HCL AT 7 MG/ML
|
Resolution 1.70 Å R-free 0.209 |
| 4CY7 Crystal structure of human insulin analogue (NMe-AlaB8)-insulin crystal form II Deposited 2014-04-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) | SO4 SULFATE ION × 1 ACT ACETATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4；0.0375 M NA2SO4, PH 4.0
|
Resolution 1.40 Å R-free 0.199 |
| 4CY7 Crystal structure of human insulin analogue (NMe-AlaB8)-insulin crystal form II Deposited 2014-04-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：YES Non-standard monomer：Yes (specific site not provided by mmCIF) | SO4 SULFATE ION × 1 ACT ACETATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4；0.0375 M NA2SO4, PH 4.0
|
Resolution 1.40 Å R-free 0.199 |
| 4EFX Highly biologically active insulin with additional disulfide bond Deposited 2012-03-30 | Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
90–110（21 aa）
|
Mutation：A10C, B4C | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.15M DL-Malic Acid, 20% w/v PEG3350, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 1.98 Å R-free 0.278 |
| 4EFX Highly biologically active insulin with additional disulfide bond Deposited 2012-03-30 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–52（28 aa）
|
Not recorded | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.15M DL-Malic Acid, 20% w/v PEG3350, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 1.98 Å R-free 0.278 |
| 4EFX Highly biologically active insulin with additional disulfide bond Deposited 2012-03-30 | Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
90–110（21 aa）
|
Mutation：A10C, B4C | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.15M DL-Malic Acid, 20% w/v PEG3350, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 1.98 Å R-free 0.278 |
| 4EFX Highly biologically active insulin with additional disulfide bond Deposited 2012-03-30 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain D
25–52（28 aa）
|
Not recorded | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.15M DL-Malic Acid, 20% w/v PEG3350, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 1.98 Å R-free 0.278 |
| 4EFX Highly biologically active insulin with additional disulfide bond Deposited 2012-03-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–52（28 aa）
Chain C
90–110（21 aa）
Chain D
25–52（28 aa）
|
Mutation：A10C, B4C Mutation：A10C, B4C | ZN ZINC ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；291 K；0.15M DL-Malic Acid, 20% w/v PEG3350, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 1.98 Å R-free 0.278 |
| 4EWW Human Insulin Deposited 2012-04-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000, cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å R-free 0.287 |
| 4EWX Human Insulin Deposited 2012-04-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000, cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.20 Å R-free 0.240 |
| 4EWZ Human Insulin Deposited 2012-04-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Betalin H, lot # 310996-1), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.79 Å R-free 0.269 |
| 4EX0 Human Insulin Deposited 2012-04-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Betalin H, lot # 310996-1), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.86 Å R-free 0.226 |
| 4EX1 Human Insulin Deposited 2012-04-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Betalin H, lot # 310996-1), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.66 Å R-free 0.239 |
| 4EXX Human Insulin Deposited 2012-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Insunorm R, lot # I 550005), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.55 Å R-free 0.263 |
| 4EY1 Human Insulin Deposited 2012-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Insunorm R, lot # I 550005), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.47 Å R-free 0.219 |
| 4EY9 Human Insulin Deposited 2012-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Insunorm R, lot # I 550005), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.47 Å R-free 0.255 |
| 4EYD Human Insulin Deposited 2012-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Insunorm R, lot # I 550005), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.47 Å R-free 0.223 |
| 4EYN Human Insulin Deposited 2012-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Insunorm R, lot # I 550005), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.53 Å R-free 0.271 |
| 4EYP Human Insulin Deposited 2012-05-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Insunorm R, lot # I 550005), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.59 Å R-free 0.223 |
| 4F0N Human Insulin Deposited 2012-05-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Novolin R, lot # XS60393), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.68 Å R-free 0.264 |
| 4F0O Human Insulin Deposited 2012-05-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium citrate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Novolin R, lot # XS60393), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.67 Å R-free 0.221 |
| 4F1A Human Insulin Deposited 2012-05-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Novolin R, lot # XS60393), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å R-free 0.213 |
| 4F1B Human Insulin Deposited 2012-05-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Novolin R, lot # TS 62987), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.59 Å R-free 0.227 |
| 4F1C Human Insulin Deposited 2012-05-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Novolin R, lot # TS 62987), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.70 Å R-free 0.225 |
| 4F1D Human Insulin Deposited 2012-05-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Humulin R, lot # A 505073), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.64 Å R-free 0.219 |
| 4F1F Human Insulin Deposited 2012-05-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Humulin R, lot # A 560347), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.68 Å R-free 0.258 |
| 4F1G Human insulin Deposited 2012-05-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Humulin R, lot # A 560347), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.64 Å R-free 0.222 |
| 4F4T Human Insulin Deposited 2012-05-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Humulin R, lot # A 505073), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.64 Å R-free 0.214 |
| 4F4V Human Insulin Deposited 2012-05-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Humulin R, lot # A 505073), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.64 Å R-free 0.264 |
| 4F51 Human Insulin Deposited 2012-05-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Humulin R, lot # A 505073), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.64 Å R-free 0.212 |
| 4F8F Human Insulin Deposited 2012-05-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；291 K；2 uL 0.1 M sodium phosphate, pH 5.5, 10% w/v PEG6000 + 2 uL 100 U/mL human insulin (Humulin R, lot # A 405936), cryoprotectant: mother liquor + 10% glycerol, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.68 Å R-free 0.198 |
| 4FG3 Crystal Structure Analysis of the Human Insulin Deposited 2012-06-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；Hanging drop: 2 uL 0.1 M sodium phosphate, 10% w/v PEG 6K + 2 uL Human Insulin 100 U/mL (Humulin R, lot #A 405936). Cryo = mother liquor + 10% glycerol, pH 5.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å R-free 0.252 |
| 4FKA High resolution structure of the manganese derivative of insulin Deposited 2012-06-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | NA SODIUM ION × 1 MN MANGANESE (II) ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；291 K；The protein solution consisted of 7.5 mg mL-1 of zinc-free insulin in 0.02 mol L-1 hydrochloric acid.
The reservoir solution was at pH 6.4 containing 1mM sodium citrate, volume fraction of aceton 10 % ,9 mmol L-1 manganese(II) sulphate monohydrate and redistilled water, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.08 Å R-free 0.194 |
| 4FKA High resolution structure of the manganese derivative of insulin Deposited 2012-06-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | MN MANGANESE (II) ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；291 K；The protein solution consisted of 7.5 mg mL-1 of zinc-free insulin in 0.02 mol L-1 hydrochloric acid.
The reservoir solution was at pH 6.4 containing 1mM sodium citrate, volume fraction of aceton 10 % ,9 mmol L-1 manganese(II) sulphate monohydrate and redistilled water, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.08 Å R-free 0.194 |
| 4FKA High resolution structure of the manganese derivative of insulin Deposited 2012-06-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | NA SODIUM ION × 3 MN MANGANESE (II) ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；291 K；The protein solution consisted of 7.5 mg mL-1 of zinc-free insulin in 0.02 mol L-1 hydrochloric acid.
The reservoir solution was at pH 6.4 containing 1mM sodium citrate, volume fraction of aceton 10 % ,9 mmol L-1 manganese(II) sulphate monohydrate and redistilled water, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.08 Å R-free 0.194 |
| 4GBC Crystal structure of aspart insulin at pH 6.5 Deposited 2012-07-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | CRS M-CRESOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；2 uL mother liquor (0.1 M MES monohydrate, pH 6.5, 1.6 M magnesium sulfate heptahydrate) + 2 uL protein (aspart insulin, 100 U/mL), VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.78 Å R-free 0.224 |
| 4GBI Crystal structure of aspart insulin at pH 6.5 Deposited 2012-07-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | CRS M-CRESOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；2 uL mother liquor (0.1 M MES, pH 6.5, 1.6 M magnesium sulfate heptahydrate) + 2 uL protein (aspart insulin, 100 U/mL), VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å R-free 0.202 |
| 4GBK Crystal structure of aspart insulin at pH 8.5 Deposited 2012-07-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | CRS M-CRESOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；2 uL mother liquor (0.1 M Tris, pH 8.5, 1.5 M ammonium sulfate, 12% v/v glycerol) + 2 uL protein (aspart insulin 100 U/mL), VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å R-free 0.266 |
| 4GBL Crystal structure of aspart insulin at pH 8.5 Deposited 2012-07-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | CRS M-CRESOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；2 uL mother liquor (0.1 M Tris, pH 8.5, 1.5 M ammonium sulfate, 12% v/v glycerol) + 2 uL protein (aspart insulin 100 U/mL), VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å R-free 0.262 |
| 4GBN Crystal structure of aspart insulin at pH 6.5 Deposited 2012-07-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | CRS M-CRESOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；2 uL mother liquor (0.1 M MES monohydrate, pH 6.5, 1.6 M magnesium sulfate heptahydrate) + 2 uL protein (aspart insulin, 100 U/mL), VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.87 Å R-free 0.214 |
| 4IUZ High resolution crystal structure of racemic ester insulin Deposited 2013-01-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-64
|
Mutation：H34D,P52K,K53P | PEG DI(HYDROXYETHYL)ETHER × 2 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 3.6；292 K；5 mg/mL protein, 0.05 M citric acid, 38% v/v PEG200, pH 3.6, VAPOR DIFFUSION, HANGING DROP, temperature 292K
|
Resolution 1.60 Å R-free 0.249 |
| 4IYD Insulin glargine crystal structure 1 Deposited 2013-01-28 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–109（20 aa）
Chain B
25–53（29 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.1 M Tris, 30% PEG-400 v/v, 0.2 M sodium citrate dihydrate, pH 8.0, vapor diffusion, sitting drop, temperature 293K
|
Resolution 1.66 Å R-free 0.225 |
| 4IYF Insulin glargine crystal structure 2 Deposited 2013-01-28 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–109（20 aa）
Chain B
25–53（29 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.1 M Tris, 30% PEG-400 v/v, 0.2 M sodium citrate dihydrate, pH 8.0, vapor diffusion, sitting drop, temperature 293K
|
Resolution 1.80 Å R-free 0.242 |
| 4NIB Crystal structure of human insulin mutant B20 D-ala, B23 D-ala Deposited 2013-11-05 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：G20(DAL), G23(DAL) Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；294 K；These insulin crystals were obtained from a co-crystallization experiment with insulin receptor fragment IR310.T. Crystals were formed in the presence of IR310.T as detailed for the IR310.T complex with native human insulin - in Menting et al. 2013, Nature 493:241-245. Crystallant was 0.7 M trisodium citrate, 0.1 M imidazole-HCl pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 294K
|
Resolution 1.40 Å R-free 0.163 |
| 4OGA Insulin in complex with Site 1 of the human insulin receptor Deposited 2014-01-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；0.9-1.1M TRI-SODIUM CITRATE, 0.1M IMIDAZOLE-HCL, 0.02% SODIUM AZIDE, PH 8.0 , VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 3.50 Å R-free 0.284 |
| 4P65 Crystal structure of an cyclohexylalanine substituted insulin analog. Deposited 2014-03-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
Chain E
90–110（21 aa）
Fragment：UNP residues 90-110
Chain F
25–54（30 aa）
Fragment：UNP residues 25-54
Chain G
90–110（21 aa）
Fragment：UNP residues 90-110
Chain H
25–54（30 aa）
Fragment：UNP residues 25-54
Chain I
90–110（21 aa）
Fragment：UNP residues 90-110
Chain J
25–54（30 aa）
Fragment：UNP residues 25-54
Chain K
90–110（21 aa）
Fragment：UNP residues 90-110
Chain L
25–54（30 aa）
Fragment：UNP residues 25-54
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；277 K；sodium citrate, phenol, sodium chloride, zinc acetate, tris
|
Resolution 1.50 Å R-free 0.203 |
| 4RXW Crystal Structure of the cobalt human insulin derivative Deposited 2014-12-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | CO COBALT (II) ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；293 K；the protein solution consisted 7.5 mg mL-1 Zn-free insulin in 0.02 M HCl, while the reservoir solution contained 1 mM solution of sodium citrate, pH 6.4, (acetone) = 10 %, 16,5 mM solution of cobalt(II) acetate and redistilled water, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.73 Å R-free 0.206 |
| 4RXW Crystal Structure of the cobalt human insulin derivative Deposited 2014-12-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | CO COBALT (II) ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；293 K；the protein solution consisted 7.5 mg mL-1 Zn-free insulin in 0.02 M HCl, while the reservoir solution contained 1 mM solution of sodium citrate, pH 6.4, (acetone) = 10 %, 16,5 mM solution of cobalt(II) acetate and redistilled water, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.73 Å R-free 0.206 |
| 4RXW Crystal Structure of the cobalt human insulin derivative Deposited 2014-12-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | CO COBALT (II) ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.4；293 K；the protein solution consisted 7.5 mg mL-1 Zn-free insulin in 0.02 M HCl, while the reservoir solution contained 1 mM solution of sodium citrate, pH 6.4, (acetone) = 10 %, 16,5 mM solution of cobalt(II) acetate and redistilled water, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.73 Å R-free 0.206 |
| 4UNE Human insulin B26Phe mutant crystal structure Deposited 2014-05-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：YES | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4；0.15 M NA2SO4, PH 4.0, CP 5 MG/ML
|
Resolution 1.59 Å R-free 0.180 |
| 4UNE Human insulin B26Phe mutant crystal structure Deposited 2014-05-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：YES | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4；0.15 M NA2SO4, PH 4.0, CP 5 MG/ML
|
Resolution 1.59 Å R-free 0.180 |
| 4UNE Human insulin B26Phe mutant crystal structure Deposited 2014-05-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：YES Mutation：YES | SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4；0.15 M NA2SO4, PH 4.0, CP 5 MG/ML
|
Resolution 1.59 Å R-free 0.180 |
| 4UNG Human insulin B26Asn mutant crystal structure Deposited 2014-05-28 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：YES | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4；0.035 M (NH4)2SO4, PH 4.0, CP = 5 MG/ML
|
Resolution 1.81 Å R-free 0.220 |
| 4UNG Human insulin B26Asn mutant crystal structure Deposited 2014-05-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：YES | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4；0.035 M (NH4)2SO4, PH 4.0, CP = 5 MG/ML
|
Resolution 1.81 Å R-free 0.220 |
| 4UNH Human insulin B26Gly mutant crystal structure Deposited 2014-05-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：YES | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4；0.08 M NA2SO4, PH 4.0, CP = 5 MG/ML
|
Resolution 2.75 Å R-free 0.355 |
| 4WDI Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2014-09-08 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain C
39–47（9 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 SO4 SULFATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；291 K；20% PEG 3350, 0.2 M Sodium malonate, and 0.1 M Bis-Tris Propane, pH 6.5
|
Resolution 2.31 Å R-free 0.283 |
| 4WDI Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2014-09-08 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain F
39–47（9 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；291 K；20% PEG 3350, 0.2 M Sodium malonate, and 0.1 M Bis-Tris Propane, pH 6.5
|
Resolution 2.31 Å R-free 0.283 |
| 4XC4 Insulin co-crystallizes in the presence of it beta-cell chaperone sulfatide Deposited 2014-12-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 NA SODIUM ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；1.3M MAGNESIUM SULFATE, 0.1M MES
|
Resolution 1.50 Å R-free 0.254 |
| 4Y19 immune complex Deposited 2015-02-07 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
75–90（16 aa）
Fragment：UNP residues 75-90
|
Not recorded | MLI MALONATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；293 K；100 mM MES pH 6.0, 2 M ammonium sulfate and 0.2 M sodium malonate
|
Resolution 2.50 Å R-free 0.196 |
| 4Y1A immune complex Deposited 2015-02-07 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
75–90（16 aa）
Fragment：UNP residues 75-90
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；BisTris, ammonium sulfate and pentaerythritol ethoxylate (3/4 EO/OH)
|
Resolution 4.00 Å R-free 0.283 |
| 4Z76 Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2015-04-06 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain C
39–47（9 aa）
Fragment：UNP residues 39-47
|
Not recorded | EDO 1,2-ETHANEDIOL × 5 GOL GLYCEROL × 2 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；291 K；G9V crystals were grown in 20% PEG 6000, 0.2 M calcium chloride, 0.1 M Tris propane pH 8.0
|
Resolution 1.88 Å R-free 0.230 |
| 4Z76 Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2015-04-06 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain F
39–47（9 aa）
Fragment：UNP residues 39-47
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 GOL GLYCEROL × 1 SO4 SULFATE ION × 11 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；291 K；G9V crystals were grown in 20% PEG 6000, 0.2 M calcium chloride, 0.1 M Tris propane pH 8.0
|
Resolution 1.88 Å R-free 0.230 |
| 4Z77 Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2015-04-06 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain C
39–47（9 aa）
Fragment：UNP residues 39-47
|
Not recorded | GOL GLYCEROL × 4 15P POLYETHYLENE GLYCOL (N=34) × 1 EDO 1,2-ETHANEDIOL × 7 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；291 K；20% PEG 6000, 0.2 M calcium chloride, 0.1 M Tris propane pH 8.0
|
Resolution 1.85 Å R-free 0.253 |
| 4Z77 Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2015-04-06 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain F
39–47（9 aa）
Fragment：UNP residues 39-47
|
Not recorded | GOL GLYCEROL × 3 15P POLYETHYLENE GLYCOL (N=34) × 2 EDO 1,2-ETHANEDIOL × 5 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；291 K；20% PEG 6000, 0.2 M calcium chloride, 0.1 M Tris propane pH 8.0
|
Resolution 1.85 Å R-free 0.253 |
| 4Z78 Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2015-04-06 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain C
39–48（10 aa）
Fragment：UNP residues 39-48
|
Not recorded | EDO 1,2-ETHANEDIOL × 3 GOL GLYCEROL × 2 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；291 K；4% PEG 4000, 0.1 M sodium acetate pH 4.6
|
Resolution 2.30 Å R-free 0.233 |
| 4Z78 Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2015-04-06 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain F
39–48（10 aa）
Fragment：UNP residues 39-48
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 GOL GLYCEROL × 2 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；291 K；4% PEG 4000, 0.1 M sodium acetate pH 4.6
|
Resolution 2.30 Å R-free 0.233 |
| 4Z78 Weak TCR binding to an unstable insulin epitope drives type 1 diabetes Deposited 2015-04-06 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain I
39–48（10 aa）
Fragment：UNP residues 39-48
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 GOL GLYCEROL × 2 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；291 K；4% PEG 4000, 0.1 M sodium acetate pH 4.6
|
Resolution 2.30 Å R-free 0.233 |
| 5AIY R6 HUMAN INSULIN HEXAMER (SYMMETRIC), NMR, 'RED' SUBSTATE, AVERAGE STRUCTURE Deposited 1998-12-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain B
25–54（30 aa）
Fragment：BETA CHAIN
Chain C
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain D
25–54（30 aa）
Fragment：BETA CHAIN
Chain E
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain F
25–54（30 aa）
Fragment：BETA CHAIN
Chain G
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain H
25–54（30 aa）
Fragment：BETA CHAIN
Chain I
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain J
25–54（30 aa）
Fragment：BETA CHAIN
Chain K
90–110（21 aa）
Fragment：ALPHA CHAIN
Chain L
25–54（30 aa）
Fragment：BETA CHAIN
|
Not recorded | IPH PHENOL × 6 |
SOLUTION NMR
NMR measurement conditions
pH 8；310 K；Pressure 1
NMR sample composition
H2O AND D2O
|
Resolution not provided |
| 5BOQ Human insulin with intra-chain chemical crosslink between modified B24 and B29 Deposited 2015-05-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: Tetrameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain E
90–110（21 aa）
Fragment：UNP residues 90-110
Chain F
25–54（30 aa）
Fragment：UNP residues 25-54
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 3；293 K；0.1 M (NH4)2SO4, 1% (v/v) dioxane
|
Resolution 1.70 Å R-free 0.232 |
| 5BOQ Human insulin with intra-chain chemical crosslink between modified B24 and B29 Deposited 2015-05-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: Tetrameric |
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
Chain G
90–110（21 aa）
Fragment：UNP residues 90-110
Chain H
25–54（30 aa）
Fragment：UNP residues 25-54
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 3；293 K；0.1 M (NH4)2SO4, 1% (v/v) dioxane
|
Resolution 1.70 Å R-free 0.232 |
| 5BPO Human insulin with intra-chain chemical crosslink between modified B27 and B29 Deposited 2015-05-28 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 3；293 K；0.05 M Li2SO4
|
Resolution 1.90 Å R-free 0.304 |
| 5BQQ Human insulin with intra-chain chemical crosslink between modified B27 and B30 Deposited 2015-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–52（28 aa）
Chain C
90–110（21 aa）
Chain D
25–52（28 aa）
Chain E
90–110（21 aa）
Chain F
25–52（28 aa）
Chain G
90–110（21 aa）
Chain H
25–52（28 aa）
Chain I
90–110（21 aa）
Chain J
25–52（28 aa）
Chain K
90–110（21 aa）
Chain L
25–52（28 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 10 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.6 M Na2SO4, 0.3 M Tris pH 7.5, 0.6 mM Zn(Ac)2, 0.06% (w/v) phenol
|
Resolution 1.54 Å R-free 0.195 |
| 5BTS Structural and biophysical characterization of a covalent insulin dimer formed during storage of neutral formulation of human insulin Deposited 2015-06-03 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；0.2 M Ammonium sulfate, 0.1 M Hepes, 25% w/v PEG3350
|
Resolution 1.77 Å R-free 0.206 |
| 5CJO Crystal Structure Analysis of Elbow-Engineered-Fab-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin Deposited 2015-07-14 | Different construct Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain a
90–109（20 aa）
|
Not recorded | EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 2 ZN ZINC ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291.15 K；6% v/v Tacsimate pH 7.0, 0.1 M HEPES pH 7.0, 8% w/v Polyethylene glycol monomethyl ether 5,000, and 8% v/v tert-butanol as additive.
|
Resolution 3.29 Å R-free 0.245 |
| 5CNY Crystal Structure of human zinc insulin at pH 5.5 Deposited 2015-07-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；293 K；2 mcL protein (6 mg/mL) + 2 mcL well (0.1 M Na2HPO4 pH 5.5, 10 % m/v PEG 6,000)
|
Resolution 1.70 Å R-free 0.213 |
| 5CO2 Crystalization of human zinc insulin at pH 5.5 Deposited 2015-07-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.5；298 K；2 mcL protein (6 mg/mL in 2 mM HCl) + 2 mcL well solution (0.1 M Na2HPO4 pH 5.5, 10 % m/v PEG 6,000)
|
Resolution 1.70 Å R-free 0.217 |
| 5CO6 Crystal structure of human zinc insulin at pH 6.5 Deposited 2015-07-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 MG MAGNESIUM ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；2 mcL protein (6 mg/mL) + 2 mcL well 0.1 M MES buffer pH 6.5, 1.6 M MgSO4 (directly from the commercially available kit Hampton Crystal Screen II, formulation 20)
|
Resolution 1.80 Å R-free 0.226 |
| 5CO9 Crystal structure of human zinc insulin at pH 6.5 Deposited 2015-07-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
Chain C
90–110（21 aa）
Fragment：UNP residues 90-110
Chain D
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；2 mcL protein (6 mg/mL) + 2 mcL well (0.1 M MES buffer pH 6.5, 1.6 M MgSO4, directly from the commercially available kit Hampton Crystal Screen II, formulation #20)
|
Resolution 1.92 Å R-free 0.237 |
| 5E7W X-ray Structure of Human Recombinant 2Zn insulin at 0.92 Angstrom Deposited 2015-10-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 ACT ACETATE ION × 3 POL N-PROPANOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 6.3；293 K；The crystals were prepared by a batch method similar to that of Baker et al, 1988 [1], modified as follows: 0.01g of insulin as a fine powder was placed in a clean test tube; 0.02M HCl was added to dissolve the protein; on addition of 0.15 mL of 0.15 M zinc acetate the solution became cloudy due to precipitation of the protein; 0.3 mL of acetone and then 0.5 mL of trisodium citrate together with 0.8 mL of water were added and the solution went clear; the pH was checked and increased with NaOH to a pH between 8 and 9 for different batches, thus ensuring complete dissolution. It was then adjusted to the required value of pH 6.3. If any slight turbidity occurred, it was removed by warming the solution. The solution was then filtered using a Millipore membrane/acetate cellulose acetate filter. This removes any nuclei which will encourage precipitation or formation of masses of small crystals.
The solution was then warmed to 50 deg C by surrounding the test tube with preheated water in a Dewar. This allowed the solution to cool slowly to room temperature. The test tube was lightly sealed with cling film; crystals formed within a few days and were of suitable size for X-ray diffraction within two weeks; the test tube containing crystals was kept at 4 degC prior to data collection. The crystal used for data collection was about 0.2 mm3.
|
Resolution 0.95 Å R-free 0.144 |
| 5EMS Crystal Structure of an iodinated insulin analog Deposited 2015-11-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.1 M sodium citrate, 0.08% zinc acetate, 2% phenol
|
Resolution 2.30 Å R-free 0.233 |
| 5EN9 High resolution x-ray crystal structure of isotope-labeled ester-insulin Deposited 2015-11-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；0.1 M HEPES, 0.2 M sodium citrate tribasic dihydrate, 13% MPD
|
Resolution 1.50 Å R-free 0.177 |
| 5EN9 High resolution x-ray crystal structure of isotope-labeled ester-insulin Deposited 2015-11-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；0.1 M HEPES, 0.2 M sodium citrate tribasic dihydrate, 13% MPD
|
Resolution 1.50 Å R-free 0.177 |
| 5ENA Xray crystal structure of isotope-labeled human insulin Deposited 2015-11-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：1-(13C=18O)PheB24 | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；0.1 M HEPES, 0.2 M sodium citrate tribasic dihydrate, 11% MPD
|
Resolution 1.35 Å R-free 0.164 |
| 5ENA Xray crystal structure of isotope-labeled human insulin Deposited 2015-11-09 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：1-(13C=18O)PheB24 | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；0.1 M HEPES, 0.2 M sodium citrate tribasic dihydrate, 11% MPD
|
Resolution 1.35 Å R-free 0.164 |
| 5HPR Insulin with proline analog HyP at position B28 in the T2 state Deposited 2016-01-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：Pro28Hyp Non-standard monomer：Yes (specific site not provided by mmCIF) | NA SODIUM ION × 2 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；295 K；300 mM Tris, 0.5 mM zinc acetate, 8.5% acetone, 0.5 M sodium citrate
|
Resolution 1.33 Å R-free 0.164 |
| 5HPR Insulin with proline analog HyP at position B28 in the T2 state Deposited 2016-01-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：Pro28Hyp Non-standard monomer：Yes (specific site not provided by mmCIF) | NA SODIUM ION × 3 GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；295 K；300 mM Tris, 0.5 mM zinc acetate, 8.5% acetone, 0.5 M sodium citrate
|
Resolution 1.33 Å R-free 0.164 |
| 5HPU Insulin with proline analog HyP at position B28 in the R6 state Deposited 2016-01-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；295 K；300 mM Tris, 17 mM zinc acetate, 1% phenol, 1.95 M sodium citrate
|
Resolution 2.20 Å R-free 0.218 |
| 5HQI Insulin with proline analog HzP at position B28 in the T2 state Deposited 2016-01-21 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：Pro28HzP Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.25；295 K；462.5 mM sodium citrate, 100 mM HEPES
|
Resolution 0.97 Å R-free 0.158 |
| 5HRQ Insulin with proline analog HzP at position B28 in the R6 state Deposited 2016-01-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Mutation：Pro28Hzp Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：Pro28Hzp Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：Pro28Hzp Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：Pro28Hzp Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：Pro28Hzp Non-standard monomer：Yes (specific site not provided by mmCIF) Mutation：Pro28Hzp Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；295 K；300 mM Tris, 17 mM zinc acetate, 1% phenol, 7.5% acetone, 2.675 M sodium citrate
|
Resolution 1.28 Å R-free 0.168 |
| 5MAM Human insulin in complex with serotonin Deposited 2016-11-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 SRO SEROTONIN × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；Zn-free human insulin was dissolved in 20 mM HCl at 5 mg/mL. The well solution contained 5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin. Hanging drops were set up in 1:1 protein:well volume ratios.
|
Resolution 2.20 Å R-free 0.280 |
| 5MAM Human insulin in complex with serotonin Deposited 2016-11-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
Chain M
90–110（21 aa）
Chain N
25–54（30 aa）
Chain O
90–110（21 aa）
Chain P
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 2 CL CHLORIDE ION × 2 SRO SEROTONIN × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；Zn-free human insulin was dissolved in 20 mM HCl at 5 mg/mL. The well solution contained 5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin. Hanging drops were set up in 1:1 protein:well volume ratios.
|
Resolution 2.20 Å R-free 0.280 |
| 5MAM Human insulin in complex with serotonin Deposited 2016-11-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain 0
90–110（21 aa）
Chain 1
25–54（30 aa）
Chain Q
90–110（21 aa）
Chain R
25–54（30 aa）
Chain S
90–110（21 aa）
Chain T
25–54（30 aa）
Chain U
90–110（21 aa）
Chain V
25–54（30 aa）
Chain W
90–110（21 aa）
Chain X
25–54（30 aa）
Chain Y
90–110（21 aa）
Chain Z
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 2 CL CHLORIDE ION × 2 SRO SEROTONIN × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；Zn-free human insulin was dissolved in 20 mM HCl at 5 mg/mL. The well solution contained 5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin. Hanging drops were set up in 1:1 protein:well volume ratios.
|
Resolution 2.20 Å R-free 0.280 |
| 5MAM Human insulin in complex with serotonin Deposited 2016-11-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain 2
90–110（21 aa）
Chain 3
25–54（30 aa）
Chain 4
90–110（21 aa）
Chain 5
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 SRO SEROTONIN × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；Zn-free human insulin was dissolved in 20 mM HCl at 5 mg/mL. The well solution contained 5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin. Hanging drops were set up in 1:1 protein:well volume ratios.
|
Resolution 2.20 Å R-free 0.280 |
| 5MHD Biosynthetic engineered A22S-B3K-B31R human insulin monomer structure in water/acetonitrile solutions. Deposited 2016-11-24 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Fragment：chain A
Chain B
25–55（31 aa）
Fragment：chain B
|
Mutation：22S | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 2.5；298 K；Ionic strength (raw mmCIF value) 1；Pressure ambient
NMR sample composition
2.5 mM None Insulin, 73 % None H2O, 27 % 2H CD3CN, H2O / CD3CN | H2O / CD3CN
NMR sample composition
2.5 mM None Insulin, 73 % 2H D2O, 27 % 2H CD3CN, D2O / CD3CN | D2O / CD3CN
|
Resolution not provided |
| 5MT3 Human insulin in complex with serotonin and arginine Deposited 2017-01-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 ARG ARGININE × 3 SRO SEROTONIN × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine.
|
Resolution 2.02 Å R-free 0.310 |
| 5MT3 Human insulin in complex with serotonin and arginine Deposited 2017-01-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
Chain M
90–110（21 aa）
Chain N
25–54（30 aa）
Chain O
90–110（21 aa）
Chain P
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 3 CL CHLORIDE ION × 2 ARG ARGININE × 3 SRO SEROTONIN × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine.
|
Resolution 2.02 Å R-free 0.310 |
| 5MT3 Human insulin in complex with serotonin and arginine Deposited 2017-01-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain Q
90–110（21 aa）
Chain R
25–54（30 aa）
Chain S
90–110（21 aa）
Chain T
25–54（30 aa）
Chain U
90–110（21 aa）
Chain V
25–54（30 aa）
Chain W
90–110（21 aa）
Chain X
25–54（30 aa）
Chain Y
90–110（21 aa）
Chain Z
25–54（30 aa）
Chain a
90–110（21 aa）
Chain b
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 1 CL CHLORIDE ION × 1 SRO SEROTONIN × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine.
|
Resolution 2.02 Å R-free 0.310 |
| 5MT3 Human insulin in complex with serotonin and arginine Deposited 2017-01-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain c
90–110（21 aa）
Chain d
25–54（30 aa）
Chain e
90–110（21 aa）
Chain f
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 3 SRO SEROTONIN × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine.
|
Resolution 2.02 Å R-free 0.310 |
| 5MT9 Human insulin in complex with serotonin and arginine Deposited 2017-01-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 ARG ARGININE × 3 SRO SEROTONIN × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine
|
Resolution 1.88 Å R-free 0.269 |
| 5MT9 Human insulin in complex with serotonin and arginine Deposited 2017-01-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
Chain M
90–110（21 aa）
Chain N
25–54（30 aa）
Chain O
90–110（21 aa）
Chain P
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 2 CL CHLORIDE ION × 2 ARG ARGININE × 3 SRO SEROTONIN × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine
|
Resolution 1.88 Å R-free 0.269 |
| 5MT9 Human insulin in complex with serotonin and arginine Deposited 2017-01-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain Q
90–110（21 aa）
Chain R
25–54（30 aa）
Chain S
90–110（21 aa）
Chain T
25–54（30 aa）
Chain U
90–110（21 aa）
Chain V
25–54（30 aa）
Chain W
90–110（21 aa）
Chain X
25–54（30 aa）
Chain Y
90–110（21 aa）
Chain Z
25–54（30 aa）
Chain a
90–110（21 aa）
Chain b
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 2 CL CHLORIDE ION × 2 SRO SEROTONIN × 7 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine
|
Resolution 1.88 Å R-free 0.269 |
| 5MT9 Human insulin in complex with serotonin and arginine Deposited 2017-01-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain c
90–110（21 aa）
Chain d
25–54（30 aa）
Chain e
90–110（21 aa）
Chain f
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 SRO SEROTONIN × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；5 mM ZnAcetate, 35 mM NaCitrate, 1.1 M NaCl, 0.3M Tris pH 7.5, 40 mM serotonin, 100 mM arginine
|
Resolution 1.88 Å R-free 0.269 |
| 5MWQ Biosynthetic engineered A21K-B31K-B32R human insulin monomer structure in water/acetonitrile solution Deposited 2017-01-19 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–56（32 aa）
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 2.5；298 K；Ionic strength (raw mmCIF value) 0；Pressure ambient
NMR sample composition
2.5 mM insulin, 73% H2O/27% CD3CN | 73% H2O/27% CD3CN
NMR sample composition
2.5 mM insulin, 73% D2O/27% CD3CN | 73% D2O/27% CD3CN
|
Resolution not provided |
| 5T7R A6-A11 trans-dicarba human insulin Deposited 2016-09-05 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：C6(ABA), C11(ABA) Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；300 K；0.9 M potassium sodium tartrate, 0.1 M Tris HCl pH 8.5, 0.5% PEG 5000 MME
|
Resolution 1.55 Å R-free 0.217 |
| 5T7R A6-A11 trans-dicarba human insulin Deposited 2016-09-05 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：C6(ABA), C11(ABA) Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；300 K；0.9 M potassium sodium tartrate, 0.1 M Tris HCl pH 8.5, 0.5% PEG 5000 MME
|
Resolution 1.55 Å R-free 0.217 |
| 5UDP High resolution x-ray crystal structure of synthetic insulin lispro Deposited 2016-12-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain D
25–54（30 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain I
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | IPH PHENOL × 3 ZN ZINC ION × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.2；292 K；0.3 M TRIS, 0.5 M sodium sulfate, 0.6 mM Zinc acetate, 0.06% phenol
|
Resolution 1.35 Å R-free 0.194 |
| 5UDP High resolution x-ray crystal structure of synthetic insulin lispro Deposited 2016-12-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain E
90–110（21 aa）
Chain H
25–54（30 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
|
Not recorded | IPH PHENOL × 3 ZN ZINC ION × 1 CL CHLORIDE ION × 1 NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.2；292 K；0.3 M TRIS, 0.5 M sodium sulfate, 0.6 mM Zinc acetate, 0.06% phenol
|
Resolution 1.35 Å R-free 0.194 |
| 5UOZ Insulin with proline analog FyP at position B28 in the T2 state Deposited 2017-02-01 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；293 K；0.3M Tris, 0.5mM Zinc Acetate, 425mM Sodium Citrate
|
Resolution 1.17 Å R-free 0.155 |
| 5UQA Insulin with proline analog FzP at position B28 in the R6 state Deposited 2017-02-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 NA SODIUM ION × 6 GOL GLYCEROL × 1 ACN ACETONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；0.3M Tris pH8, 17mM Zinc Acetate, 1% Phenol, 0.3875M Sodium Citrate, 2.1% Acetone
|
Resolution 1.31 Å R-free 0.182 |
| 5URT Insulin with proline analog DhP at position B28 in the T2 state Deposited 2017-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.75；293 K；200mM Sodium Citrate, 100mM Hepes pH 7.75
|
Resolution 1.18 Å R-free 0.142 |
| 5URT Insulin with proline analog DhP at position B28 in the T2 state Deposited 2017-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | NA SODIUM ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.75；293 K；200mM Sodium Citrate, 100mM Hepes pH 7.75
|
Resolution 1.18 Å R-free 0.142 |
| 5URU Insulin with proline analog DhP at position B28 in the R6 state Deposited 2017-02-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；300mM Tris pH 8, 17mM Zinc Acetate, 1% Phenol, 313mM Sodium Citrate, 11.25% Acetone
|
Resolution 2.41 Å R-free 0.246 |
| 5URU Insulin with proline analog DhP at position B28 in the R6 state Deposited 2017-02-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；300mM Tris pH 8, 17mM Zinc Acetate, 1% Phenol, 313mM Sodium Citrate, 11.25% Acetone
|
Resolution 2.41 Å R-free 0.246 |
| 5USP Insulin with proline analog Pip at position B28 in the T2 state Deposited 2017-02-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；275mM Sodium Citrate, 100mM Hepes pH 8.0
|
Resolution 1.17 Å R-free 0.153 |
| 5USP Insulin with proline analog Pip at position B28 in the T2 state Deposited 2017-02-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；275mM Sodium Citrate, 100mM Hepes pH 8.0
|
Resolution 1.17 Å R-free 0.153 |
| 5USS Insulin with proline analog PiP at position B28 in the R6 state Deposited 2017-02-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；300mM Tris pH 8, 17mM Zinc Acetate, 1% phenol, 313mM Sodium Citrate, 11.25% Acetone
|
Resolution 2.06 Å R-free 0.225 |
| 5USV Insulin with proline analog AzeP at position B28 in the T2 state Deposited 2017-02-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.75；293 K；238mM Sodium citrate, 100mM Hepes pH 7.75
|
Resolution 1.30 Å R-free 0.159 |
| 5USV Insulin with proline analog AzeP at position B28 in the T2 state Deposited 2017-02-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.75；293 K；238mM Sodium citrate, 100mM Hepes pH 7.75
|
Resolution 1.30 Å R-free 0.159 |
| 5UU2 Insulin with proline analog ThioP at position B28 in the T2 state Deposited 2017-02-15 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；238mM Sodium Citrate, 100mM Hepes pH 8.5
|
Resolution 1.22 Å R-free 0.156 |
| 5UU2 Insulin with proline analog ThioP at position B28 in the T2 state Deposited 2017-02-15 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；238mM Sodium Citrate, 100mM Hepes pH 8.5
|
Resolution 1.22 Å R-free 0.156 |
| 5UU3 Insulin with proline analog DfP at position B28 in the R6 state Deposited 2017-02-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；300mM Tris pH 8, 17mM Zinc Acetate, 1% phenol, 425mM Sodium Citrate, 15% Acetone
|
Resolution 2.25 Å R-free 0.292 |
| 5UU3 Insulin with proline analog DfP at position B28 in the R6 state Deposited 2017-02-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain M
90–110（21 aa）
Chain N
25–54（30 aa）
Chain O
90–110（21 aa）
Chain P
25–54（30 aa）
Chain Q
90–110（21 aa）
Chain R
25–54（30 aa）
Chain S
90–110（21 aa）
Chain T
25–54（30 aa）
Chain U
90–110（21 aa）
Chain V
25–54（30 aa）
Chain W
90–110（21 aa）
Chain X
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 5 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；300mM Tris pH 8, 17mM Zinc Acetate, 1% phenol, 425mM Sodium Citrate, 15% Acetone
|
Resolution 2.25 Å R-free 0.292 |
| 5UU4 Insulin with proline analog ThioP at position B28 in the R6 state Deposited 2017-02-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；300mM Tris pH 8, 17mM Zinc Acetate, 1% Phenol, 275mM Sodium Citrate, 9.38% Acetone
|
Resolution 1.97 Å R-free 0.264 |
| 5VIZ X-Ray structure of Insulin Glargine Deposited 2017-04-17 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–109（20 aa）
Chain B
25–53（29 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；291 K；Microbatch
|
Resolution 1.70 Å R-free 0.183 |
| 5WBT Solution Structure and Dynamics of an Ultra-Stable Single-Chain Insulin Analog STUDIES OF AN ENGINEERED MONOMER AND IMPLICATIONS FOR RECEPTOR BINDING Deposited 2017-06-29 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–54（30 aa）
Fragment：residues 25-110
Chain A
90–110（21 aa）
Fragment：residues 25-110
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7.4；298 K；Ionic strength (raw mmCIF value) 0；Pressure 1
NMR sample composition
1 mM [U-13C; U-15N] Single chain insulin SCI-b, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 5WOB Crystal Structure Analysis of Fab1-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin Deposited 2017-08-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain a
90–109（20 aa）
Chain b
90–109（20 aa）
|
Not recorded | ZN ZINC ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291.15 K；0.1M Sodium cacodylate, pH6.5; 0.2M MgCl2; 10% PEG3000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
|
Resolution 3.95 Å R-free 0.291 |
| 5WOB Crystal Structure Analysis of Fab1-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin Deposited 2017-08-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain c
90–109（20 aa）
Chain d
90–109（20 aa）
|
Not recorded | ZN ZINC ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291.15 K；0.1M Sodium cacodylate, pH6.5; 0.2M MgCl2; 10% PEG3000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
|
Resolution 3.95 Å R-free 0.291 |
| 5WOB Crystal Structure Analysis of Fab1-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin Deposited 2017-08-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain e
90–109（20 aa）
Chain f
90–109（20 aa）
|
Not recorded | ZN ZINC ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291.15 K；0.1M Sodium cacodylate, pH6.5; 0.2M MgCl2; 10% PEG3000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
|
Resolution 3.95 Å R-free 0.291 |
| 5WOB Crystal Structure Analysis of Fab1-Bound Human Insulin Degrading Enzyme (IDE) in Complex with Insulin Deposited 2017-08-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain g
90–109（20 aa）
Chain h
90–109（20 aa）
|
Not recorded | ZN ZINC ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；291.15 K；0.1M Sodium cacodylate, pH6.5; 0.2M MgCl2; 10% PEG3000, VAPOR DIFFUSION, HANGING DROP, temperature 291.15K
|
Resolution 3.95 Å R-free 0.291 |
| 6B3Q Cryo-EM structure of human insulin degrading enzyme in complex with insulin Deposited 2017-09-22 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain a
1–110（110 aa）
Chain b
1–110（110 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.8
cryo-EM vitrification conditions
Cryogen ETHANE；The cryo grids were made using Spotiton and homemade plunger
|
Resolution 3.70 Å |
| 6B70 Cryo-EM structure of human insulin degrading enzyme in complex with FAB H11-E heavy chain, FAB H11-E light chain and insulin Deposited 2017-10-03 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain a
1–110（110 aa）
Chain c
1–110（110 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.8
cryo-EM vitrification conditions
Cryogen ETHANE；The cryo grids were made using Spotiton and homemade plunger
|
Resolution 3.70 Å |
| 6BFC Cryo-EM structure of human insulin degrading enzyme in complex with insulin Deposited 2017-10-26 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain a
1–110（110 aa）
Chain b
1–110（110 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.8
cryo-EM vitrification conditions
Cryogen ETHANE；Grids made using Spotiton
|
Resolution 3.70 Å |
| 6CE7 Insulin Receptor ectodomain in complex with one insulin molecule Deposited 2018-02-11 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain N
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5；Hepes Saline (HBS)
cryo-EM vitrification conditions
Cryogen ETHANE；Grids made with SpotItOn
|
Resolution 7.40 Å |
| 6CE9 Insulin Receptor ectodomain in complex with two insulin molecules Deposited 2018-02-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 8 PDB declaration: octameric |
Chain K
90–110（21 aa）
Chain N
90–110（21 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5；Hepes Saline (HBS)
cryo-EM vitrification conditions
Cryogen ETHANE；Grids made with SpotItOn
|
Resolution 4.30 Å |
| 6CEB Insulin Receptor ectodomain in complex with two insulin molecules - C1 symmetry Deposited 2018-02-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 8 PDB declaration: octameric |
Chain K
90–110（21 aa）
Chain N
90–110（21 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5；Hepes Saline (HBS)
cryo-EM vitrification conditions
Cryogen ETHANE；Grids made with SpotItOn
|
Resolution 4.70 Å |
| 6CK2 Insulin analog containing a YB26W mutation Deposited 2018-02-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | ZN ZINC ION × 6 IPH PHENOL × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；Crystals were obtained by hanging-drop vapor diffusion at room temperature in the presence of a 1:1.7 ratio of Zn2+ to protein monomer and a 3.5:1 ratio of phenol to protein monomer in Tris-HCl
|
Resolution 2.25 Å R-free 0.247 |
| 6GNQ Monoclinic crystalline form of human insulin, complexed with meta-cresol Deposited 2018-05-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | CRS M-CRESOL × 6 EDO 1,2-ETHANEDIOL × 6 ZN ZINC ION × 2 IS8 isothiocyanate × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 6.1；298 K；sodium-monopotassium phosphate buffer, zinc acetate, m-cresol
|
Resolution 2.20 Å R-free 0.279 |
| 6GNQ Monoclinic crystalline form of human insulin, complexed with meta-cresol Deposited 2018-05-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain M
90–110（21 aa）
Chain N
25–54（30 aa）
Chain O
90–110（21 aa）
Chain P
25–54（30 aa）
Chain Q
90–110（21 aa）
Chain R
25–54（30 aa）
Chain S
90–110（21 aa）
Chain T
25–54（30 aa）
Chain U
90–110（21 aa）
Chain V
25–54（30 aa）
Chain W
90–110（21 aa）
Chain X
25–54（30 aa）
|
Not recorded | CRS M-CRESOL × 6 EDO 1,2-ETHANEDIOL × 4 ZN ZINC ION × 2 IS8 isothiocyanate × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 6.1；298 K；sodium-monopotassium phosphate buffer, zinc acetate, m-cresol
|
Resolution 2.20 Å R-free 0.279 |
| 6GV0 Insulin glulisine Deposited 2018-06-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain B
25–54（30 aa）
Chain D
25–54（30 aa）
Chain G
90–110（21 aa）
Chain I
90–110（21 aa）
|
Not recorded | ZN ZINC ION × 6 FMT FORMIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；0.2-0.4M Mg-formate 0.1M BisTris buffer
|
Resolution 1.26 Å R-free 0.152 |
| 6H3M The crystal structure of a human seleno-insulin analog Deposited 2018-07-19 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain J
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.8 M NaCl, 35 mM NaCitrate, 0.5 mM ZnAcetate, 0.3 M Tris pH 7.5
|
Resolution 1.82 Å R-free 0.229 |
| 6H3M The crystal structure of a human seleno-insulin analog Deposited 2018-07-19 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain B
25–54（30 aa）
Chain E
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.8 M NaCl, 35 mM NaCitrate, 0.5 mM ZnAcetate, 0.3 M Tris pH 7.5
|
Resolution 1.82 Å R-free 0.229 |
| 6H3M The crystal structure of a human seleno-insulin analog Deposited 2018-07-19 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.8 M NaCl, 35 mM NaCitrate, 0.5 mM ZnAcetate, 0.3 M Tris pH 7.5
|
Resolution 1.82 Å R-free 0.229 |
| 6H3M The crystal structure of a human seleno-insulin analog Deposited 2018-07-19 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain F
25–54（30 aa）
Chain K
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.8 M NaCl, 35 mM NaCitrate, 0.5 mM ZnAcetate, 0.3 M Tris pH 7.5
|
Resolution 1.82 Å R-free 0.229 |
| 6H3M The crystal structure of a human seleno-insulin analog Deposited 2018-07-19 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.8 M NaCl, 35 mM NaCitrate, 0.5 mM ZnAcetate, 0.3 M Tris pH 7.5
|
Resolution 1.82 Å R-free 0.229 |
| 6H3M The crystal structure of a human seleno-insulin analog Deposited 2018-07-19 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain I
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.8 M NaCl, 35 mM NaCitrate, 0.5 mM ZnAcetate, 0.3 M Tris pH 7.5
|
Resolution 1.82 Å R-free 0.229 |
| 6H3M The crystal structure of a human seleno-insulin analog Deposited 2018-07-19 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 7 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain N
90–110（21 aa）
Chain Q
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.8 M NaCl, 35 mM NaCitrate, 0.5 mM ZnAcetate, 0.3 M Tris pH 7.5
|
Resolution 1.82 Å R-free 0.229 |
| 6H3M The crystal structure of a human seleno-insulin analog Deposited 2018-07-19 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 8 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain P
25–54（30 aa）
Chain R
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1.8 M NaCl, 35 mM NaCitrate, 0.5 mM ZnAcetate, 0.3 M Tris pH 7.5
|
Resolution 1.82 Å R-free 0.229 |
| 6HN5 Leucine-zippered human insulin receptor ectodomain with single bound insulin - "upper" membrane-distal part Deposited 2018-09-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 9 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å |
| 6JK8 Cryo-EM structure of the full-length human IGF-1R in complex with insulin Deposited 2019-02-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
1–110（110 aa）
Chain D
1–110（110 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；PBS with detergent
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 5.00 Å |
| 6JR3 Crystal structure of insulin hexamer fitted into cryo EM density map where each dimer was kept as rigid body Deposited 2019-04-02 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 14.50 Å |
| 6NWV Insulin Lispro Analog Deposited 2019-02-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Mutation：P52K, K53P Mutation：P52K, K53P Mutation：P52K, K53P Mutation：P52K, K53P Mutation：P52K, K53P Mutation：P52K, K53P | CRS M-CRESOL × 7 ZN ZINC ION × 2 GOL GLYCEROL × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；0.1 M HEPES sodium pH 7.5; 0.4 M Potassium sodium tartrate tetrahydrate.
|
Resolution 1.60 Å R-free 0.257 |
| 6O17 Recombinant Human Insulin Deposited 2019-02-18 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；298 K；PEG 6000 30%
|
Resolution 1.58 Å R-free 0.201 |
| 6P4Z Structure of gadolinium-caged cobalt (III) insulin hexamer Deposited 2019-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | CO COBALT (II) ION × 6 GD GADOLINIUM ATOM × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；18% (w/v) PEG 12,000 and 0.1 M HEPES pH 7.0
|
Resolution 1.80 Å R-free 0.239 |
| 6S34 Zinc free, dimeric human insulin determined to 1.35 Angstrom resolution Deposited 2019-06-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.2 M Sodium Citrate, 0.1 M Sodium Hepes, pH 7.5, 20 % isopropanol
|
Resolution 1.35 Å R-free 0.177 |
| 6S4I Crystal structure of zinc free A14E, B25H, B29K(N(eps)-[2-(2-[2-(2-[2-(Octadecandioyl-gamma-Glu)amino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl]), desB30 human insulin Deposited 2019-06-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Mutation：Y14E Mutation：F25H,des30 | NO3 NITRATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；310 K；Protein solution: 25 mg/ml insulin added 0.1% (w/v) NVoy
Precipitant: 6.0 M ammonium nitrate, 0.1 M Tris pH 8.5
|
Resolution 1.51 Å R-free 0.212 |
| 6S4J Crystal structure of zinc free A14E, B25H, B29K(N(eps)-[2-(2-[2-(2-[2-(Octadecandioyl-gamma-Glu)amino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl]), desB27, desB30 human insulin Deposited 2019-06-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Mutation：Y14E Mutation：F25H,des27,des30 | IMD IMIDAZOLE × 3 KUT KUT [2-(2-[2-(2-[2-(Octadecandioyl-gamma-Glu)amino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl] × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；0.12M monosaccharides, 0.1M buffer system 1 pH 6.5, 20% (v/v) PEG500MME, 10% (w/v) Peg 20000 (F1 from Marpheus screen, Molecular Dimensions)
|
Resolution 1.50 Å R-free 0.210 |
| 6SOF human insulin receptor ectodomain bound by 4 insulin Deposited 2019-08-29 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 12 PDB declaration: dodecameric |
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 4.30 Å |
| 6TC2 Monoclinic human insulin in complex with p-coumaric acid Deposited 2019-11-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
1–110（110 aa）
Chain B
1–110（110 aa）
Chain C
1–110（110 aa）
Chain D
1–110（110 aa）
Chain E
1–110（110 aa）
Chain F
1–110（110 aa）
Chain G
1–110（110 aa）
Chain H
1–110（110 aa）
Chain I
1–110（110 aa）
Chain J
1–110（110 aa）
Chain K
1–110（110 aa）
Chain L
1–110（110 aa）
|
Not recorded | ZN ZINC ION × 2 PO4 PHOSPHATE ION × 3 HC4 4'-HYDROXYCINNAMIC ACID × 5 SCN THIOCYANATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 5.82；298 K；12.78 mg/mL insulin, 0.77 mM zinc acetate, 40 mM p-coumaric acid, 3.2%(w/v) PEG-1000, 10 mM sodium thiocyanate, 0.4 M phosphate mixture (Na2HPO4, KH2PO4), pH = 5.82
|
Resolution 1.36 Å R-free 0.188 |
| 6TYH Four-Disulfide Insulin Analog A22/B22 Deposited 2019-08-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Fragment：ADD ENGINEERED MUTATION INSTEAD OF EXPRESSION TAG
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Fragment：ADD ENGINEERED MUTATION INSTEAD OF EXPRESSION TAG
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Fragment：ADD ENGINEERED MUTATION INSTEAD OF EXPRESSION TAG
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Fragment：ADD ENGINEERED MUTATION INSTEAD OF EXPRESSION TAG
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Fragment：ADD ENGINEERED MUTATION INSTEAD OF EXPRESSION TAG
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Fragment：ADD ENGINEERED MUTATION INSTEAD OF EXPRESSION TAG
Chain L
25–54（30 aa）
|
Mutation：R22C Mutation：R22C Mutation：R22C Mutation：R22C Mutation：R22C Mutation：R22C | IPH PHENOL × 7 ACN ACETONE × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 2 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；Sodium Citrate, Phenol, Acetone, Zinc acetate
|
Resolution 1.60 Å R-free 0.196 |
| 6VEP Human insulin in complex with the human insulin microreceptor in turn in complex with Fv 83-7 Deposited 2020-01-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；300 K；Protein: 4.5 mg/ml in 10 mM HEPES pH 7.5
Well condition: 16% PEG 3350, 0.2 M sodium thiocyanate
|
Resolution 2.90 Å R-free 0.225 |
| 6VEP Human insulin in complex with the human insulin microreceptor in turn in complex with Fv 83-7 Deposited 2020-01-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Other combination Heteromer；Protein × 6 PDB declaration: hexameric |
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；300 K；Protein: 4.5 mg/ml in 10 mM HEPES pH 7.5
Well condition: 16% PEG 3350, 0.2 M sodium thiocyanate
|
Resolution 2.90 Å R-free 0.225 |
| 6VEP Human insulin in complex with the human insulin microreceptor in turn in complex with Fv 83-7 Deposited 2020-01-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Other combination Heteromer；Protein × 6 PDB declaration: hexameric |
Chain M
90–110（21 aa）
Chain N
25–54（30 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；300 K；Protein: 4.5 mg/ml in 10 mM HEPES pH 7.5
Well condition: 16% PEG 3350, 0.2 M sodium thiocyanate
|
Resolution 2.90 Å R-free 0.225 |
| 6VEP Human insulin in complex with the human insulin microreceptor in turn in complex with Fv 83-7 Deposited 2020-01-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Other combination Heteromer；Protein × 6 PDB declaration: hexameric |
Chain S
90–110（21 aa）
Chain T
25–54（30 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；300 K；Protein: 4.5 mg/ml in 10 mM HEPES pH 7.5
Well condition: 16% PEG 3350, 0.2 M sodium thiocyanate
|
Resolution 2.90 Å R-free 0.225 |
| 6VER Human insulin analog: [GluB10,TyrB20]-DOI Deposited 2020-01-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–46（22 aa）
|
Mutation：H10E, G20Y | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；300 K；Well condition: 100 mM Tri-HCl (pH 8.5) + 0.28 M magnesium formate. Protein: The insulin analog was prepared in a mixture that also contained receptor fragments: 5 mg/ml (IR310.T).Fv83-7 in 10mM HEPES-NaOH (pH7.5) + 0.02% NaN3 plus three mol equivalents of the IR-A alphaCT peptide 704-719 plus 1.8 mol equivalents of the analog. The analog crystallized in isolation from the receptor fragments and it is not known whether the receptor fragments aided crystallization
|
Resolution 1.05 Å R-free 0.205 |
| 6VES Human insulin analog: [GluB10,HisA8,ArgA9]-DOI Deposited 2020-01-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–46（22 aa）
|
Mutation：T8H, S9R Mutation：H10E | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；300 K；WELL CONDITION: 0.2 M calcium acetate, 0.1 M imidazole (pH 8) + 10% w/v PEG 8000
Protein was provided as a sample comprising 5 mg/ml (IR310.T).Fv83-7 in 10mM HEPES-NaOH (pH7.5) + 0.02% NaN3 plus three mol equivalents of the IR-A alphaCT peptide 704-719 plus 1.8 mol of the analog
|
Resolution 1.85 Å R-free 0.239 |
| 6VET Human insulin analog: [GluB10,HisA8,ArgA9,TyrB20]-DOI Deposited 2020-01-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–46（22 aa）
|
Mutation：T8H, S9R Mutation：H10E,G20Y | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；300 K；Well condition: 0.3 M magnesium formate plus 0.1 M TrisHCl. Protein: The insulin analog was prepared in a mixture that also contained receptor fragments: 5 mg/ml (IR310.T).Fv83-7 in 10mM HEPES-NaOH (pH7.5) + 0.02% NaN3 plus three mol equivalents of the IR-A alphaCT peptide 704-719 plus 1.8 mol equivalents of the analog. The analog crystallized in isolation from the receptor fragments and it is not known whether the receptor fragments aided crystallization
|
Resolution 1.46 Å R-free 0.238 |
| 6VET Human insulin analog: [GluB10,HisA8,ArgA9,TyrB20]-DOI Deposited 2020-01-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–46（22 aa）
|
Mutation：T8H, S9R Mutation：H10E,G20Y | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；300 K；Well condition: 0.3 M magnesium formate plus 0.1 M TrisHCl. Protein: The insulin analog was prepared in a mixture that also contained receptor fragments: 5 mg/ml (IR310.T).Fv83-7 in 10mM HEPES-NaOH (pH7.5) + 0.02% NaN3 plus three mol equivalents of the IR-A alphaCT peptide 704-719 plus 1.8 mol equivalents of the analog. The analog crystallized in isolation from the receptor fragments and it is not known whether the receptor fragments aided crystallization
|
Resolution 1.46 Å R-free 0.238 |
| 6VET Human insulin analog: [GluB10,HisA8,ArgA9,TyrB20]-DOI Deposited 2020-01-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain E
90–110（21 aa）
Chain F
25–46（22 aa）
|
Mutation：T8H, S9R Mutation：H10E,G20Y | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；300 K；Well condition: 0.3 M magnesium formate plus 0.1 M TrisHCl. Protein: The insulin analog was prepared in a mixture that also contained receptor fragments: 5 mg/ml (IR310.T).Fv83-7 in 10mM HEPES-NaOH (pH7.5) + 0.02% NaN3 plus three mol equivalents of the IR-A alphaCT peptide 704-719 plus 1.8 mol equivalents of the analog. The analog crystallized in isolation from the receptor fragments and it is not known whether the receptor fragments aided crystallization
|
Resolution 1.46 Å R-free 0.238 |
| 6X4X B24Y DKP insulin Deposited 2020-05-24 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7.4；298 K；Ionic strength (raw mmCIF value) 0.1；Pressure 1
NMR measurement conditions
pH 7.4；303 K；Ionic strength (raw mmCIF value) 0.1；Pressure 1
NMR sample composition
0.5 mM 13C, 15N B24YDKP, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
0.5 mM B24DKP, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 6Z7W Human insulin in complex with the analytical antibody HUI-018 Fab Deposited 2020-06-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；0.2 M Hepes, pH 7, 20 % (v/w) PEG 8000
|
Resolution 2.42 Å R-free 0.275 |
| 6Z7W Human insulin in complex with the analytical antibody HUI-018 Fab Deposited 2020-06-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain O
90–110（21 aa）
Chain P
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；0.2 M Hepes, pH 7, 20 % (v/w) PEG 8000
|
Resolution 2.42 Å R-free 0.275 |
| 6Z7W Human insulin in complex with the analytical antibody HUI-018 Fab Deposited 2020-06-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；0.2 M Hepes, pH 7, 20 % (v/w) PEG 8000
|
Resolution 2.42 Å R-free 0.275 |
| 6Z7W Human insulin in complex with the analytical antibody HUI-018 Fab Deposited 2020-06-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
Chain M
90–110（21 aa）
Chain N
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；0.2 M Hepes, pH 7, 20 % (v/w) PEG 8000
|
Resolution 2.42 Å R-free 0.275 |
| 6Z7W Human insulin in complex with the analytical antibody HUI-018 Fab Deposited 2020-06-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain M
90–110（21 aa）
Chain N
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；0.2 M Hepes, pH 7, 20 % (v/w) PEG 8000
|
Resolution 2.42 Å R-free 0.275 |
| 6Z7W Human insulin in complex with the analytical antibody HUI-018 Fab Deposited 2020-06-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain O
90–110（21 aa）
Chain P
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；0.2 M Hepes, pH 7, 20 % (v/w) PEG 8000
|
Resolution 2.42 Å R-free 0.275 |
| 6Z7Y Human insulin in complex with the analytical antibody OXI-005 Fab Deposited 2020-06-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.2 M magnesium chloride, 0.1 M Tris, pH 8, 20 % (w/v) PEG 6000
|
Resolution 2.20 Å R-free 0.253 |
| 6Z7Y Human insulin in complex with the analytical antibody OXI-005 Fab Deposited 2020-06-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.2 M magnesium chloride, 0.1 M Tris, pH 8, 20 % (w/v) PEG 6000
|
Resolution 2.20 Å R-free 0.253 |
| 7BW7 Cryo-EM Structure for the Ectodomain of the Full-length Human Insulin Receptor in Complex with 1 Insulin. Deposited 2020-04-13 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 3 PDB declaration: trimeric |
Chain D
25–53（29 aa）
Chain D
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.10 Å |
| 7BW8 Cryo-EM Structure for the Insulin Binding Region in the Ectodomain of the Full-length Human Insulin Receptor in Complex with 1 Insulin Deposited 2020-04-14 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 3 PDB declaration: trimeric |
Chain D
25–53（29 aa）
Chain D
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.80 Å |
| 7BWA Cryo-EM Structure for the Ectodomain of the Full-length Human Insulin Receptor in Complex with 2 Insulin Deposited 2020-04-14 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain E
25–53（29 aa）
Fragment：UNP residues 25-53, UNP residues 54-77, UNP residues 90-110
Chain E
90–110（21 aa）
Fragment：UNP residues 25-53, UNP residues 54-77, UNP residues 90-110
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.90 Å |
| 7BWA Cryo-EM Structure for the Ectodomain of the Full-length Human Insulin Receptor in Complex with 2 Insulin Deposited 2020-04-14 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Insufficient information Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
25–53（29 aa）
Fragment：UNP residues 25-53, UNP residues 54-77, UNP residues 90-110
Chain D
90–110（21 aa）
Fragment：UNP residues 25-53, UNP residues 54-77, UNP residues 90-110
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.90 Å |
| 7JP3 Des-B29,B30-insulin Deposited 2020-08-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
25–52（28 aa）
Chain A
90–110（21 aa）
Chain B
25–52（28 aa）
Chain B
90–110（21 aa）
Chain C
25–52（28 aa）
Chain C
90–110（21 aa）
Chain D
25–52（28 aa）
Chain D
90–110（21 aa）
Chain E
25–52（28 aa）
Chain E
90–110（21 aa）
Chain F
25–52（28 aa）
Chain F
90–110（21 aa）
|
Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; Mutation：;Residues corresponding to B chain amino acids 29-30 were deleted, and Pro-28 was mutated to Lys. This, in effect, is the equivalent of deleting only residues 28 and 30 of the wild-type B chain. ; | IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；1:2.5 ratio of Zn2+ to protein monomer in 0.02M Tris-HCl, 0.05M sodium citrate, 5% acetone, 0.03% phenol, 0.01% zinc acetate, PH 8.0
|
Resolution 1.95 Å R-free 0.249 |
| 7MD4 Insulin receptor ectodomain dimer complexed with two IRPA-3 partial agonists Deposited 2021-04-03 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 12 PDB declaration: dodecameric |
Chain O
90–110（21 aa）
Chain P
25–54（30 aa）
Chain Q
90–110（21 aa）
Chain R
25–54（30 aa）
Chain S
90–110（21 aa）
Chain T
25–54（30 aa）
Chain U
90–110（21 aa）
Chain V
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.50 Å |
| 7MD5 Insulin receptor ectodomain dimer complexed with two IRPA-9 partial agonists Deposited 2021-04-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 12 PDB declaration: dodecameric |
Chain O
90–110（21 aa）
Chain P
25–54（30 aa）
Chain Q
90–110（21 aa）
Chain R
25–54（30 aa）
Chain S
90–110（21 aa）
Chain T
25–54（30 aa）
Chain U
90–110（21 aa）
Chain V
25–54（30 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 5.20 Å |
| 7MQO The insulin receptor ectodomain in complex with a venom hybrid insulin analog - "head" region Deposited 2021-05-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–46（22 aa）
Chain C
90–110（21 aa）
Chain D
25–46（22 aa）
|
Mutation：N21H Mutation：H10E, G20L Mutation：N21H Mutation：H10E, G20L | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 12 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；Equal parts HBS( 50 mM HEPES pH 7.5, 150 mM NaCl ) and TBS (25 mM Tris pH 8.5, 150 mM NaCl)
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å |
| 7MQR The insulin receptor ectodomain in complex with four venom hybrid insulins - symmetric conformation Deposited 2021-05-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 10 PDB declaration: decameric |
Chain A
90–110（21 aa）
Chain B
25–46（22 aa）
Chain C
90–110（21 aa）
Chain D
25–46（22 aa）
Chain G
90–110（21 aa）
Chain H
25–46（22 aa）
Chain I
90–110（21 aa）
Chain J
25–46（22 aa）
|
Mutation：N21H Mutation：H10E, G20L Mutation：N21H Mutation：H10E, G20L Mutation：N21H Mutation：H10E, G20L Mutation：N21H Mutation：H10E, G20L | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 20 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；Equal parts HBS(50 mM HEPES pH 7.5, 150 mM NaCl ) and TBS (25 mM Tris pH 8.5, 150 mM NaCl)
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.10 Å |
| 7MQS The insulin receptor ectodomain in complex with three venom hybrid insulin molecules - asymmetric conformation Deposited 2021-05-06 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain A
90–110（21 aa）
Chain B
25–46（22 aa）
Chain C
90–110（21 aa）
Chain D
25–46（22 aa）
Chain G
90–110（21 aa）
Chain H
25–46（22 aa）
|
Mutation：N21H Mutation：H10E, G20L Mutation：N21H Mutation：H10E, G20L Mutation：N21H Mutation：H10E, G20L | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；Equal parts HBS(50 mM HEPES pH 7.5, 150 mM NaCl ) and TBS (25 mM Tris pH 8.5, 150 mM NaCl)
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.40 Å |
| 7NHU Crystal structure of desB30 insulin produced by cell free protein synthesis Deposited 2021-02-11 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Mutation：des30 | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2 M sodium formate, 20 % (w/v) PEG 3350
|
Resolution 1.40 Å R-free 0.171 |
| 7PG0 Low resolution Cryo-EM structure of full-length insulin receptor bound to 3 insulin with visible ddm micelle, conf 1 Deposited 2021-08-12 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.8
cryo-EM vitrification conditions
Cryogen ETHANE；Blotted for 3s prior to plunging
|
Resolution 7.60 Å |
| 7PG2 Low resolution Cryo-EM structure of full-length insulin receptor bound to 3 insulin, conf 1 Deposited 2021-08-12 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.8
cryo-EM vitrification conditions
Cryogen ETHANE；Blotted for 3s prior to plunging
|
Resolution 6.70 Å |
| 7PG3 Low resolution Cryo-EM structure of the full-length insulin receptor bound to 3 insulin, conf 2 Deposited 2021-08-12 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.8
cryo-EM vitrification conditions
Cryogen ETHANE；Blotted for 3s prior to plunging
|
Resolution 7.30 Å |
| 7PG4 Low resolution Cryo-EM structure of the full-length insulin receptor bound to 2 insulin, conf 3 Deposited 2021-08-12 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.8
cryo-EM vitrification conditions
Cryogen ETHANE；Blotted for 3s prior to plunging
|
Resolution 9.10 Å |
| 7QAC The T2 structure of polycrystalline cubic human insulin Deposited 2021-11-16 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
POWDER DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 8.56；293 K；13.494 mg/ml insulin, 0.818 mM zinc acetate, 10.563 mM sodium thiocyanate, 0.4 M sodium potassium phosphate (Na2HPO4/KH2PO4)
X-ray crystallization conditions
BATCH MODE；pH 7.88；293 K；13.494 mg/ml insulin, 0.818 mM zinc acetate, 10.563 mM sodium thiocyanate, 0.4 M sodium potassium phosphate (Na2HPO4/KH2PO4)
X-ray crystallization conditions
BATCH MODE；pH 8.02；293 K；13.494 mg/ml insulin, 0.818 mM zinc acetate, 10.563 mM sodium thiocyanate, 0.4 M sodium potassium phosphate (Na2HPO4/KH2PO4)
X-ray crystallization conditions
BATCH MODE；pH 8.17；293 K；13.494 mg/ml insulin, 0.818 mM zinc acetate, 10.563 mM sodium thiocyanate, 0.4 M sodium potassium phosphate (Na2HPO4/KH2PO4)
X-ray crystallization conditions
BATCH MODE；pH 8.26；293 K；13.494 mg/ml insulin, 0.818 mM zinc acetate, 10.563 mM sodium thiocyanate, 0.4 M sodium potassium phosphate (Na2HPO4/KH2PO4)
X-ray crystallization conditions
BATCH MODE；pH 8.17；293 K；13.494 mg/ml insulin, 0.818 mM zinc acetate, 10.563 mM sodium thiocyanate, 0.4 M sodium potassium phosphate (Na2HPO4/KH2PO4)
|
Resolution 2.29 Å |
| 7QGF Cubic Insulin SAD phasing at 14.2 keV Deposited 2021-12-08 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain AAA
90–110（21 aa）
Chain BBB
25–53（29 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.4 M NAPO4/NA2HPO4 PH 10.4, 0.001 M EDTA,30%ETHYLENE GLYCOL
|
Resolution 1.20 Å R-free 0.165 |
| 7QID tentative model of the human insulin receptor ectodomain bound by three insulin Deposited 2021-12-14 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 10 PDB declaration: decameric |
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 5.00 Å |
| 7RKD X-Ray structure of Insulin Analog GLULISINE Deposited 2021-07-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICROBATCH；293.15 K；0.1 M Magnesium formate dihydrate
|
Resolution 1.25 Å R-free 0.215 |
| 7RZE Insulin Degrading Enzyme pO/pC Deposited 2021-08-27 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain a
90–110（21 aa）
Chain b
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å |
| 7RZF Insulin Degrading Enzyme O/pC Deposited 2021-08-27 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain a
90–110（21 aa）
Chain b
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å |
| 7RZI Insulin Degrading Enzyme pC/pC Deposited 2021-08-27 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain a
90–110（21 aa）
Chain b
25–54（30 aa）
Chain c
90–110（21 aa）
Chain d
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å |
| 7S4Y Serial Macromolecular Crystallography at ALBA Synchrotron Light Source - Insulin Deposited 2021-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；298 K；insulin was dissolved in 5 mM zinc chloride, 25 mM HCl at a concentration of 5-10 mg/ml. Cuboid-shaped microcrystals were obtained in 35.2 mM sodium citrate pH 7, and 5% (v/v) acetone as precipitant
|
Resolution 1.71 Å R-free 0.258 |
| 7S4Y Serial Macromolecular Crystallography at ALBA Synchrotron Light Source - Insulin Deposited 2021-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；298 K；insulin was dissolved in 5 mM zinc chloride, 25 mM HCl at a concentration of 5-10 mg/ml. Cuboid-shaped microcrystals were obtained in 35.2 mM sodium citrate pH 7, and 5% (v/v) acetone as precipitant
|
Resolution 1.71 Å R-free 0.258 |
| 7SL1 Full-length insulin receptor bound with site 1 binding deficient mutant insulin (A-V3E) Deposited 2021-10-22 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain C
25–54（30 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
90–110（21 aa）
|
Mutation：V3E Mutation：V3E | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å |
| 7SL2 Full-length insulin receptor bound with site 2 binding deficient mutant insulin (A-L13R) -- asymmetric conformation Deposited 2021-10-22 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions | Assembly 1 Protein heterocomplex Heteromer；Protein × 10 PDB declaration: decameric |
Chain C
25–54（30 aa）
Chain D
25–54（30 aa）
Chain E
25–54（30 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
90–110（21 aa）
Chain I
90–110（21 aa）
Chain J
90–110（21 aa）
|
Mutation：L13R Mutation：L13R Mutation：L13R Mutation：L13R | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.60 Å |
| 7SL3 Full-length insulin receptor bound with site 2 binding deficient mutant insulin (A-L13R) -- symmetric conformation Deposited 2021-10-22 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain C
25–54（30 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
90–110（21 aa）
|
Mutation：L13R Mutation：L13R | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å |
| 7SL4 Full-length insulin receptor bound with site 2 binding deficient mutant insulin (B-L17R) -- asymmetric conformation Deposited 2021-10-22 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain C
25–54（30 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
90–110（21 aa）
|
Mutation：L17R Mutation：L17R | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 5.00 Å |
| 7SL6 Full-length insulin receptor bound with site 2 binding deficient mutant insulin (B-L17R) -- symmetric conformation Deposited 2021-10-22 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain C
90–110（21 aa）
Chain D
90–110（21 aa）
Chain E
25–54（30 aa）
Chain F
25–54（30 aa）
|
Mutation：L17R Mutation：L17R | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.70 Å |
| 7SL7 Full-length insulin receptor bound with both site 1 binding deficient mutant insulin (A-V3E) and site 2 binding deficient mutant insulin (A-L13R) Deposited 2021-10-22 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 10 PDB declaration: decameric |
Chain C
90–110（21 aa）
Chain D
90–110（21 aa）
Chain E
90–110（21 aa）
Chain F
90–110（21 aa）
Chain G
25–54（30 aa）
Chain H
25–54（30 aa）
Chain I
25–54（30 aa）
Chain J
25–54（30 aa）
|
Mutation：L13R Mutation：L13R Mutation：V3E Mutation：V3E | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å |
| 7STH Full-length insulin receptor bound with unsaturated insulin WT (2 insulin bound) symmetric conformation Deposited 2021-11-13 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
1–110（110 aa）
Chain D
1–110（110 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.50 Å |
| 7STI Full-length insulin receptor bound with unsaturated insulin WT (1 insulin bound) asymmetric conformation Deposited 2021-11-13 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain C
1–110（110 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.90 Å |
| 7STJ Full-length insulin receptor bound with unsaturated insulin WT (2 insulins bound) asymmetric conformation (Conformation 1) Deposited 2021-11-14 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
1–110（110 aa）
Chain D
1–110（110 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.40 Å |
| 7STK Full-length insulin receptor bound with unsaturated insulin WT (2 insulins bound) asymmetric conformation (Conformation 2) Deposited 2021-11-14 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
1–110（110 aa）
Chain D
1–110（110 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.00 Å |
| 7U6E Head region of insulin receptor ectodomain (A-isoform) bound to the non-insulin agonist IM462 Deposited 2022-03-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Fragment：UNP residues 90-110
Chain B
25–54（30 aa）
Fragment：UNP residues 25-54
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 6 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å |
| 7V3P Cryo-EM structure of the IGF1R/insulin complex Deposited 2021-08-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.60 Å |
| 7YQ4 human insulin receptor bound with A62 DNA aptamer and insulin - locally refined Deposited 2022-08-05 | Different structure-quality metrics | Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: pentameric |
Chain A
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.95 Å |
| 7YQ5 human insulin receptor bound with A62 DNA aptamer and insulin Deposited 2022-08-05 | Different structure-quality metrics | Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: pentameric |
Chain A
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.27 Å |
| 7Z5L Crystal structure of human insulin, crystallised in the presence of macrophage migration inhibitory factor (MIF) and dimethyl sulfoxide (DMSO) Deposited 2022-03-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | SO4 SULFATE ION × 1 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1 M Tris pH 7.5, 1.25 M ammonium sulfate and 8% (v/v) 2-propanol
|
Resolution 1.40 Å R-free 0.171 |
| 7Z5Q Crystal structure of human insulin, crystallised in the presence of macrophage migration inhibitory factor (MIF) and p-Hydroxyphenylpyruvate (HPP) Deposited 2022-03-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1 M Tris pH 7.5, 1.25 M ammonium sulfate and 8% (v/v) 2-propanol
|
Resolution 1.80 Å R-free 0.183 |
| 8EYX Cryo-EM structure of 4 insulins bound full-length mouse IR mutant with physically decoupled alpha CTs (C684S/C685S/C687S; denoted as IR-3CS) Asymmetric conformation 1 Deposited 2022-10-29 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain D
1–110（110 aa）
Chain E
1–110（110 aa）
Chain F
1–110（110 aa）
Chain G
1–110（110 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.50 Å |
| 8EYY Cryo-EM structure of 4 insulins bound full-length mouse IR mutant with physically decoupled alpha CTs (C684S/C685S/C687S, denoted as IR-3CS) Asymmetric conformation 2 Deposited 2022-10-29 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain C
1–110（110 aa）
Chain D
1–110（110 aa）
Chain E
1–110（110 aa）
Chain F
1–110（110 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.90 Å |
| 8EZ0 Cryo-EM structure of 4 insulins bound full-length mouse IR mutant with physically decoupled alpha CTs (C684S/C685S/C687S; denoted as IR-3CS) Symmetric conformation Deposited 2022-10-29 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain D
1–110（110 aa）
Chain E
1–110（110 aa）
Chain F
1–110（110 aa）
Chain G
1–110（110 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.70 Å |
| 8GSG T3R3 form of Human insulin with single Zn Deposited 2022-09-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | CRS M-CRESOL × 6 NA SODIUM ION × 3 ZN ZINC ION × 3 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；283 K；0.1 M HEPES pH7.5,10% (v/v) PEG 6000, 5% (v/v) MPD
|
Resolution 2.05 Å R-free 0.205 |
| 8GUY human insulin receptor bound with two insulin molecules Deposited 2022-09-14 | Different construct Different mutation/modification Different oligomeric state Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain C
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.18 Å |
| 8HGZ Crystal structure of insulin Deposited 2022-11-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain E
90–110（21 aa）
Chain F
25–53（29 aa）
Chain I
90–110（21 aa）
Chain J
25–53（29 aa）
|
Not recorded | IPH PHENOL × 3 ZN ZINC ION × 2 CL CHLORIDE ION × 2 MYR MYRISTIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
|
Resolution 1.70 Å R-free 0.258 |
| 8HGZ Crystal structure of insulin Deposited 2022-11-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain M
90–110（21 aa）
Chain N
25–53（29 aa）
|
Not recorded | IPH PHENOL × 2 ZN ZINC ION × 2 CL CHLORIDE ION × 2 MYR MYRISTIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
|
Resolution 1.70 Å R-free 0.258 |
| 8HSF Insulin triple mutant INS-RQD Deposited 2022-12-19 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Mutation：S9R,H10Q,E13D | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；1M Imidazole
|
Resolution 2.90 Å R-free 0.283 |
| 8HSF Insulin triple mutant INS-RQD Deposited 2022-12-19 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Mutation：S9R,H10Q,E13D | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；1M Imidazole
|
Resolution 2.90 Å R-free 0.283 |
| 8HSK Insulin single mutant INS-Q Deposited 2022-12-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
|
Mutation：H10Q | SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；0.2M Ammonium sulphate, 0.1M MES monohydrate, 30% w/v PEG MME
|
Resolution 1.64 Å R-free 0.165 |
| 8IPZ Crystal structure of insulin detemir Deposited 2023-03-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M sodium acetate trihydrate, 0.1M TRIS hydrochloride
|
Resolution 1.40 Å R-free 0.230 |
| 8IPZ Crystal structure of insulin detemir Deposited 2023-03-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain E
90–110（21 aa）
Chain F
25–53（29 aa）
Chain G
90–110（21 aa）
Chain H
25–53（29 aa）
|
Not recorded | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M sodium acetate trihydrate, 0.1M TRIS hydrochloride
|
Resolution 1.40 Å R-free 0.230 |
| 8OKY Crystal structure of D-ProB26-DTriA analogue of human insulin Deposited 2023-03-29 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–51（27 aa）
|
Mutation：D-ProB26 Non-standard monomer：Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.2；293 K；0.3 M Tris/HCl pH 8.2, 0.6 M Na2SO4, 0.6 mM ZnAc
|
Resolution 1.17 Å R-free 0.166 |
| 8ONI Human insulin in complex with the analytical antibody S1 Fab Deposited 2023-04-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain B
25–54（30 aa）
Chain I
90–110（21 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1 M HEPES pH 7.5, 25%(w/v) PEG 2000 MME
|
Resolution 2.30 Å R-free 0.237 |
| 8ONI Human insulin in complex with the analytical antibody S1 Fab Deposited 2023-04-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain F
25–54（30 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1 M HEPES pH 7.5, 25%(w/v) PEG 2000 MME
|
Resolution 2.30 Å R-free 0.237 |
| 8ONK Human insulin in complex with the analytical antibody S1 Fab and the analytical antibody HUI-001 Fab Deposited 2023-04-03 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain B
25–54（30 aa）
Chain I
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1 M TRIS pH 7.5, 15%(w/v) PEG 6000
|
Resolution 3.40 Å R-free 0.311 |
| 8ONK Human insulin in complex with the analytical antibody S1 Fab and the analytical antibody HUI-001 Fab Deposited 2023-04-03 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain A
25–54（30 aa）
Chain D
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1 M TRIS pH 7.5, 15%(w/v) PEG 6000
|
Resolution 3.40 Å R-free 0.311 |
| 8ONP Human insulin trans-HypB26-DTIA analogue Deposited 2023-04-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–50（26 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4；293 K；0.1 M Na2SO4
|
Resolution 1.77 Å R-free 0.271 |
| 8ONR Crystal structure of human insulin trans-HypB26-DTI analogue Deposited 2023-04-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–50（26 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | SO4 SULFATE ION × 2 IPH PHENOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.2；292 K；0.3M Na2SO4
0.3M Tris pH 8.2
0.6mM ZnAc
0.06% Phenol
|
Resolution 1.88 Å R-free 0.312 |
| 8PI4 Crystal structure of human insulin desB30 precursor with an Alanine-Methionine-Lysine C-peptide in dimer (T2) conformation Deposited 2023-06-21 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
25–53（29 aa）
Chain A
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；291 K；0.2 M sodium acetate trihydrate, 0.1 M Tris, pH 8.5, 30 % (w/v) PEG 4000
|
Resolution 1.25 Å R-free 0.175 |
| 8PI5 Crystal structure of human insulin desB30 precursor with an Alanine-Methionine-Lysine C-peptide in hexamer (T3R3) conformation Deposited 2023-06-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: dimeric |
Chain B
25–53（29 aa）
Chain B
90–110（21 aa）
Chain D
25–53（29 aa）
Chain D
90–110（21 aa）
|
Not recorded | ZN ZINC ION × 12 CL CHLORIDE ION × 3 RCO RESORCINOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；291 K；6 mg/ml protein, 20 mM resorcinol, 0.5 Zn2+ (from zinc acetate) per insuln monomer in water, pH 7.95
precipitant: 0.1 M Bicine, pH 9.0, 2 % (v/v) 1,4-dioxane, 10 % (w/v) PEG 20000
|
Resolution 1.66 Å R-free 0.179 |
| 8PI6 Crystal structure of the monomeric zinc free human insulin A22K, B3E, B26E, B29R, desB30 precursor with a Ser-Glu-Asp-Trp-Trp-Arg C-peptide and a Glu-Glu-Gly-Glu-Pro-Arg N-terminal extension Deposited 2023-06-21 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–53（29 aa）
Chain A
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；291 K；8 mg/ml protein in water
precipitant: 0.1 M sodium citrate, pH 5.6, 1.o M ammonium phosphate monobasic
|
Resolution 2.14 Å R-free 0.288 |
| 8PI6 Crystal structure of the monomeric zinc free human insulin A22K, B3E, B26E, B29R, desB30 precursor with a Ser-Glu-Asp-Trp-Trp-Arg C-peptide and a Glu-Glu-Gly-Glu-Pro-Arg N-terminal extension Deposited 2023-06-21 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–53（29 aa）
Chain B
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；291 K；8 mg/ml protein in water
precipitant: 0.1 M sodium citrate, pH 5.6, 1.o M ammonium phosphate monobasic
|
Resolution 2.14 Å R-free 0.288 |
| 8PI6 Crystal structure of the monomeric zinc free human insulin A22K, B3E, B26E, B29R, desB30 precursor with a Ser-Glu-Asp-Trp-Trp-Arg C-peptide and a Glu-Glu-Gly-Glu-Pro-Arg N-terminal extension Deposited 2023-06-21 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
25–53（29 aa）
Chain C
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；291 K；8 mg/ml protein in water
precipitant: 0.1 M sodium citrate, pH 5.6, 1.o M ammonium phosphate monobasic
|
Resolution 2.14 Å R-free 0.288 |
| 8PI6 Crystal structure of the monomeric zinc free human insulin A22K, B3E, B26E, B29R, desB30 precursor with a Ser-Glu-Asp-Trp-Trp-Arg C-peptide and a Glu-Glu-Gly-Glu-Pro-Arg N-terminal extension Deposited 2023-06-21 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain D
25–53（29 aa）
Chain D
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；291 K；8 mg/ml protein in water
precipitant: 0.1 M sodium citrate, pH 5.6, 1.o M ammonium phosphate monobasic
|
Resolution 2.14 Å R-free 0.288 |
| 8PI6 Crystal structure of the monomeric zinc free human insulin A22K, B3E, B26E, B29R, desB30 precursor with a Ser-Glu-Asp-Trp-Trp-Arg C-peptide and a Glu-Glu-Gly-Glu-Pro-Arg N-terminal extension Deposited 2023-06-21 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 5 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain E
25–53（29 aa）
Chain E
90–110（21 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.6；291 K；8 mg/ml protein in water
precipitant: 0.1 M sodium citrate, pH 5.6, 1.o M ammonium phosphate monobasic
|
Resolution 2.14 Å R-free 0.288 |
| 8RRP Insulin Icodec - A14E B16H B25H B29Ne-C20 diacid-LgGlu-2xAdo desB30 human insulin Deposited 2024-01-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 6 PDB declaration: hexameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
Chain E
90–110（21 aa）
Chain F
25–53（29 aa）
|
Mutation：Y14E Mutation：Y14E Mutation：Y14E | ACT ACETATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；293 K；0.02 calcium chloride
30 % 2-methyl-2,4-pentanediol
0.1M acetate pH4.6
|
Resolution 2.00 Å R-free 0.217 |
| 8RVT Structure of full-length human insulin fibrils Deposited 2024-02-02 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 10 PDB declaration: decameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
SOLID-STATE NMR
NMR measurement conditions
pH 1.9；298 K；Ionic strength (raw mmCIF value) 0.01；Pressure 1
NMR sample composition
10 mg/L [U-100% 13C; U-100% 15N] Insulin chain A, 10 mg/mL [U-100% 13C; U-100% 15N] Insulin chain B, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 8SBD Cryo-EM structure of insulin amyloid-like fibril that is composed of two antiparallel protofilaments Deposited 2023-04-03 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 32 PDB declaration: 32-meric |
Chain A
90–110（21 aa）
Chain B
90–110（21 aa）
Chain C
90–110（21 aa）
Chain D
90–110（21 aa）
Chain E
90–110（21 aa）
Chain F
90–110（21 aa）
Chain G
90–110（21 aa）
Chain H
90–110（21 aa）
Chain I
90–110（21 aa）
Chain J
90–110（21 aa）
Chain K
90–110（21 aa）
Chain L
90–110（21 aa）
Chain M
90–110（21 aa）
Chain N
90–110（21 aa）
Chain O
90–110（21 aa）
Chain P
90–110（21 aa）
Chain a
25–54（30 aa）
Chain b
25–54（30 aa）
Chain c
25–54（30 aa）
Chain d
25–54（30 aa）
Chain e
25–54（30 aa）
Chain f
25–54（30 aa）
Chain g
25–54（30 aa）
Chain h
25–54（30 aa）
Chain i
25–54（30 aa）
Chain j
25–54（30 aa）
Chain k
25–54（30 aa）
Chain l
25–54（30 aa）
Chain m
25–54（30 aa）
Chain n
25–54（30 aa）
Chain o
25–54（30 aa）
Chain p
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å |
| 8VCX Human TCR A2.13 in complex with DQ8-InsCpep Deposited 2023-12-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 5 PDB declaration: pentameric |
Chain C
64–78（15 aa）
|
Mutation：G9E, L11C | PO4 PHOSPHATE ION × 1 GOL GLYCEROL × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293.15 K；0.2 M Potassium sodium tartrate, 24% PEG 3350
|
Resolution 2.59 Å R-free 0.238 |
| 8VDD Crystal structure of Proinsulin C-peptide bound to HLA-DQ8 Deposited 2023-12-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain C
64–78（15 aa）
|
Mutation：G9E, L11C | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293.15 K；0.2 M K Na tartrate, 14% w/v PEG 20,000 with seeding and additive C8 silver bullet
|
Resolution 2.60 Å R-free 0.280 |
| 8WU0 Crystal structure of lisargine Deposited 2023-10-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–109（20 aa）
Chain B
25–56（32 aa）
Chain C
90–109（20 aa）
Chain D
25–56（32 aa）
|
Not recorded | ZN ZINC ION × 2 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 7.5；283 K；24% (v/v) 2-Propanol, 0.2 M Sodium citrate tribasic dihydrate, 0.1 M HEPES sodium pH 7.5
|
Resolution 1.95 Å R-free 0.214 |
| 8YYS Cryo-EM structure of the complex IR with two insulin Deposited 2024-04-04 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain C
1–110（110 aa）
Chain D
1–110（110 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.14 Å |
| 8Z4B Crystal structure of LysB22-AspB28 insulin analog at ambient structure Deposited 2024-04-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: 12-meric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZN ZINC ION × 6 CL CHLORIDE ION × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；2.4 M NaCl, 100 mM Tris-HCl at pH 7.4, 6 mM ZnCI2, 20 (w/v) poly(ethylene glycol) PEG-8000
|
Resolution 2.50 Å R-free 0.357 |
| 9CIV X-Ray Structure of Insulin Analog DETEMIR Deposited 2024-07-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | IPH PHENOL × 3 ZN ZINC ION × 6 CL CHLORIDE ION × 6 CRS M-CRESOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICROBATCH；293 K；0.2M Lithium sulfate monohydrate, 0.1M Tris pH 8.5, 25% w/v PEG 3350
|
Resolution 1.60 Å R-free 0.248 |
| 9DNN Insulin receptor in complex with both insulin and de novo designed site-2 binder "S2B". Deposited 2024-09-17 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric |
Chain C
1–110（110 aa）
Chain D
1–110（110 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 6.10 Å |
| 9IBB Rhombohedral crystalline form of human insulin complexed with m-cresol Deposited 2025-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | CRS M-CRESOL × 2 SCN THIOCYANATE ION × 1 ZN ZINC ION × 2 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 7.5；294.15 K；13.14 mg/mL human insulin, 0.80 mM zinc acetate, 0.51% v/v m-cresol in ethanol, 10.25 mM sodium thiocyanate, 0.4 M sodium-monopotassium phosphate mixture
|
Resolution 1.84 Å R-free 0.224 |
| 9LVC Temperature induces a shift from the dihexamer to the hexamer form of insulin Deposited 2025-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
|
Resolution 2.30 Å R-free 0.287 |
| 9LVC Temperature induces a shift from the dihexamer to the hexamer form of insulin Deposited 2025-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain E
90–110（21 aa）
Chain F
25–53（29 aa）
Chain G
90–110（21 aa）
Chain H
25–53（29 aa）
|
Not recorded | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
|
Resolution 2.30 Å R-free 0.287 |
| 9LVD Temperature induces a shift from the dihexamer to the hexamer form of insulin (200K) Deposited 2025-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
|
Resolution 2.85 Å R-free 0.330 |
| 9LVE Temperature induces a shift from the dihexamer to the hexamer form of insulin (300K) Deposited 2025-02-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
|
Resolution 2.88 Å R-free 0.388 |
| 9LVX di-hexamer form of insulin detemir at ambient temperature Deposited 2025-02-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
|
Resolution 2.70 Å R-free 0.322 |
| 9LVX di-hexamer form of insulin detemir at ambient temperature Deposited 2025-02-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain E
90–110（21 aa）
Chain F
25–53（29 aa）
Chain G
90–110（21 aa）
Chain H
25–53（29 aa）
|
Not recorded | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
|
Resolution 2.70 Å R-free 0.322 |
| 9LVY hexamer form of insulin detemir at ambient temperature Deposited 2025-02-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
|
Not recorded | IPH PHENOL × 6 ZN ZINC ION × 6 CL CHLORIDE ION × 6 MYR MYRISTIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.2M sodium acetate trihydrate, 0.1M tris hydrochloride pH 9
|
Resolution 2.85 Å R-free 0.338 |
| 9M4X Cubic insulin crystal, Esrapid, at pH 2 Deposited 2025-03-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–109（20 aa）
Chain B
25–53（29 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20mM citric acid, 0.5M sodium phosphate dibasic dihydrate, 0.1M sodium sulfate, pH 2
|
Resolution 1.40 Å R-free 0.221 |
| 9M4Y Cubic insulin crystal, Esrapid, at pH 3 Deposited 2025-03-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–109（20 aa）
Chain B
25–53（29 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20mM citric acid, 0.5M sodium phosphate dibasic dihydrate, 0.1M sodium sulfate, pH 3
|
Resolution 1.40 Å R-free 0.214 |
| 9M4Z Cubic insulin crystal, Esrapid, at pH 4 Deposited 2025-03-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–109（20 aa）
Chain B
25–53（29 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20mM citric acid, 0.5M sodium phosphate dibasic dihydrate, 0.1M sodium sulfate, pH 4
|
Resolution 1.50 Å R-free 0.217 |
| 9M50 Cubic insulin crystal, Esrapid, at pH 5 Deposited 2025-03-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–109（20 aa）
Chain B
25–53（29 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20mM citric acid, 0.5M sodium phosphate dibasic dihydrate, 0.1M sodium sulfate, pH 5
|
Resolution 1.40 Å R-free 0.211 |
| 9M51 Cubic insulin crystal, Esrapid, at pH 6 Deposited 2025-03-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–109（20 aa）
Chain B
25–53（29 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；20mM citric acid, 0.5M sodium phosphate dibasic dihydrate, 0.1M sodium sulfate, pH 6
|
Resolution 1.76 Å R-free 0.226 |
| 9PUW Insulin Receptor bound to Ins-AC-S2 Deposited 2025-07-31 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric |
Chain P
25–53（29 aa）
Chain R
25–53（29 aa）
|
Not recorded | No recorded non-water small molecule | ELECTRON MICROSCOPY mmCIF provides none of the parsed conditions | Resolution 3.64 Å |
| 9PVO Novel site 1 interaction of the IR/Ins-AC-S2 complex Deposited 2025-08-03 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain R
25–53（29 aa）
|
Not recorded | No recorded non-water small molecule | ELECTRON MICROSCOPY mmCIF provides none of the parsed conditions | Resolution 3.89 Å |
| 9QLD Rhombohedral crystalline form of human insulin complexed with m-nitrophenol Deposited 2025-03-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | ZCQ 3-nitrophenol × 1 SCN THIOCYANATE ION × 1 ZN ZINC ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 7.5；294.15 K；12.78 mg/mL human insulin, 0.77 mM zinc acetate, 40.06 mM m-nitrophenol, 10.09 mM sodium thiocyanate, 0.4 M sodium-monopotassium phosphate mixture
|
Resolution 2.55 Å R-free 0.240 |
| 9QLD Rhombohedral crystalline form of human insulin complexed with m-nitrophenol Deposited 2025-03-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
|
Not recorded | ZCQ 3-nitrophenol × 1 ZN ZINC ION × 1 ACT ACETATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 7.5；294.15 K；12.78 mg/mL human insulin, 0.77 mM zinc acetate, 40.06 mM m-nitrophenol, 10.09 mM sodium thiocyanate, 0.4 M sodium-monopotassium phosphate mixture
|
Resolution 2.55 Å R-free 0.240 |
| 9R48 Spitrobot-2 advances time-resolvedcryo-trapping crystallography to under 25 ms: Human insulin, pH 9.0 (apo state) Deposited 2025-05-07 | Different construct Different mutation/modification Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 9；293 K；1.0 M sodium/potassium phosphate, pH 9.0
|
Resolution 1.65 Å R-free 0.196 |
| 9R49 Spitrobot-2 advances time-resolvedcryo-trapping crystallography to under 25 ms: Human insulin, pH 4.5 (25 ms soaking) Deposited 2025-05-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 9；293 K；1.0 M sodium/potassium phosphate, pH 9.0 & crystal soaking in pH 4.5 for 25 ms
|
Resolution 1.64 Å R-free 0.198 |
| 9R4A Spitrobot-2 advances time-resolvedcryo-trapping crystallography to under 25 ms: Human insulin, pH 4.5 (50 ms soaking) Deposited 2025-05-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 9；293 K；1.0 M sodium/potassium phosphate, pH 9.0 & crystal soaking in pH 4.5 for 50 ms
|
Resolution 1.45 Å R-free 0.196 |
| 9R4B Spitrobot-2 advances time-resolvedcryo-trapping crystallography to under 25 ms: Human insulin, pH 4.5 (250 ms soaking) Deposited 2025-05-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 9；293 K；1.0 M sodium/potassium phosphate, pH 9.0 & crystal soaking in pH 4.5 for 250 ms
|
Resolution 1.50 Å R-free 0.208 |
| 9R4C Spitrobot-2 advances time-resolvedcryo-trapping crystallography to under 25 ms: Human insulin, pH 4.5 (500 ms soaking) Deposited 2025-05-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 9；293 K；1.0 M sodium/potassium phosphate, pH 9.0 & crystal soaking in pH 4.5 for 500 ms
|
Resolution 1.41 Å R-free 0.201 |
| 9R4E Spitrobot-2 advances time-resolvedcryo-trapping crystallography to under 25 ms: Human insulin, pH 4.5 (5 s soaking) Deposited 2025-05-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 9；293 K；1.0 M sodium/potassium phosphate, pH 9.0 & crystal soaking in pH 4.5 for 5 s
|
Resolution 1.30 Å R-free 0.194 |
| 9UTJ Monoclinic crystal structure of acid-stable protracted insulin Deposited 2025-05-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–53（29 aa）
Chain C
90–110（21 aa）
Chain D
25–53（29 aa）
Chain E
90–110（21 aa）
Chain F
25–53（29 aa）
Chain G
90–110（21 aa）
Chain H
25–53（29 aa）
Chain I
90–110（21 aa）
Chain J
25–53（29 aa）
Chain K
90–110（21 aa）
Chain L
25–53（29 aa）
|
Not recorded | CRS M-CRESOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 CA CALCIUM ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；200mM CaCl2 buffered in 100mM Tris-HCl pH 8,5, 30% (v/v) 2-Methyl-2,4-pentanediol, 8% (w/v) PEG 8000
|
Resolution 1.95 Å R-free 0.235 |
| 9UTK Monoclinic crystal structure of acid-stable protracted insulin (293 K) Deposited 2025-05-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 12 PDB declaration: dodecameric |
Chain A
90–110（21 aa）
Chain B
25–54（30 aa）
Chain C
90–110（21 aa）
Chain D
25–54（30 aa）
Chain E
90–110（21 aa）
Chain F
25–54（30 aa）
Chain G
90–110（21 aa）
Chain H
25–54（30 aa）
Chain I
90–110（21 aa）
Chain J
25–54（30 aa）
Chain K
90–110（21 aa）
Chain L
25–54（30 aa）
|
Not recorded | IPH PHENOL × 6 ZN ZINC ION × 2 CL CHLORIDE ION × 2 CA CALCIUM ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；200mM CaCl2 buffered in 100mM Tris-HCl pH 8,5, 30% (v/v) 2-Methyl-2,4-pentanediol, 8% (w/v) PEG 8000
|
Resolution 2.38 Å R-free 0.302 |
369 other PDB entries and 583 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | INS_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A； PDBConstruct 1–21； UniProt 90–110 |
